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ABSTRACT
Lynch syndrome (LS) is the most prevalent cause of hereditary colorectal
cancer (CRC) and confers high risks for several other types of cancer. Universal
tumor screening (UTS) of all newly diagnosed patients with CRC can improve LS
identification and decrease associated morbidity and mortality among patients
and family members. However, for UTS to be effective, patients who screen
positive must pursue genetic counseling and confirmatory germline testing (i.e.,
high patient reach). The purposes of this study were to characterize UTS
programs, identify barriers and facilitators to implementation, document whether
there have been negative outcomes, and determine institutional and
implementation conditions that are associated with high and low patient reach.
Using two conceptual frameworks, RE-AIM and Consolidated Framework for
Implementation Research, a baseline survey was conducted of 25
representatives from different institutions performing UTS. Descriptive statistics
were used to illustrate similarities and differences among programs. A multiplecase study was then conducted by extracting data from surveys and interviews of
representatives from 15 different institutions where UTS programs had been
operational for over 6 months and where aggregated patient outcome data were
available. Qualitative comparative analysis was performed to make systematic
cross-case comparisons and identify conditions uniquely associated with high or
low patient reach. Data were triangulated to create models explaining how UTS
vi

implementation and system-level factors influence patient reach.
Few patient concerns or negative outcomes were reported. UTS procedures
and patient reach were highly variable. All 5 high-reach (H-R) centers have
genetics professionals disclose positive screening results and either do not
require a referral from another health care provider or have streamlined the
referral process. Although 2 of the 5 mid-reach (M-R) centers also share these
conditions, they have a less automated follow-up procedure and report difficulty
contacting patients as a barrier. Both of the academic institutions with low patient
reach (L-R) did not receive patient information that would allow them to follow-up
on positive screening results. The three non-academic L-R institutions reported a
high proportion of challenges to facilitators during implementation and did not
have genetic professionals disclose positive screening results to patients.
Implementing a combination of procedures to streamline UTS protocols and
procedures, eliminate barriers to patient follow-through after a positive tumor
screen, and incorporate a high level of involvement of genetic professionals in
contacting patients and disclosing screening results are expected to lead to
improvement in patient reach.
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SECTION I: INTRODUCTION
Background and Significance
Colorectal cancer (CRC) is the third most common type of cancer and
third leading cause of cancer-related death in the United States (U.S.)
("Colorectal Cancer Facts & Figures 2011-2013,"). Lynch syndrome (LS) is the
most prevalent cause of hereditary CRC, occurring in 1 out of every 35 CRC
patients (Hampel et al., 2008). Several retrospective studies have found that LS
confers a 50-70% lifetime risk of CRC (Barrow et al., 2008; Hampel et al., 2005;
Stoffel et al., 2009), a 40-60% chance of endometrial cancer in females (Barrow
et al., 2009; Hampel et al., 2005; Stoffel et al., 2009), and increased risks for
several other malignancies including cancers of the ovary, stomach, small
intestine, hepatobiliary tract, urinary tract, brain, and skin (Barrow et al., 2009;
Watson et al., 2008). The first prospective study confirmed prior retrospective
study findings and also found pancreatic cancer and female breast cancer risks
are increased among LS carriers (Win et al., 2012).
Diagnosing LS alters cancer surveillance recommendations for patients
with CRC (due to high risks for secondary cancers) and provides the opportunity
to prevent cancer among patients' at-risk relatives through increased cancer
screening and/or surgical prevention options (Järvinen et al., 2009; Schmeler et
al., 2006; Stupart, Goldberg, Algar, & Ramesar, 2009; Vasen et al., 2010). The
public health significance of diagnosing LS is acknowledged in the following
1

provisional Healthy People (HP) 2020 Genomics Objective: “Increase the
proportion of persons with newly diagnosed colorectal cancer [CRC] who receive
genetic testing to identify Lynch syndrome (or familial CRC syndromes)”
("Genomics - Healthy People,").
Despite the public health significance of diagnosing LS, 28% to 70% of
CRC patients who have LS remain unidentified when screening is limited to
tumors from patients who meet certain age or family history criteria (Hampel et
al., 2008; Morrison et al., 2011; Tranø, Sjursen, Wasmuth, Hofsli, & Vatten, 2010;
van Lier et al., 2011). Universal screening of tumors from all newly diagnosed
patients with CRC has the potential to improve the identification of LS. Several
studies have demonstrated the feasibility, efficacy, and theoretical costeffectiveness of universal tumor screening (UTS) for LS (Gudgeon et al., 2011;
Hampel et al., 2008; Ladabaum et al., 2011; Morrison et al., 2011; Mvundura,
Grosse, Hampel, & Palomaki, 2010; Tranø et al., 2010). Nevertheless, the impact
that universal genetic screening policies will have on institutions or individuals is
largely uncertain as UTS for LS is the first universal screening to be implemented
for the purpose of detecting hereditary disease in adults.
Currently, in the United States, at least 35 cancer centers or hospitals are
performing UTS for LS, with wide institutional variability in terms of the following:
a) tumor screening methodology (i.e., IHC, MSI, with or without automatic reflex
testing via hypermethylation or BRAF); b) whether explicit informed consent is
obtained or an option to “opt out” is presented; c) what types of information are
provided to the patients; d) who is responsible for follow-up with positive
2

(abnormal) screens; and e) how patients are given results (Beamer et al., 2012;
Cohen, 2013). In addition, the percentage of patients with a positive screen who
follow-through with genetic counseling and testing (i.e., patient reach) is highly
variable, differing by more than 50% across cancer centers for which data has
been published (Heald et al., 2013; Lynch, 2011; South et al., 2009).
Potential risks of UTS for LS are believed to be minimal (Hampel, 2010).
However, in several studies that occurred prior to UTS implementation, patients
with CRC expressed concern that genetic testing for hereditary CRC may lead to
adverse psychological outcomes for themselves or their family members (Kinney
et al., 2000; Kinney, DeVellis, Skrzynia, & Millikan, 2001; Lerman, Marshall,
Audrain, & Gomez-Caminero, 1996; Ramsey, Wilson, Spencer, Geidzinska, &
Newcomb, 2003). Patients with CRC have also expressed concerns about costs
associated with genetic testing (Cragun, Malo, Pal, Shibata, & Vadaparampil,
2012; Kinney et al., 2001; Ramsey et al., 2003).
Recognizing the need to pool Lynch syndrome tumor screening resources
and to track outcomes, several institutions came together in September of 2011
to form the Lynch Syndrome Screening Network (LSSN). Since the initial
meeting, the LSSN has grown to include approximately 91 institutions across the
United States; however, as of June 2012, only 35 of these institutional members
were known to be performing routine screening for LS on tumors from all newly
diagnosed CRC patients. To meet the needs of the many centers that are still
trying to implement UTS, the LSSN has already created a website that houses
tumor screening resources (www.lynchscreening.net). However, information
3

about keys to successful implementation, “best practices”, and ways to overcome
barriers is lacking from the website.
Three centers have previously reported aggregated patient data showing the
percentage of patients who follow through with genetic counseling and germline
genetic testing after a positive screen (i.e., patient reach) varies by over 50%
(Lynch, 2011; South et al., 2009; Heald et. al, 2013). Two of these centers have
also published or presented prospective data suggesting that changes in their
protocol and follow-up procedures have improved patient reach (Hampel et. al,
2012; Heald et. al, 2013). However, further research into 'real-world'
implementation is needed to assess cost effectiveness as well as unanticipated
consequences or negative patient outcomes. Furthermore, determining how
implementation and system-level factors influence patient reach can help identify
'best practices' that can be used to maximize the effectiveness of UTS programs
in order to justify the development of infrastructure and cost required for UTS
implementation on a national level.
This research is significant to public health because programs that
automatically screen tumors from all newly diagnosed CRC patients have the
potential to identify the 28% to 70% of CRC patients with LS who are missed
using common practices of limiting screening to those who fulfill certain age (<50
years) or medical/family history criteria (Hampel et al., 2008; Morrison et al.,
2011; Tranø et al., 2010; van Lier et al., 2011). This allows for the prevention or
early detection of secondary cancers among patients and provides an
opportunity to diagnose family members who have LS in order to prevent
4

associated morbidity and mortality. UTS also has the potential to improve the
identification of LS among ethnic minorities who are currently less likely to be
identified and/or referred for genetic counseling and testing for hereditary cancer
(Hall & Olopade, 2006; Kupfer, McCaffrey, & Kim, 2006; Shields, Burke, & Levy,
2008).
Study Purpose and Objectives
The long-term goal of this ongoing line of research is to improve the ability
of universal tumor screening programs (UTS) programs to achieve the Healthy
People 2020 provisional objective: “Increase the proportion of persons with newly
diagnosed CRC who receive genetic testing to identify Lynch syndrome”
(“Genomics - Healthy People”.) and thereby reduce the morbidity and mortality
associated with hereditary cancer. The objectives of the current study were: 1) to
compare current UTS screening programs at U.S. institutions (i.e., hospitals and
cancer centers); 2) compile a list of “lessons learned” during implementation; 3)
document any negative outcomes; and 4) determine “best UTS practices”.
Theoretical Frameworks, Research Questions, and Hypothesis
The RE-AIM evaluation framework ("DCCPS: Cancer Control Research:
Implementation Science: RE-AIM," ; Glasgow, Klesges, Dzewaltowski,
Estabrooks, & Vogt, 2006; Glasgow, Nelson, Strycker, & King, 2006; Glasgow,
Vogt, & Boles, 1999) and constructs from the Consolidated Framework for
Implementation Research (CFIR) (Damschroder et al., 2009; Damschroder &
Hagedorn, 2011) were used to meet the aforementioned objectives and answer
research questions listed in Table I-1. The goal of RE-AIM is to enhance the
5

quality, speed, and impact of efforts to translate research into practice in a
manner that considers both internal and external validity (“DCCPS: Cancer
Control Research: Implementation Science: RE-AIM,” n.d.; Glasgow et al., 1999).
RE-AIM aids in evaluating programs by assessing the following dimensions that
may impact generalizability of findings: Reach, Effectiveness, Adoption,
Implementation, and Maintenance (see Table I-1 for dimension descriptions). In
the current study, RE-AIM was used to identify patient Reach (i.e., the proportion
of patients with an abnormal screen who follow-through with genetic counseling
and germline testing), real-world Effectiveness (i.e., unanticipated consequences
/ negative outcomes of UTS), reasons for UTS program Adoption, differences in
program Implementation, and the extent to which programs have changed (i.e.,
Maintenance).
The Consolidated Framework for Implementation Research (CFIR) aided
in identifying key system-level and implementation factors related to UTS. The
CFIR was developed in 2009 to open the black box of the Implementation
dimension in RE-AIM and aids in research planning by consolidating constructs
from various implementation theories and an established evidence base
spanning multiple scientific disciplines (Damschroder et al., 2009). These
constructs are organized into five domains described in Table I-2. Various
constructs were selected for inclusion in the CFIR based on their perceived
relevance in a variety of health care contexts and research demonstrating that
they are related to the adoption, implementation, and/or effectiveness of
6

evidence-based recommendations (Damschroder et al., 2009). Table I-2 lists
constructs from the CFIR and provides a brief description of each.
A number of CFIR constructs come from Diffusion of Innovations, which is
a theoretical framework explaining how and why new ideas, practices, or
technologies (i.e., innovations) are communicated through channels over time
(Rogers, 2003). Diffusion of Innovations is primarily used to explain factors
associated with decisions to adopt, implement, maintain, and sustain innovations
(Glanz, 2008; Rogers, 2003). Research guided by Diffusion of Innovations has
provided a number of valuable insights, including a recognition regarding “...the
importance of achieving a good fit between the attributes of an innovation, the
adopting individual or organization, and the environment or context where the
process takes place” (Glanz et al., 2008; p. 330).
Ironically, this insight also highlights some acknowledged criticisms of
diffusion research, including a “tendency to hold individuals responsible for their
problems, rather than the system of which the individual is a part” (Glanz et al.,
2008; p.329) and limitations in the ability of Diffusion of Innovations to contribute
to an understanding of the complex organizations where innovation adoption
decisions often take place (Glanz et al., 2008). The CFIR addresses these
concerns through its focus on institutions as important units of analysis and its
inclusion of a number of constructs specific to organizations. These additional
constructs can be used to explore how organizational characteristics or systemlevel factors may influence adoption, implementation processes, and
7

effectiveness of innovations. Additionally, the CFIR includes constructs specific to
the implementation process itself, and thereby allows exploration into how
aspects of this process may increase or reduce the chance for successful
outcomes that result from innovation implementation. CFIR developers never
intended for all constructs to be utilized in any single study (Damschroder et al.,
2009; Damschroder & Hagedorn, 2011). As such, a subset of constructs (i.e.,
contextual factors) from the CFIR that were hypothesized to play a role in
implementation and effectiveness of LS UTS programs were used to develop
questions for the surveys and interview guides. Table I-3 lists outcomes used to
define successful UTS programs as well as conditions that might influence these
outcomes.
Subsequently, the central hypothesis for the current study was that high
patient Reach and few unanticipated or negative outcomes occur among UTS
programs that possess one or more combinations of the following contextual
factors: 1) streamlined UTS procedures (i.e., fewer steps need to be taken by
patients in order to follow-up with genetic counseling and germline testing or
patients can have genetic counseling at the same time or in the same location as
other follow-up appointments); 2) direct involvement of genetic professionals in
patient follow-up; 3) high quality communication among specialists (based on
self-reported ratings by the primary contact and others involved with UTS at each
institution); 4) consideration of patient needs and resources; 5) positive
implementation climate (i.e., ratings of the extent to which UTS is rewarded,
8

supported, and expected within the institution) (Klein & Sorra, 1996); 6) high level
of implementation readiness (based on ratings of how open the institution is to
new initiatives and how much planning was done prior to implementation); and 7)
positive attitudes toward LS UTS among key personnel who serve in
administrative positions or are directly involved with UTS. The central study
hypothesis was tested by employing a multiple-case study and qualitative
comparative analysis (QCA) of data from several UTS programs.
Dissertation Organization
This dissertation includes two manuscripts that will eventually be
submitted to peer-reviewed journals. The first manuscript presents the main
findings of the current study within the RE-AIM framework (Section II). The
purpose of the second manuscript (Section III) is to disseminate information on
the utility of Qualitative Comparative Analysis in mixed methods research. To this
end, the second manuscript includes: 1) findings from systematic reviews in Pub
Med and the Journal of Mixed Methods Research illustrating the slow rate of
diffusion of Qualitative Comparative Analysis (QCA) into health research and
limited adoption among mixed-methods researchers; 2) a practical illustration of
how to apply this hybrid technique using data from the multiple-case study; and
3) advantages and limitations to QCA. Section IV of this dissertation concludes
with an overall summary, study implications, future directions, and a description
of additional manuscripts that are planned after the submission of this
dissertation.
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Table I-1. Applying the RE-AIM Framework and Consolidated Framework for Implementation
Research (CFIR) to Evaluate Lynch Syndrome Universal Tumor Screening (LS UTS) Programs
RE-AIM Dimension

Research Questions

Relevant CFIR
Domains (see
Table I-2)

Reach
Absolute number, proportion,
and representativeness of
individuals who participate.

• What proportion of patients who screen
positive follow-through with genetic
counseling and germline testing at
each respective institution?

• NA

Efficacy / effectiveness
The impact of an intervention
on outcomes (including
potential negative effects).

• Have there been any unexpected
outcomes or negative effects
associated with UTS implementation?

• NA

Adoption
Absolute number, proportion,
and representativeness of
settings and staff who
currently offer a program.
Characteristics of the
intervention may increase the
likelihood of adoption.

• What led to the adoption of UTS?
• Who was involved in making the
decision to adopt UTS?
• What characteristics of the
centers/institutions may increase the
likelihood of adopting UTS?
• What characteristics of UTS (e.g.,
compatibility, complexity) relate to the
decision to adopt it?

Implementation
Consistency of delivery, time
and cost of the program, and
what adaptations to the
program are made in various
settings.

• Describe those involved in
implementation. Were they the same
as those who decided to adopt UTS?
• What impact did key individuals have
on implementation?
• How was screening implemented (what
was involved in planning & initiation)?
• What challenges had to be overcome
when implementing screening?
• What is the institution's screening
protocol?
• Does implementation vary based on
characteristics of the protocol chosen,
institution, or individuals?

Maintenance
How the intervention and its
effects change over time.

What changes have been made to UTS
programs over time?

10

•

Individuals
involved
• Inner setting,
Outer setting
• Intervention
characteristics

• Individuals
involved
• Implementation
Process
• Intervention
(protocol)
characteristics,
Inner setting,
Outer setting,
Individuals
involved

• Individuals
• Inner & Outer
setting
• Intervention
characteristics

Table I-2. Domains and Constructs of the Consolidated Framework for Implementation Research
(CFIR)
CFIR
Domains and
Constructs

Description

Intervention -- Characteristics of the intervention such as complexity, cost, and relative
advantage that influence adoption, implementation, etc.
Intervention
source

Perception of key stakeholders about whether the intervention is externally or
internally developed to solve a local problem and the legitimacy of the source
(Greenhalgh, Robert, Macfarlane, Bate, & Kyriakidou, 2004). Externally
developed interventions and lack of user input can lead to ineffective
implementation (Helfrich, Weiner, McKinney, & Minasian, 2007; Kitson et al.,
2008; Klein, Conn, & Sorra, 2001).

Evidence
strength and
quality

Stakeholder's perceptions of the quality and validity of evidence that the
intervention will have desired outcomes (Fitzgerald, Ferlie, & Hawkins, 2003).
Although evidence to support the intervention is important and can increase the
likelihood that it will be adopted (Kitson et al., 2008), evidence is typically not
sufficient to ensure adoption, nor is it always a primary consideration when
deciding whether to adopt an innovation (Denis, Hébert, Langley, Lozeau, &
Trottier, 2002; Fitzgerald et al., 2003).

Relative
advantage

Stakeholder beliefs about the benefits of UTS compared with the status quo or an
alternative (Rogers, 2003). Relative advantage and observability are constructs
from Diffusion of Innovations (Rogers, 2003). They are combined because
benefits, if visible to the stakeholders, aid adoption and implementation (Denis et
al., 2002; Feldstein & Glasgow, 2008; Greenhalgh et al., 2004; Grol & Grimshaw,
2003; Grol, Bosch, Hulscher, Eccles, & Wensing, 2007).

Adaptability

Perceptions about whether and how an intervention can be tailored to meet
specific needs or characteristics of an institution (Rogers, 2003). There are
generally 'core components' that are necessary elements of the intervention and
an 'adaptable periphery' (Greenhalgh et al., 2004). According to Diffusion of
Innovations, programs that can easily be modified to are more likely to be
adopted (Rogers, 2003).

Trialability

Ability to test an intervention on a small scale and reverse implementation if
warranted (Rogers, 2003). According to Diffusion of Innovations, trialability has a
strong positive association with adoption (Greenhalgh et al., 2004; Rogers,
2003). It also increases the likelihood of effective implementation because
piloting provides experience that can be used to improve full scale
implementation (Kitson et al., 2008)

Complexity

Perceived difficulty of implementation (duration, scope, radicalness,
disruptiveness, centrality and number of steps required) (Rogers, 2003).
According to Diffusion of Innovations complexity plays a critical role in the
decision to adopt an innovation. In addition, simple interventions are more likely
to be effective (Greenhalgh et al., 2004). Assessing complexity can also help in
understanding and avoiding unintended consequences (Kochevar & Yano, 2006).

Design quality Perceived excellence in how the intervention is presented/assembled (Grol et al.,
and
2007). When the quality of the intervention is perceived to be poor, it can evoke
packaging
negative attitudes among users and decrease intervention use and effectiveness
(Grol et al., 2007; Helfrich et al., 2007; K J Klein, Conn, & Sorra, 2001).
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Table I-2 (continued).
Costs

Costs of the intervention as well as implementation costs (Rogers, 2003). Cost is
a characteristic from Diffusion of Innovations and is negatively associated with
adoption (Rogers, 2003; Teplensky, Pauly, Kimberly, Hillman, & Schwartz, 1995).
Cost is also likely to influence how the intervention is implemented and its overall
effectiveness.

Outer setting - Economic, political, and social context in which an organization resides.
Patient needs
and resources

The extent to which patient needs, barriers, and facilitators are accurately
known and prioritized. (Feldstein & Glasgow, 2008; Graham & Logan, 2004). A
number of implementation theories postulate that taking these issues into
account will increase the chance that the intervention will be effective (Ferlie &
Shortell, 2001; Kitson et al., 2008). Quality improvement initiatives have proven
more successful if there has been a strong focus on the patients' needs (Ferlie
& Shortell, 2001).

Cosmopolitanism

Degree to which the organization is networked with other external institutions
(i.e., social capital of the organization) (Greenhalgh et al., 2004). The degree of
external networking increases the likelihood of implementing new practices
quickly once advantages become apparent (Greenhalgh et al., 2004).

Peer pressure

Competitive pressure to implement an intervention (to either obtain a
competitive edge or because other organizations already have implemented it)
(Greenhalgh et al., 2004). There is strong evidence that peer pressure
influences organizational adoption or programs / interventions / technologies
(Greenhalgh et al., 2004).

External
policies and
incentives

External strategies to spread interventions (e.g., mandates, pay-forperformance, political directives, recommendations, collaboratives) (Greenhalgh
et al., 2004; Mendel, Meredith, Schoenbaum, Sherbourne, & Wells, 2008).
Many times these strategies lead to adoption and increase effective
implementation, but there are some exceptions (Greenhalgh et al., 2004; Grol et
al., 2007; Klein & Sorra, 1996).

Inner setting - Structural, political, and cultural contexts through which implementation
proceeds.
Structural
characteristics

Social architecture (i.e., how people are clustered into smaller groups and how
actions are coordinated), age, maturity, and size of an organization
(Damanpour, 1991; Greenhalgh et al., 2004). Several structural characteristics
have been found to be significantly associated with implementation
effectiveness, often with mixed results (Frambach & Schillewaert, 2002). A
greater number of departments involved in decision making may slow down the
process, but generally increases successful implementation (Damanpour, 1991;
Greenhalgh et al., 2004).

Networks and Nature, quality, and extent of social networks (social capital). Formal and
communication informal communications within an organization (Greenhalgh et al., 2004;
Helfrich et al., 2007). Coordination and teamwork across departments and
specialties is typically important for effective implementation of programs or
initiatives (Feldstein & Glasgow, 2008; Ferlie & Shortell, 2001). Clear role
definitions and high quality communication increase the likelihood of success
(Simpson & Dansereau, 2007).
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Table I-2 (continued).
Organizational
Culture

Norms, values and basic assumptions of a given organization (these are
relatively stable, socially constructed, subconscious) (Gershon, Stone, Bakken,
& Larson, 2004; Scott, Mannion, Davies, & Marshall, 2003). The ways in which
culture is defined vary, but it has been shown to influence implementation
effectiveness in complex ways (Helfrich et al., 2007; Scott et al., 2003).
Organizations that emphasize or value flexibility over centralized control and
those that value human relations and a supportive climate are expected to be
more successful with implementation.

Implementation Absorptive capacity for change, shared receptivity of those involved, extent to
climate
which involvement with the intervention is rewarded, supported, or expected
within the organization. (Gershon et al., 2004; Greenhalgh et al., 2004; Klein &
Sorra, 1996). Climate includes the following 6 sub-constructs:
Tension for change – degree to which stakeholders perceive current situation as
needing change.
Compatibility – degree of fit between the meaning and values of the intervention
and individual's and institution's values as well as fit with work flow and
systems. Greater perceived fit = greater likelihood of adoption according to
Diffusion of Innovations and empirical research (Greenhalgh et al., 2004; Klein
& Sorra, 1996; Rogers, 2003).
Relative priority – shared perception of how important implementation is. The
higher the priority the more likely it is to be successful (Helfrich et al., 2007).
Organizational incentives/rewards – include but are not limited to goal-sharing
awards, performance reviews, raises in salary, increased stature or respect.
Strong incentives increase the likelihood of implementation success (Helfrich et
al., 2007; Klein et al., 2001). The number of different types of incentives has
been positively related to use of best practices by healthcare organizations
(Shortell et al., 2001).
Goals and feedback – Goals that are specific, incremental, and attainable
increase effective implementation. Feedback has been shown to have small to
moderate effects (Jamtvedt, Young, Kristoffersen, O'Brien, & Oxman, 2006).
Learning climate – climate where leaders recognize they are fallible and need
input, and team members feel their input is valued. This is hypothesized to
influence the ability of an organization to fully assimilate an intervention
(Greenhalgh et al., 2004).
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Table I-2 (continued).
Readiness for Tangible and immediate indicators of organizational commitment to its decision
implementation (Greenhalgh et al., 2004; Kitson et al., 2008). This includes 3 sub-constructs.
Leadership engagement – commitment, involvement, and accountability of
managers. This is critical to successful implementation (Meyer & Goes, 1988). It
leads to a stronger implementation climate (Helfrich et al., 2007; Klein, et al.,
2001).
Available resources – level of resources implemented (i.e., money, time, space).
The level of resources is positively associated with implementation, but does
not guarantee success (Klein et al., 2001).
Access to information and knowledge – Access to easy to use information about
UTS and how to incorporate it is essential for successful implementation
(Greenhalgh et al., 2004; Helfrich et al., 2007; K J Klein et al., 2001). Timely, on
the job training (particularly if provided at a team level) contributes to success
(Greenhalgh et al., 2004). This is also critical to get key stakeholders engaged
(Grol et al., 2007).
Individuals - Individuals in the inner or outer setting can promote or hinder the
implementation process and alter program effectiveness.
Knowledge
and beliefs
about the
intervention

Familiarity with principles related to the intervention and how-to knowledge as
well as positive and negative attitudes about the intervention and value placed on
the intervention (Klein & Sorra, 1996; Rogers, 2003). Principles and how-to
knowledge are constructs from Diffusion of Innovations (Rogers, 2003). Attitudes
are key constructs in some theories that explain individual behavior change.

Self-efficacy

Individual belief in capability to execute behavior needed to achieve
implementation goals. Perceived ability to perform a specific action within a
specific context (Bandura, 1997). This construct is included in multiple theories of
behavior change (Glanz, Rimer, & Viswanath, 2008) However, self-efficacy is
originally attributed to Bandura.

Individual
stage of
change

Progression toward use of the intervention. Stage depends on the specific model
used (i.e., Prochaska's Transtheoretical model, Roger's Diffusion of Innovations,
etc) (Levesque, Cummins, Prochaska, & Prochaska, 2006; Prochaska &
DiClemente, 1983; Rogers, 2003).

Individual
identification
with the
organization

How individuals perceive the organization and their relationship and commitment
to the organization ("AHRQ Innovations Exchange | Will It Work Here? A
Decisionmaker's Guide to Adopting Innovations," ; Cropanzano, Rupp, & Byrne,
2003). This can affect the willingness of individuals to fully engage in
implementation efforts, but this construct has not been widely studied in health
care settings.
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Table I-2 (continued).
Process - Include actions that lead to implementation, protocol and procedures, and
ongoing reflection.
Planning

Degree to which the methods and tasks for implementation and evaluation are
developed (Damanpour, 1991; Greenhalgh et al., 2004; Rogers, 2003). Although
planning is generally necessary for implementing institutional programs
(Greenhalgh et al., 2004), additional research is needed into how planning
influences implementation effectiveness.

Engaging

Attracting and involving appropriate people in implementation using social
marketing, education, role modeling, training, and other activities (“AHRQ
Innovations Exchange | Will It Work Here? A Decisionmaker’s Guide to Adopting
Innovations,” n.d.; Greenhalgh et al., 2004; Kitson et al., 2008). If implementation
leaders are similar to intended users they are more likely to adopt the
intervention (Greenhalgh et al., 2004). Chances of success are greater if all
stakeholders are engaged early on in the process (Greenhalgh et al., 2004).

Executing

Carrying out the implementation according to plan (Carroll et al., 2007;
Damanpour, 1991; Edmondson, Bohmer, & Pisano, 2001; Helfrich et al., 2007).
In cases where there is not a plan, assessing execution is difficult. Execution
quality may be related to the following: level of fidelity to the plan, intensity of
implementation, timeliness of task completion, and degree of engagement of key
stakeholders (Carroll et al., 2007; Edmondson et al., 2001).

Reflecting
and
evaluating

Quantitative and qualitative feedback about the progress and quality of
implementation. Team debriefing and reflection ("AHRQ Innovations Exchange |
Will It Work Here? A Decisionmaker's Guide to Adopting Innovations,").
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Table I-3. Study Outcomes and Contextual Factors for Qualitative Comparative Analysis
(QCA)
Outcomes of Lynch Syndrome Universal Tumor Screening (LS UTS)
1. The proportion of patients who screen positive and follow-through with genetic
counseling and germline testing
2. Unexpected problems, patient concerns, negative outcomes
3. Problems with reimbursement for tumor screening
a

Conditions that May Influence LS UTS Outcomes
•

•

•

•

•

Intervention Characteristics
o Complexity
o Costs
Outer Setting
o Knowledge of patient needs and resources
o Extent to which patient needs are considered
Inner Setting
o Quality of communication within the organization, coordination across
departments, and clearly defined roles
o Degree to which implementation was supported
Process
o Ability to attract and motivate the appropriate people necessary for
implementation
o How UTS was implemented (procedures/protocol) including:
• screening method (IHC, MSI, both)
• when and how positive results are given to patients
• how results are tracked
• whether a referral is necessary for patient to receive genetic
counseling
Individuals involved
o Attitudes, knowledge, and experiences regarding UTS
o Who discloses positive tumor screening results and follows-up with patients
o Who tracks results
o Who discusses germline testing

a

Note: Conditions are derived from the 5 domains of the Consolidated Framework for
Implementation Research
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SECTION II: IMPLEMENTATION EFFECTIVENESS OF UNIVERSAL TUMOR
SCREENING FOR LYNCH SYNDROME
Abstract
Background: Universal tumor screening (UTS) of all newly diagnosed
colorectal cancer (CRC) patients improves the identification of Lynch syndrome,
the most common cause of hereditary CRC, and provides an opportunity for
prevention and early detection of cancers. However, for UTS to be effective, a
high proportion of patients who screen positive must pursue genetic counseling
and germline testing (i.e., high patient reach).
Objective: This study uses the RE-AIM framework to characterize UTS
programs, identify barriers and facilitators to UTS implementation, document any
negative outcomes, and identify implementation factors associated with different
levels of patient reach.
Methods: A web-based survey was conducted of 25 key contacts from
institutions in the U.S. that were actively implementing UTS. Frequencies were
used to identify similarities and differences among programs. Qualitative
comparative analysis (QCA) of all 15 institutions where patient outcome data
were available was performed to identify conditions uniquely associated with
levels of patient reach.
Results: All 5 high-reach (H-R) centers have genetics professionals
disclose positive screening results and either do not require a referral from
another health care provider or have streamlined the referral process. Although 2
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of the 5 mid-reach (M-R) centers also share these conditions, they have a less
automated UTS protocol and report difficulty contacting patients as a barrier. The
3 remaining M-R centers and all 5 low-reach centers lacked all of the key
conditions associated with H-R centers.
Conclusions: Streamlining UTS procedures, eliminating key barriers, and
incorporating a high level of involvement of genetics professionals is expected to
improve patient reach.
Introduction
Colorectal cancer (CRC) is the third most common type of cancer and third
leading cause of cancer-related death in the United States ("Colorectal Cancer
Facts & Figures 2011-2013,"). Occurring in approximately 1 out of every 35
patients with CRC, Lynch syndrome is the most common cause of hereditary
CRC (Hampel et al., 2008). Lynch syndrome confers a 50-70% lifetime risk of
CRC (Barrow et al., 2008; Hampel et al., 2005; Stoffel et al., 2009) , a 40-60%
chance of endometrial cancer (Barrow et al., 2009; Hampel et al., 2005; Stoffel et
al., 2009), and increased risks for several other malignancies (Barrow et al.,
2009; Watson et al., 2008).
The significance of diagnosing Lynch syndrome for preventing cancers
and improving health outcomes has been acknowledged in the following
provisional Healthy People (HP) 2020 Genomics Objective: “Increase the
proportion of persons with newly diagnosed colorectal cancer [CRC] who receive
genetic testing to identify Lynch syndrome (or familial CRC syndromes)”
(“Genomics - Healthy People”). Screening tumors from all newly diagnosed
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patients with CRC has the potential to substantially improve the identification of
Lynch syndrome; and reduce cancer incidence among at-risk family members
("Recommendations from the EGAPP Working Group," 2009). Furthermore,
several studies have demonstrated universal tumor screening (UTS) feasibility,
efficacy, and theoretical cost-effectiveness (Gudgeon et al., 2011; Hampel et al.,
2008; Ladabaum et al., 2011; Morrison et al., 2011; Mvundura et al., 2010; Tranø
et al., 2010).
At least 35 institutions (i.e., cancer centers, hospitals) in the U.S. perform
UTS, but screening methods vary across institutions (Beamer et al., 2012;
Cohen, 2013). For example, microsatellite instability (MSI) testing and/or
immunohistochemical (IHC) testing can be used as the initial screening method.
Secondary screening tests using BRAF or hypermethylation can be performed on
a sub-set of screen-positive tumors in order to reduce the need to follow-up with
a proportion of screen-positive patients who do not likely have Lynch syndrome
(Bellcross et al., 2012; Palomaki, McClain, Melillo, Hampel, & Thibodeau, 2009;
"Recommendations from the EGAPP Working Group," 2009).
Regardless of the screening protocol, UTS will only be successful if
patients who screen positive subsequently undergo genetic counseling and
germline testing. Genetic counseling is critical to help the patient understand the
following: 1) Lynch syndrome substantially increases lifetime risks for several
types of cancer; 2) family members could also have Lynch syndrome; and 3)
successful prevention or early detection of cancers among patients with Lynch
syndrome is possible through increased surveillance and surgical options.
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Germline testing to identify the underlying gene mutation in a family allows other
unaffected relatives to be tested for Lynch syndrome. The percentage of patients
with a positive screen who follow-through with genetic counseling and germline
testing (i.e., patient reach) is highly variable, differing by more than 50% across
the few cancer centers for which data has been published (Heald et al., 2013;
Lynch, 2011; South et al., 2009).
Recognizing the need for additional research into the public health impact
of UTS and desire to enhance the effectiveness of these efforts, the RE-AIM
evaluation framework (Glasgow et al., 1999) was employed to conduct a
multiple-case study of UTS programs. The RE-AIM framework aids in multi-level,
comprehensive program evaluation through the identification of factors within five
dimensions defined in the current study as follows:
1) Reach - percentage of patients at an institution with a positive tumor
screen who follow-through with genetic counseling and germline testing
2) Efficacy - potential negative effects and unanticipated outcomes
3) Adoption - reasons for performing UTS and characteristics of
participating institutions that have adopted UTS
4) Implementation - consistency of UTS delivery as well as adaptations
made in various settings
5) Maintenance - changes in the intervention and its effects over time.
Subsequently, the objectives of this study were to: 1) quantify patient
Reach at multiple different institutions that have implemented UTS; 2) identify
negative or unanticipated outcomes of UTS (i.e., Effectiveness); 3) determine
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reasons for UTS Adoption; 4) characterize similarities and differences in
Implementation across institutions; 5) identify barriers and facilitators to
Implementation; and 6) determine what conditions are associated with high and
low patient Reach in order to characterize “best UTS practices.
With regard to the sixth objective, the researchers hypothesized that high
patient Reach would occur among programs that possess one or more
combinations of the following conditions: 1) streamlined UTS procedures (i.e.,
implementation of automatic reflex testing, fewer steps need to be taken by
patients in order to follow-up with genetic counseling and germline testing, and/or
referrals from other health care providers are not a barrier); 2) direct involvement
of genetic professionals in results disclosure and patient follow-up; and 3)
support for implementation (i.e., facilitators outweigh barriers or challenges that
were faced during implementation). Conversely, low patient reach was
hypothesized to occur when one or more of these factors were not present.
Methods
Study Design
After obtaining approval from the University's Institutional Review Board a
multiple-case study was initiated in the fall of 2012. Data for the multiple-case
study were obtained primarily from initial surveys of primary institutional
representatives. In addition, data from follow-up surveys and interviews
performed approximately six-months after the initial surveys were used to
illustrate the RE-AIM dimension Maintenance and inform the interpretation of the
findings.
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Participant Recruitment and Procedures
Initial surveys of primary institutional representatives. Using the
LSSN listserv, an e-mail invitation containing information about the study was
directed to all primary representatives of the 35 institutional members of the
Lynch Syndrome Screening Network (LSSN) that were performing universal
tumor screening (UTS), and to approximately 27 institutional representatives that
were in the process of actively planning or implementing UTS. Institutions that
limit screening based on age or other criteria were not included in the study.
Interested representatives who contacted the principal investigator (PI) and
qualified for the study were asked to review the consent form, complete an online
survey, and indicate whether they would be willing to be contacted in the future.
Follow-up survey and interview with institutional representatives.
Nearly six months after the baseline survey, all 15 participants from institutions
that had been screening for more than six-months at the time of the initial survey
and had access to patient reach data were sent a personal e-mail invitation and
link to complete a follow-up survey designed to obtain patient reach updates,
UTS protocol/procedural details or changes, and interest in participating in a
follow-up interview.
Interviews lasting an average of 50 minutes were conducted by the PI
with10 of the 15 institutional representatives. Interview data was used to fill in
missing details and to clarify discrepant information from the two surveys. During
the interviews notes were taken by the PI and interviews were audio recorded in
order for the PI to verify details as needed. At the end of the interviews
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participants were asked to forward an invitation to participate in a brief interview
or survey to other individuals at their institution who had been involved with UTS.
Interviews with additional key personnel. Eight primary representatives
agreed to forward an e-mail invitation to one or two individuals at their center.
Brief 15-30 minute interviews were completed with three pathologists and one
program director from four institutions and 45-60 minute interviews were
completed with two individuals who could fill in missing details about
implementation at a fifth institution.
Measures
Initial survey. The baseline survey was developed to collect information
regarding: a) institutional characteristics; b) factors influencing UTS adoption; c)
UTS protocol (including follow-up procedures); d) barriers and facilitators to UTS
implementation; e) percentage of patients who follow-through with genetic
counseling and germline testing after a positive screen; and f) barriers or
facilitators to patient follow-through. The survey was reviewed for face and
content validity by a medical geneticist, two genetic counselors, an
epidemiologist, and a behavioral cancer scientist, all of whom were familiar with
Lynch syndrome tumor screening. The revised survey included five open-ended
questions and approximately 20 multi-part, closed-ended questions that also
allowed participants to write in additional responses or details. The online survey
was piloted by two genetic counselors and a nurse practitioner, all of whom were
involved in setting up a UTS program for Lynch syndrome at their respective
institutions.
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Patient reach was operationalized using two survey questions that assessed
the percentage of screen positive patients under the current institutional
screening protocol who 1) pursue germline genetic testing and 2) receive genetic
counseling. Response options were the same for both questions: 1 = <10%; 2 =
11-25%; 3 = 26-40%; 4 = 41-55%; 5 = 56-70%; 6 = 71-85%; and 7 =>85%.
Ordinal response categories for the two questions were averaged to create
patient reach scores with a possible range from 1-7. After arranging cases in
descending order by patient reach, the researchers identified two natural breaks
and used these to categorize cases into the following three groups; “high-reach”
(H-R); “mid-reach” (M-R); and “low-reach” (L-R).
Follow-up survey. The follow-up survey was developed by the PI to help
clarify responses from the initial survey, obtain additional details, and identify
changes that may have occurred in patient reach and UTS protocol or
procedures. The follow-up survey was reviewed for face and content validity by a
medical geneticist, three genetic counselors, and a behavioral cancer scientist,
all of whom were familiar with Lynch syndrome tumor screening.
Interview guides. Semi-structured interview guides used for follow-up
interviews included several open-ended questions about UTS implementation
and experiences as well as several institution-specific questions designed to
clarify and expand upon information collected from the surveys. The guides were
tailored for each participating institution by the PI with input from a medical
geneticist and experts in behavioral health research. A subset of relevant
questions was selected by the PI for inclusion in interviews of other key
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personnel based on their expertise and role in UTS implementation.
Data Analysis
Frequencies and percentages for responses to closed-ended survey
questions were generated using an Excel spreadsheet. After grouping together
eight centers where patient reach data were not available and stratifying the
other fifteen centers according to patient reach, frequencies of responses to
closed-ended questions were generated for each of the four groups. Open-ended
survey and interview responses were categorized according to patient reach and
then reviewed by the PI to identify commonalities and diversity in themes across
centers for each of the RE-AIM dimensions.
Qualitative comparative analysis (QCA) was used to test the study
hypothesis and determine which combinations of factors were uniquely
associated with high and low patient reach among the 15 centers where patient
reach data were available. QCA is an analytic technique for performing crosscase comparative analyses in order to systematically identify and simplify key
factors (i.e., conditions) that are “sufficient” for an outcome of interest to occur
(Ragin, 1989; Rihoux & Ragin, 2009). Although QCA is different from inferential
statistics, conditions are analogous to independent variables that are
hypothesized to influence the outcome of interest (i.e., patient reach).
Conditions were coded for use in QCA as follows: 1=condition present;
and 0=condition absent. Patient reach was coded into two variables as follows: 1)
H-R=1 for all institutions with a patient reach score of 5 or above and H-R=0 for
all other institutions; 2) L-R=1 for all institutions with a patient reach score of 2 or
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below and L-R=0 for all other institutions. Specialized software (fsQCA 2.0) was
used to perform a sufficiency analysis using the truth table approach ("Citing
fs/QCA 2.0,") in order to determine whether one or more combination of
conditions are unique to centers that reported high patient reach (H-R). A
separate sufficiency analysis was performed to determine combinations of
conditions that are unique to centers reporting low patient reach (L-R). Steps
used to perform QCA are included in Table II.1.
Results
Institutions and Participants
Of the 35 health care providers who were serving as institutional
representatives for the Lynch Syndrome Screening Network (LSSN) and worked
at institutions that had implemented UTS, 20 (57%) responded to an e-mail
invitation and provided baseline data via the online survey. An additional 3
representatives from centers that were in the process of implementing UTS also
completed relevant portions of the survey. Based on survey responses, 15
institutions met the following a priori inclusion criteria for use in hypothesis
testing: 1) UTS had been fully implemented for 6 months or longer at the time of
the initial survey; and 2) data needed to determine patient reach were provided.
All primary contact persons were genetic counselors, except for one
physician who responded from an institution that was still in the process of
implementing UTS. Table II-2 provides demographic characteristics of all
participating institutions and lists these same characteristics after stratifying
centers into four groups according to the availability of patient reach data. Four of
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the five H-R institutions were academic/research centers that were designated by
the National Cancer Institute (NCI) as either a comprehensive cancer center
(CCC) or cancer center (CC). In contrast, three of the five M-R and three of the
five L-R institutions were classified as non-academic institutions with only one
classified as a NCI-CCC. Most institutions had been performing UTS for over one
year as of October 2012. The total number of colorectal cancer patients screened
and number of positive screens over a six month time period were highly variable
across institutions (Table II-2).
Patient Reach
Frequencies showing the percentages of patients who followed through
with genetic counseling and with germline testing after a positive tumor screen
are reported in Table II-3. There is wide variability on these two measures across
centers, with no overlap between H-R and L-R institutions.
Effectiveness
Patient concerns, unanticipated outcomes, or problems with
reimbursement related to UTS rarely or sometimes occurred (Table II-3).
Institutional representatives provided descriptions of these events in open-ended
responses or follow-up interviews. For instance, one representative described
how a couple of patients expressed surprise because they were unaware that
tumor screening was part of the surgical informed consent they signed; and two
representatives indicated that a few patients expressed concerns about their
inability to pay for genetic counseling and/or germline testing. One representative
also indicated that one patient did not really want the results but felt obliged to
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follow-up on them and undergo germline testing. Unanticipated outcomes that
were described included the need to plan for how to handle results from prison
inmates or from patients who are deceased. Other challenges included how to
follow-up when results are equivocal (i.e., partial loss of protein expression on
IHC) or when results are atypical (i.e., absence of MLH1 and MSH6).
A fair number of institutional representatives were uncertain whether
reimbursement for tumor screening was an issue. However, in follow-up
interviews, individuals at four centers where screening is performed on tumor
resections indicated that there is usually no additional fee recovered for tumor
screening because it is included as part of the overall costs that insurers
reimburse as part of the inpatient surgery. At another institution where the
protocol was changed so that tumor biopsies rather than tumor resections are
screened, the pathologist indicated that because biopsies are performed as
outpatient procedures, fees could be recovered.
Reasons for UTS Adoption
The most commonly identified reason for adopting UTS was to “improve
the identification of individuals with Lynch syndrome”, followed by “to benefit
relatives of patients with Lynch syndrome”. Several other reasons were also
selected and are listed in Table II-4. None of the centers checked “to increase
revenue” as a reason for adoption. The number of reasons checked by
representatives varied, but there did not appear to be any consistent patterns or
associations between reasons for adoption and patient reach.
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Barriers and Facilitators to Implementation
Only three institutional representatives checked “no real barriers or
challenges” when asked about barriers to implementing UTS at their institution
(Table II-5). Interestingly, all three representatives reporting no barriers
represented academic institutions, including two H-R centers and 1 L-R center.
Concerns about informed consent and about screening costs or reimbursement
were the most commonly cited barriers or challenges to implementation. Difficulty
convincing key stakeholders why UTS is important, general lack of knowledge by
key stakeholders, and communication barriers between stakeholders were
reported by institutional representatives from several M-R and L-R centers as
well as centers where outcomes data were not reported; in contrast, these were
selected as barriers to implementation at the non-academic H-R center, but none
of the other H-R centers.
The most commonly cited facilitators to implementation were collaborative
relationships that existed across departments, obtaining useful information from
other centers that had implemented UTS, and having an institutional champion
who worked hard to implement UTS (Table II-5). None of the institutional
representatives reported having protected time for planning UTS. There were no
apparent trends between implementation facilitators and patient reach. However,
all institutions except three L-R centers and the 1 non-academic H-R center
reported a greater number of implementation facilitators than barriers/challenges.
Heterogeneity in Implementation
UTS protocols were found to be heterogeneous among the different
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institutions (Table II-6). In reviewing the type of screening performed by each
institution (IHC versus MSI), who orders the screening, where the screening is
performed, or whether patients are consented or receive information prior to
screening, no clear patterns seemed to distinguish centers with high or low
patient reach. Most centers use immunohistochemical (IHC) testing in
conjunction with automatic reflex testing (i.e. BRAF or hypermethylation) to help
rule out Lynch syndrome in patients who screen positive on IHC (due to absence
of the MLH1 protein), but do not need to follow-up with genetic counseling or
germline testing unless their personal or family history would indicate otherwise.
In contrast to screening protocols, follow-up procedures when patients
have a positive tumor screen appeared to systematically differ by patient reach
(Table II-7). With the exception of two L-R centers, a Master’s trained genetic
counselor routinely receives information on patients who screen positive. In
addition, all H-R centers routinely have genetic counselors disclose positive
screening results to patients; two of the five M-R centers also have genetic
counselors routinely disclose positive screening results to patients. In contrast, all
L-R centers have various and even multiple types of non-genetics professionals
disclose screening results. Additionally, all L-R centers and three M-R centers
indicated that the primary mechanism by which germline testing is ordered
required that the patient’s physician refer the patient for genetic counseling.
Although none of the H-R centers indicated that referral was the primary
mechanism by which germline testing is ordered, two H-R centers do have
genetic counselors obtain referrals or enter referrals into the system on behalf of

30

the physicians.
Differences in procedures for handling negative tumor screening results
were also identified (Table II-8). Most centers include negative results as an
addendum in the pathology report, but do not report these results to patients.
Two centers send letters with results of negative screening to the patients. In
their letters they include a list of clinical characteristics that may indicate a
hereditary predisposition to cancer and recommend that patients see a genetic
counselor if any of these pertain to the patient or their family. A few primary
contact persons indicated that they will review negative screening results and
contact physicians if patients are young (i.e., under age 40 or 50) or if medical
records document any personal or family history features that might indicate a
hereditary predisposition.
System-level and Implementation Influences on Patient Reach
Potential barriers to high patient reach. Barriers to patient followthrough with genetic counseling or germline testing on closed-ended survey
items are summarized in Table II-9. Lack of insurance or financial means to pay
for genetic counseling or germline testing and patients are dealing with too many
concerns at the time of diagnosis were the most commonly checked barriers by
the institutional representatives. Only one H-R institution cited lack of referral as
a barrier; and at this center other health professionals occasionally disclose
positive screening results. Lack of patient referral was reported as a problem for
all M-R and L-R centers except the 2 M-R centers where genetic counselors
routinely disclose positive screening results. All L-R centers and over half of the
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M-R centers reported lack of understanding about the importance of germline
testing among health care providers as a barrier, but this was not cited as a
barrier by any of the H-R centers. Difficulty contacting patients was cited as a
barrier at three M-R centers including the two where a genetic counselor usually
discloses positive screening results and a third where the genetic counselor
contacts physicians to solicit referrals before following up with patients to arrange
genetic counseling and germline testing.
Potential facilitators for high patient reach. Due to the researchers’
uncertainty about potential facilitators to genetic counseling and germline testing,
facilitators were assessed using two open-ended questions asking participants
what they have found to help or what they think might help to increase patient
follow-through with genetic counseling and germline testing. The majority of
participants completed these open-ended questions; and their answers primarily
consisted of ways to reduce key barriers.
Two of the four H-R centers whose representative completed the question
about genetic counseling facilitators identified that meeting the patients at
another follow-up appointment (i.e. post-operative visit) was helpful; and the
other two indicated that having the genetic counselor contact patients facilitates
genetic counseling follow-through. The other H-R representative did not provide
a comment. Two representatives from M-R centers commented that increasing
the likelihood that physicians make referrals or that continuing education of
physicians regarding the importance of genetic counseling and germline testing
for patients with a positive screen would facilitate higher rates of patient follow-
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through with genetic counseling. All but one L-R center representative provided a
comment; and their responses all indicated that genetic counselors need to
contact patients directly and/or that physicians need more education on the
importance of genetic counseling and germline testing.
The only two H-R centers that commented on how to facilitate germline
testing indicated that improved insurance would facilitate testing. One of the M-R
centers again commented that physicians need more education. Another M-R
center suggested that physicians need to stress to the patient why it is important
that the patient follow-through when they make a referral. This respondent also
mentioned the need for better insurance coverage to facilitate testing. All four L-R
centers that responded to this question reiterated the need to get patients in for
genetic counseling or have the genetic counselor contact patients directly.
Implementation factors associated with high and low patient reach.
The presence and absence of conditions hypothesized to be associated with high
and/or low patient reach based on data from the initial survey are shown in Table
II-10. Although patterns of configurations are discernible based on this table,
QCA was used to systematically formulate concise solutions that show which
conditions are uniquely and consistently associated with high patient reach as
well as those associated with low patient reach. QCA solutions are listed as part
of a results summary table (Table II-11).
Maintenance at Six-month Follow-up
Although results from the initial and follow-up surveys were largely
consistent, several centers reported changes in patient reach at the six-month
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follow-up. By far the most striking case was one L-R institution where Reach
changed from 1.5 on the initial survey to 5 at six-month follow-up. This change in
patient reach coincided with the initiation of automatic reflex testing to rule out
some patients who did not need to be referred for genetic counseling because
they were unlikely to have Lynch syndrome. Another explanation postulated by
the primary representative for the increase in patient Reach included additional
physician education that occurred over time and a subsequent increase in
referrals. Although genetic counselors at this institution do not disclose screenpositive results to patients, a genetic counselor routinely attends a bi-weekly
case conference where each of the patients is discussed. At that time the
counselor reminds physicians of the need for and importance of referral for
patients with a positive tumor screen. Additionally, after the case conference, the
genetic counselor mails and faxes letters to one or more of the patients’ treating
physicians in order to reiterate what was discussed during the case conference
and provide directions on how to complete the patient referral. Once a referral is
received, the genetic counselor contacts the patients. Thus the genetic counselor
is highly involved in follow-up with the physicians and patients, despite not
disclosing positive screening results.
No other institutions reported changes in their protocols since the initial
survey. However three other institutions moved into or out of the M-R set due to
relatively small changes in patient reach. The institution with the second highest
patient reach score of the five original M-R centers shifted into the bottom of the
H-R set at six-month follow-up. Interviews with the primary contact and two other
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individuals involved with UTS at this institution suggested that their success may
be due to the extensive efforts of the genetic counselor who requests referrals
from one or more of the treating physicians for each patient with a positive
screen. Although she does not disclose screening results directly to patients she
reports typically being successful at obtaining a referral; she then calls the patient
to arrange follow-up and explain the importance of counseling and germline
testing. Additionally, it was clear from interviews that the genetic counselor, a key
administrator, the pathologist, and many (if not most) physicians at this institution
are supportive of UTS and have received a substantial amount of education
about hereditary colorectal cancer from various sources including the genetic
counselor, presentations at a regularly held multidisciplinary tumor board, and
two representatives from a laboratory that offers germline testing for Lynch
syndrome.
This institution, along with the aforementioned L-R institution where patient
reach improved after ensuring that BRAF reflex testing is automatic, both
demonstrate that if the environment is supportive, physicians are well educated,
and the genetic counselor takes on an extensive role to follow-up on all positive
tumor screening results, then patient reach can be relatively high even when
various different referring physicians disclose results of tumor screening to
patients. Nevertheless, despite improvements, patient reach scores at these two
centers remained lower than the six-month follow-up scores at the four academic
H-R centers where genetic counselors routinely disclose positive results.
The only H-R institution that is not an academic center reported a small
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decrease in patient reach, changing from 5 to 4.5 at six-month follow-up. Upon
interviewing the counselor at this institution, she indicated that her initial report of
the percentage of patients with a positive screen who had genetic counseling
was more reflective of the proportion of patients she talks to and offers genetic
counseling, but some patients who are concerned about costs of genetic
counseling, who have Medicaid (which does not cover the cost of genetic
counseling in that state), or who lack insurance do not actually come in for
genetic counseling even though she talks with them by phone. Furthermore, she
reported that a couple of physicians do not always let her disclose positive tumor
screening results to their patients.
The last institution to be reclassified was originally at the very bottom of
the M-R set in terms of patient reach. At six-month follow-up this institution would
have been reclassified into the L-R group due to a small decrease in patient
reach from 2.5 to 2. Notably, this institution did not share any of the
characteristics associated with H-R centers.
Results Summary and Proposed Model of High and Low Patient Reach
Table II-11 provides a summary of study results within the RE-AIM
framework. Consistent with the methodology employed in the multiple-case study
(Ragin, 1989), QCA solutions in conjunction with substantive knowledge obtained
at six-month follow-up were used to formulate a causal model to explain high and
low patient reach.
High patient reach. Institutions with high patient reach (H-R) have
instituted a combination of procedures to streamline UTS protocols and
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procedures, eliminate barriers to patient follow-through after a positive tumor
screen, and incorporate a high level of involvement of genetic professionals in
contacting physicians and/or patients. More specifically, H-R centers either do not
require patients who have a positive screen to be referred by another health care
provider for genetic counseling and germline testing or obtaining a referral is not
reported as a barrier because genetic counselors contact physicians to request
referrals as part of a standardized process that is agreed upon and/or supported
by the physicians. The need for referrals presumably adds complexity to the
procedures and causes patient reach to be highly contingent upon multiple
different health care providers' knowledge about the importance of genetic
counseling and germline testing as well as health care providers' actions to both
convey this importance to the patient and to make a referral.
In the current study, elimination of the need for referral altogether only
occurred at centers where genetic professionals receive and disclose positive
screening results to patients. This latter condition could be contributing to higher
patient follow-through because direct patient contact allows the genetics
professional to build rapport with the patients early on in the process and to
convey to patients the importance of genetic counseling and germline testing. At
four of the original H-R centers, disclosure of positive screening results was
almost always performed by a master’s trained genetic counselor. However, at
one H-R center, it has become increasingly common for patients to receive
positive results disclosure by a nurse who is knowledgeable about Lynch
syndrome, had years of experience working with and observing cancer genetic
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counseling sessions, and was considered highly qualified by the genetic
counselor.
Even if a genetic counselor or someone knowledgeable and well-trained in
cancer genetic counseling discloses positive screening results, patient reach is
logically contingent upon successfully contacting the patients. In the current
study, difficulties contacting patients were reported as a barrier to patient reach
by the two M-R centers where genetic counselors usually disclosed positive
tumor screening results to patients, but not at any H-R centers. Nevertheless, at
six-month follow-up, representatives from H-R centers admitted that patient
contact was occasionally a barrier or that patient contact used to pose a barrier;
however, three of these centers helped to overcome this barrier by having a
genetic counselor or nurse meet the patient at a follow-up appointment (i.e.,
surgical post-op appointment). Unfortunately this approach is not always feasible
due to limited genetics personnel or at centers where follow-up appointments
occur at several different locations that are not in close proximity to the
counselors (i.e., private practices). Interestingly, physical distance between the
locations of genetic counselors and post-op appointments was the impetus for
having a nurse, rather than master’s trained genetic counselor, disclose positive
screening results during post-op appointments at one of the original H-R centers.
Additional reasons why certain institutions may experience difficulty with
patient follow-through were elucidated during a follow-up interview with a genetic
counselor who personally discloses positive screening results to patients by
phone at one of the M-R institutions. Her institution is located in a
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socioeconomically disadvantaged city where several patients do not even attend
their post-operative appointments. Therefore, even if genetic counselors were
available to meet patients at the post-op appointments, patient reach may
continue to be problematic.
Finally, automatic reflex testing streamlines the tumor screening process
by eliminating the need to follow-up with a proportion of patients who do not likely
have Lynch syndrome and by eliminating additional steps required to order reflex
testing. The absence of automatic reflex testing may also partially explain why
the two M-R centers where genetic counselors disclose results reported lower
patient reach than H-R centers.
Low patient reach. Conditions associated with low patient reach (L-R)
provide additional insights into the potential relationships between
implementation and patient reach. One of the two conditional configurations
unique to L-R centers included the absence of having a genetics professional
disclose the results of positive tumor screening to patients in combination with
the presence of a higher ratio of implementation challenges compared to
implementation facilitators. The latter condition may be indicative of several
different types of organizational challenges or communication barriers that could
inhibit high patient reach.
Nevertheless, challenges during implementation are insufficient to prevent
relatively high patient reach from eventually being achieved. Evidence for this
comes from two participating institutions. The first is the non-academic center
that was originally classified in the H-R set, but dropped into the M-R set at six-
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month follow-up. Despite facing a number of implementation challenges, UTS
planning occurred during a period of over two years, several people worked very
hard to implement UTS, and patient reach was relatively low when first
implemented. Notably, two individuals from this institution commented that it
takes time for physicians to really see the benefits of UTS and/or to agree to
have the counselor disclose screening results to patients. Indeed a key
difference between this center and the L-R centers is that the genetic counselor
usually discloses screening results to patients. The other center that proves a
high ratio of implementation challenges to facilitators does not prevent
improvement in patient reach is the L-R center that was able to achieve relatively
high patient reach at six-month follow-up after streamlining their protocol.
As for the two academic L-R centers, neither of the representatives at
these institutions reported experiencing more challenges than facilitators during
the implementation process. However, these centers presumably have low
patient reach because the genetic counselors do not routinely receive a list of
patients who screen positive and they are subsequently unable to follow-up with
physicians or patients. Interestingly, the representative at one of these two
centers indicated in open-ended responses that patient follow-through was
higher under her old protocol when she used to receive a list of patients who
screened positive and could contact physicians to help ensure patients were
referred. Unfortunately the protocol was changed due to concerns that were
raised about patient privacy under the Health Insurance Portability and
Accountability Act (i.e., HIPAA).
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With the exception of these two L-R centers, all other institutional
representatives reported receiving key information on patients who had a positive
screen. A few of the representatives volunteered that they were given access to
this information by making the argument that genetics was part of the healthcare
team and/or that having one person review all results is critical for quality
assurance or to reduce legal liability for the institution. Recognizing the legal
liability issue, the L-R academic center that never provided patient results to the
genetics program began doing so just prior to the six-month follow-up. At that
time, the institutional representative confirmed that a number of patients had not
been referred. Furthermore, in at least one case, the screening result had not
been followed up on appropriately because BRAF testing had not been
completed. Subsequently automatic BRAF testing was initiated along with
changes that would allow the genetic counselor to disclose positive screening
results and directly follow-up with patients.
Discussion
To our knowledge this is the first study to quantify and compare outcomes
at multiple institutions that have implemented universal tumor screening (UTS)
programs, whereby tumors from all newly diagnosed patients with colorectal
cancer (CRC) are screened for Lynch syndrome. Two prior national surveys
revealed heterogeneity in the implementation of Lynch syndrome tumor
screening protocols across the U.S. and documented that a high proportion of
centers reported problems with patients not following through with genetic
counseling and germline testing after a positive screen (Beamer et al., 2012;
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Cohen, 2013). Additionally, two centers have now independently reported data on
their institutional experiences with UTS which revealed how patient reach
increased following changes to their institutional follow-up procedures so that
genetic counselors receive and disclose positive screening results to patients
and take an active role to initiate genetic counseling and germline testing (Heald
et al., 2013; Hampel, 2012).
Despite the longitudinal experiences at these two institutions, whether or
not genetic counselors received and disclosed the results of screen positive
tumors was not correlated with whether or not problems with patient followthrough were reported according to results from a recently published national
survey of cancer genetic counselors (Cohen, 2013). Importantly, differences in
patient follow-through were not quantified as part of that national survey and the
bivariate statistical approach did not allow for the possibility that having genetic
counselors disclose positive screening results was alone insufficient to prevent
difficulties with patient follow-through.
The current study expands upon these earlier studies and contributes
uniquely to the literature by documenting wide institutional variation in patient
reach and providing additional evidence for several key leverage points that are
likely to improve patient reach. The current study also provides potential insights
as to why a finding from the national survey by Cohen (2013) initially seemed
contradictory to the longitudinal experiences that have been reported. More
specifically, in the current study, genetic counselor disclosure of screen-positive
results was indeed insufficient to ensure high patient reach. However, this did not
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mean that the involvement of genetic counselors was unimportant. On the
contrary, results from the current study suggest that the involvement of genetic
counselors is part of a more complex recipe for achieving high patient reach; a
recipe in which difficulties with patient contact and other barriers such as the
need for a physician referral must be overcome.
There are several strengths to the current multiple-case study that support
data credibility, reliability and validity (Baxter & Jack, 2008; Yin, 2008) Baxter.
First, information gathered six months after the initial survey from institutional
representatives at 13 of the 15 institutions enabled confirmation of initial survey
results. In addition, member checks were initiated in which summaries of the
institutional data were shared with institutional representatives and reviewed for
accuracy during an interview or e-mail correspondence with 11 of the15
institutional representatives. Almost all institutional representatives reported
having good tracking systems in place and they were quite confident in the
accuracy of the patient reach numbers they reported. However, there were a
couple of centers where the representatives were not as confident in their
numbers because they admitted that germline testing could be performed by a
surgeon or oncologist without their knowledge. However, these representatives
did not believe this was occurring regularly.
One limitation of the study was the inability to verify or collect patient reach
data in a systematic fashion and necessitated the reliance on numbers reported
by each institutional representative. Other study limitations stemmed from an
imperfect system of categorizing institutions into three patient reach groups as
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well as fluctuations in patient reach that occurred over time. Nevertheless, with
the exception of the center where the protocol changed, institutions remained in
their classification group or there was limited movement of institutions into or out
of the M-R group. Furthermore, evidence for the proposed model is supported by
findings that M-R institutions with the highest patient reach shared more key
characteristics of H-R centers, whereas M-R centers with the lowest patient
reach tended to share features of L-R institutions.
Additional limitations related to the measures used in the current study
include the use of: data collected from a single individual at all but five of the
institutions; conditions that were measured as either absent or present; and
measures that failed to capture a number of nuances that distinguish between
institutions. Additional data from open-ended survey responses and at six-month
follow-up helped to elucidate some of these nuances. Thus, despite
measurement limitations, general patterns of conditions associated with high and
low patient reach among these cases remained evident in support of the
proposed models.
Although models generated from multiple case studies can serve as a
“vehicle for generalizing results” (Yin, 2008; p. 40), the ability to generalize
findings from this study may also be limited because the primary institutional
representatives were all genetic counselors and a fair number of centers that
participated in the current study are believed to be innovators and early adopters
(Rogers, 2004). Thus, the conditions identified as being important for high patient
reach in this study may not be feasible at all institutions and additional paths to
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success may need to be identified or forged. Therefore other institutions that
have achieved high patient reach should continue to be identified in order to
confirm, revise, or add to the institution-level mechanisms identified to be
associated with high patient reach in the current model.
Although the study design limits the ability to assert causality, the “causal”
model is strengthened given that two institutions have meticulously documented
improvements in patient reach after implementing some of the same follow-up
procedures identified to be important in the current study (Hampel, 2012, Leach
et al, 2013). Furthermore, one representative from a L-R institution in the current
study reported that patient follow-through was higher under her institution’s
former protocol where she received results of positive screens and could followup with physicians to help ensure a referral was made. Lastly, the L-R institution
that improved patient reach substantially at six-month follow-up streamlined their
procedures by instituting automatic reflex testing, thereby providing additional
support for this component of the complex causal model associated with high
patient reach. Together these experiences increase confidence that if institutions
model their UTS program after the H-R institutions in this study they have greater
odds of experiencing higher patient reach. However, simply modeling UTS
procedures after H-R institutions would not necessarily guarantee high patient
reach, especially if the patient population is difficult to contact or has a high rate
of uninsured or underinsured patients.
Finally, data available for the current study did not allow us to account for
the influence that differences in patient populations may have on patient reach.
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Nevertheless, patient-level factors were identified in the current study as barriers
to patient follow-through by institutional representatives, particularly those at
centers with streamlined procedures, a high level of involvement in follow-up by
genetic counselors, and removal of other system-level barriers. In order to
determine the relative influence of patient-level versus system-level effects on
patient outcomes, a large, multi-site effectiveness study that employs multilevel
modeling should be undertaken.
Utilization of the RE-AIM framework in planning, evaluating, and
presenting findings from future studies are needed to provide a more complete
assessment of the public health impact of UTS programs. Although RE-AIM
aided in planning and summarizing results, the current study was not designed to
fully characterize each RE-AIM dimension. For instance, practical considerations
necessitated limiting the definition of patient reach even though the true public
health impact of UTS lies in its ability to have broader reach through the
identification of family members with Lynch syndrome. Additionally, the current
study was not designed to assess the overall proportion or representativeness of
all U.S. institutions that have adopted UTS. Subsequently, data on adoption
using more representative sampling techniques is needed to determine the
overall public health impact of UTS, confirm that a disproportionately high
number of academic/ research institutions across the U.S. have adopted UTS as
suggested by findings from two national surveys (Beamer, et al 2012; Cohen,
2013), and determine whether those institutions that employ a master’s trained
genetic counselor are also more likely to adopt UTS compared to other

46

institutions. This additional information on adoption would be useful because
adoption patterns have the potential to increase disparities in the identification of
hereditary cancer among certain geographic regions or minority populations.
Conclusion
Universal screening of tumors from all newly diagnosed patients with
colorectal cancer is a promising method to achieve the Healthy People 2020
provisional objective: “Increase the proportion of persons with newly diagnosed
colorectal cancer [CRC] who receive genetic testing to identify Lynch syndrome”.
Current results provide evidence that universal tumor screening programs can be
successful. In addition, the study provides a model based on empirical data from
15 institutions that helps to further explain how implementation and system-level
factors can influence patient reach. This information could be used to inform
decision-making by stakeholders and potentially improve patient reach so that
the long-term goal of reducing high levels of morbidity and mortality associated
with hereditary cancer can be achieved.
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Table II-1. Summary of Steps Used to Perform Crisp-set QCA
csQCA steps

Application of QCA steps in the current study

(a) Outcome =patient reach
Defined as the percentage of patients who follow-through with genetic
counseling and germline testing following an abnormal tumor screen at
each institution. Operationalized based on two survey questions as
described in the manuscript.
(b) Assign
(b) Cases naturally fell into three groups or sets: high-reach (H-R); middichotomous set
reach (M-R); and low-reach (L-R). Cases with a patient reach score >5
membership scores for were included in the H-R set (coded as H-R=1). All other cases were
the outcome
coded H-R=0 and are referred to with a tilde to indicate they are not in
the high-reach set (i.e., ~H-R). For the second analysis, cases with a
patient reach score <2 were coded as L-R=1 and all others as L-R=0.
Step 1:
(a) Determine, define,
and operationalize the
outcome of interest

Step 2: Select Cases

Several high-reach and several low-reach institutions were needed.
However, to maximize both sample size and diversity in contextual
variables, all available cases that met the minimum a priori inclusion
criteria were used in the analysis.

(a) Based on theory and knowledge of the cases, the following
conditions were hypothesized to be associated with H-R when either
present (+) or absent (-): 1) reflex testing on a subset of tumors is
performed automatically to rule out patients with an initial positive
(b) Assign
screen who do not need genetic counseling and germline testing (+); 2)
dichotomous set
genetics professional discloses positive screening results to patients
membership scores for (+); 3) difficulty contacting patients was reported as a barrier (-); 4)
each condition
referral from another health care provider was reported as the primary
mechanism by which germline testing is conducted (-). Similarly, the
(c) Create a data
following conditions hypothesized to be associated with L-R when
matrix of scores for
either present (+) or absent (-) were selected based on theory and
conditions
knowledge of the cases: 1) number of barriers to implementation were
> to number of facilitators (+); 2) genetics receives a copy of all positive
screens (-); 3) genetics professional discloses positive screening
results to patients (-); 4) referral is needed as a primary mechanism by
which germline testing is ordered (+)
(b) All of the conditions were already dichotomized as either present=1
or absent=0 based on how they were asked as part of the survey.
(c) A data matrix was created by listing membership scores for the
outcome and key conditions for each case.
Step 3:
(a) Identify key
conditions

Step 4: Determine
None of the conditions were originally hypothesized to be necessary for
whether conditions are either high patient reach or low patient reach. Thus, a necessary
necessary for the
analysis was not conducted.
outcome
Step 5: Determine
whether certain
conditions are sufficient
for the outcome using
the “truth table”
approach

Although not necessary for the presence of high or low patient reach,
conditions may still be sufficient for the respective outcome either when
occurring alone or in combination with other conditions. Using fsQCA
2.0, two truth tables were created showing all possible configurations of
conditions for each of the two selected outcomes (i.e., H-R and L-R).
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Table II-1 (continued).
Step 6: Examine the
truth table and resolve
contradictions

No contradictions were identified.

Step 7: Use computer
software to generate
solutions through
multiple comparisons
of case configurations
in the truth table

Using fsQCA 2.0 software, a “Standard Analysis” was performed to
identify conditions associated with H-R and a second analysis was
performed to identify conditions associated with L-R. This software
uses the Quine-McCluskey algorithm (which is based on Boolean
simplification) to make multiple comparisons of case configurations
represented in the truth table and logically simplify the data. The idea
behind this minimization procedure is that if two configurations differ in
only one condition, yet produce the same outcome, then the condition
that distinguishes the two configurations can be considered irrelevant
to the outcome and removed to create a simpler expression.
During this process, input from the researchers was required to select
prime implicants and determine which simplifying assumptions were
tenable. The software then used this information to generate three
solutions (complex, parsimonious, and intermediate) with H-R as the
outcome; and in a separate analysis three solutions were generated
with L-R as the outcome. Only the intermediate or parsimonious
solutions are shown in Table II-11. The other solutions are available
from the primary author.

Step 8: Determine if
the influence of
conditions is
symmetrical

To determine if conditions associated with H-R are the same as those
associated with the absence of the outcome (~H-R), steps 4-6 were
repeated using ~H-R as the outcome. Similarly, these steps were
repeated using ~L-R as the outcome.

Step 9: Evaluate the
consistency and
coverage of the
solutions

For each of the analyses for the four outcomes (H-R, L-R, ~H-R, and
~L-R) the overall solution consistencies were 1; indicating that the
respective combination of conditions were consistently associated with
the respective outcome. For each analysis the overall coverage was 1;
indicating that all of the cases with the presence of the outcome fit the
solution.

Step 10: Interpret the
resulting solutions and
create causal models

Even when conditions are uniquely and consistently associated with an
outcome, it does not necessarily mean they cause the outcome.
However, these solutions in conjunction with theories, frameworks, and
details about the cases can be used to develop a causal theoretical
model that describes how the conditions might lead to the outcome.
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Table II-2. Demographic Characteristics of Institutions and their Respective Universal Tumor Screening
(UTS) Programs

Characteristics

Institution type
Academic / research institution
Non-academic institution
a
Designations
National Comprehensive
Cancer Network Member
NCI designated comprehensive
cancer center
NCI designated cancer center
How long ago screening was
initiated
Currently in the process

All
institutions
(N=23)

H-R
(n=5)

M-R
(n=5)

L-R
(n=5)

n (%)

n (%)

n (%)

n (%)

Outcome
not
reported
(n=8)
n (%)

10 (44)

4 (80)

2 (40)

2 (40)

2 (25)

13 (56)

1 (20)

3 (60)

3 (60)

6 (75)

4 (17)

2 (40)

1 (20)

1 (20)

0 (0)

6 (26)

3 (60)

2 (40)

1 (20)

0 (0)

2 (9)

1 (20)

0 (0)

0 (0)

1 (12.5)

3 (13)

0 (0)

0 (0)

0 (0)

3 (37.5)

1 (4)

0 (0)

0 (0)

0 (0)

1 (12.5)

3-5 months

1 (4)

0 (0)

0 (0)

0 (0)

1 (12.5)

6-12 months

5 (22)

0 (0)

2 (40)

2 (40)

1 (12.5)

>1 year

13 (54)

5 (100)

3 (60)

3 (60)

2 (25)

<10

1 (4)

0 (0)

0 (0)

0 (0)

1 (12.5)

10-29

3 (13)

1 (20)

0 (0)

0 (0)

2 (25)

30-49

5 (22)

0 (0)

3 (60)

1 (20)

1 (12.5)

50-69

2 (9)

1 (20)

0 (0)

1 (20)

0 (0)

70-89

3 (13)

0 (0)

1 (20)

2 (40)

0 (0)

90-109

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

>110
Uncertain/ not applicable

5 (22)

3 (60)

0 (0)

1 (20)

1 (12.5)

4 (17)

0 (0)

1 (20)

0 (0)

3 (37.5)

2 (9)

0 (0)

0 (0)

0 (0)

2 (25)

1-2

1 (4)

0 (0)

1 (20)

0 (0)

0 (0)

3-5

5 (22)

1 (20)

1 (20)

2 (40)

1 (12.5)

<3 months

# patients that have been screened
in last 6 months or less if recently
implemented UTS

# patients with a positive screen in
last 6 months or less if recently
implemented UTS
0

6-10

6 (26)

1 (20)

2 (40)

2 (40)

1 (12.5)

11-15

3 (13)

2 (40)

0 (0)

1 (20)

0 (0)

16-20

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

over 20
Uncertain / not applicable

2 (9)

1 (20)

1 (20)

0 (0)

0 (0)

4 (17)

0 (0)

0 (0)

0 (0)

4 (50)

a

Notes: NCCN and NCI designations are independent, but there is overlap and thus column
percentages
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a

Table II-3. Patient Reach and Effectiveness

b

All
institutions
(N=23)

H-R
(n=5)

M-R
(n=5)

L-R
(n=5)

Outcome
not
reported*
(n=8)

<10%

5 (22)

0 (0)

1 (20)

4 (80)

0 (0)

11-25%

2 (9)

0 (0)

0 (0)

1 (20)

1 (12.5)

26-40%

1 (4)

0 (0)

1 (20)

0 (0)

0 (0)

41-55%

3 (13)

1 (20)

2 (40)

0 (0)

0 (0)

Questions and response options

% patients with positive screen
that receive genetic counseling

56-70%

2 (9)

1 (20)

1 (20)

0 (0)

0 (0)

71-85%

3 (13)

2 (40)

0 (0)

0 (0)

1 (12.5)

>85%
Uncertain / not applicable

1 (4)

1 (20)

0 (0)

0 (0)

0 (0)

6 (26)

0 (0)

0 (0)

0 (0)

6 (75)

% patients with a positive screen
that pursue germline testing
<10%

5 (22)

0 (0)

0 (0)

5 (100)

0 (0)

11-25%

1 (4)

0 (0)

1 (20)

0 (0)

0 (0)

26-40%

4 (17)

0 (0)

3 (60)

0 (0)

1 (12.5)

41-55%

3 (13)

2 (20)

1 (20)

0 (0)

0 (0)

56-70%

1 (4)

1 (20)

0 (0)

0 (0)

0 (0)

71-85%

1 (4)

1 (20)

0 (0)

0 (0)

0 (0)

>85%
Uncertain / not applicable

1 (4)

1 (20)

0 (0)

0 (0)

0 (0)

7 (30)

0 (0)

0 (0)

0 (0)

7 (87.5)

Never

9 (39)

2 (40)

5 (100)

1 (20)

1 (12.5)

Rarely

3 (13)

3 (60)

0 (0)

0 (0)

0 (0)

Patients express concerns about
UTS

1 (4)

0 (0)

0 (0)

0 (0)

1 (12.5)

10 (43)

0 (0)

0 (0)

4 (60)

6 (75)

9 (39)

2 (40)

3 (60)

2 (40)

2 (25)

Rarely

6 (26)

2 (40)

1 (20)

2 (40)

1 (12.5)

Uncertain / not applicable

8 (35)

1 (20)

1 (20)

1 (20)

5 (62.5)

5 (22)

1 (20)

2 (40)

0 (0)

2 (25)

2 (9)

1 (20)

0 (0)

1 (20)

0 (0)

Sometimes
Uncertain / not applicable
Problems or unanticipated
outcomes
Never

Problems with reimbursement for tumor
screening
Never
Rarely

3 (60)
3 (60)
4 (80)
6 (75)
Uncertain / not applicable
16 (70)
a
Notes: Percentage of patients receiving genetic counseling and germline testing after a positive tumor
screen.
b
Negative or unanticipated outcomes or problems related to universal tumor screening ( UTS).
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Table II-4. Reasons for Universal Tumor Screening (UTS) Adoption
a

All
Institutions
b
(N=22)

H-R
(n=5)

n (%)
M-R
(n=4)

Recommended by EGAPP

15 (68)

3 (60)

4 (100)

3 (60)

5 (62.5)

Improve identification of patients with LS

21 (91)

5 (100)

4 (100)

5 (100)

7 (87.5)

Reduce cancer mortality

12 (55)

4 (80)

1 (25)

2 (40)

5 (62.5)

“Keep up” with other institutions

10 (45)

1 (25)

3 (75)

2 (40)

4 (50)

Survey question

Generate increased revenue
Benefit relatives of patients with LS
Other

c

L-R
(n=5)

Outome not
reported
(n=8)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

17 (77)

5 (100)

3 (75)

4 (80)

5 (62.5)

2 (9)

a

1 (25)

1 (12.5)

Notes: Column percentages do not add to 100 because multiple options could be chosen.
One primary contact person representing a M-R institution did not answer these questions because
she was not involved in the program when UTS was first implemented.
c
Other included: “We felt it was becoming standard of care”; “Our umbrella organization recommended”
b
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Table II-5. Implementation Barriers and Facilitators

Survey question

All
Instituti
ons
(N=22)

H-R
(n=5)

n (%)
M-R
(n=4)

3 (14)

2 (40)

0 (0)

a

L-R
(n=5)

Outcome
not
reported
(n=8)

1 (20)

0 (0)

Implementation Barriers
No real barriers or challenges
Lack of stakeholder knowledge about LS

6 (27)

0 (0)

2 (50)

2 (40)

2 (25)

Concerns about reimbursement / costs

14 (64)

2 (40)

2 (50)

3 (60)

7 (87.5)

Difficulty deciding on screening method

4 (18)

0 (0)

0 (0)

2 (40)

2 (25)

Disagreement on how to handle results

3 (14)

0 (0)

1 (25)

2 (40)

0 (0)

Difficulty convincing key stakeholders why UTS
is important

9 (41)

0 (0)

1 (25)

1 (20)

7 (87.5)

Challenge to arrange time for stakeholders to
meet
Concerns about need for informed consent

12 (55)

2 (40)

2 (50)

2 (40)

6 (75)

16 (73)

3 (60)

2 (50)

4 (80)

7 (87.5)

One or more individuals tried to prevent UTS

1 (4.5)

1 (1)

0 (0)

0 (0)

0 (0)

Communication barriers existed between
stakeholders
Whether to include option to 'opt out' was
debated
Lack of laboratory expertise/resources
Perception that other screening method was
bettercor more cost effective
Other

7 (32)

0 (0)

1 (25)

2 (40)

4 (50)

6 (27)

1 (20)

1 (25)

2 (40)

2 (25)

2 (9)

0 (0)

0 (0)

0 (0)

2 (25)

1 (4.5)

1 (20)

0 (0)

0 (0)

0 (0)
1 (12.5)

Implementation Facilitators
High risk multidisciplinary colorectal cancer clinicclnic5 (23)
Prior to UTS, already routinely screening a
9 (41)
subset of tumors
13 (59)
“Institutional champion” worked to implement

4 (80)

4 (100)

3 (60)

2 (25)

Collaborative relationships across departments

16 (73)

5 (100)

4 (100)

3 (60)

4 (50)

Support from high-level administrator or
supervisor

12 (55)

2 (40)

3 (75)

3 (60)

4 (50)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

14 (64)

3 (60)

3 (75)

4 (80)

4 (50)

Multiple planning meetings helped facilitate

10 (45)

2 (40)

2 (50)

3 (60)

3 (37.5)

Institution willing to try something new to
improve patient care

9 (41)

3 (60)

1 (25)

3 (60)

2 (25)

12 (55)

1 (20)

0 (0)

3 (60)

8 (100)

Protected time provided for planning
Useful information obtained from other institution

Total # Barriers > Total # Facilitators
a

2 (40)

0 (0)

1 (20)

2 (25)

2 (40)

2 (50)

3 (60)

2 (25)

Notes: Column percentages do not add to 100 because multiple options could be chosen.
b
One primary contact person representing a M-R institution did not answer these questions because she
was not involved in the program when UTS was first implemented.
c
“Physicians did not realize that this had become a national and community care standard; our
pathologists were under a spending freeze and not allowed to bring on new tests; concern about
Medicare fraud and reimbursement in general; misunderstanding the cost of testing (physicians thought it
was much higher than it is)”
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Table II-6. Variability in Tumor Screening Protocols
All
institutions
a
( N=22)

H-R
(n=5)

M-R
(n=5)

L-R
(n=5)

Outcomes
not
reported
(n=7)

3 (14)

0 (0)

2 (40)

1 (20)

0 (0)

Colorectal tumor resections

12 (55)

5

2 (40)

2 (40)

3 (43)

Colorectal tumor biopsies and resections

7 (32)

0 (0)

1 (20)

2 (40)

4 (57)

Endometrial tumors

14 (64)

5

2 (40)

3 (60)

4 (57)

Type of tumors screened
Colorectal tumor biopsies

Method of screening colorectal tumors
Immunohistochemical (IHC) testing

4 (18)

0 (0)

2 (40)

2 (40)

1 (14)

IHC with automatic reflex testing

14 (64)

4(80)

3 (60)

1 (20)

5 (71)

Microsatellite Instability (MSI) testing

1 (4.5)

0 (0)

0 (0)

0 (0)

1 (14)

MSI with automatic reflex testing

2 (9)

0 (0)

0 (0)

2 (40)

0 (0)

1 (4.5)

1 (20)

0 (0)

0 (0)

0 (0)

8 (36)

1 (20)

5 (100)

0 (0)

2 (29)

Pathologist

6 (27)

2 (40)

0 (0)

4 (80)

0 (0)

Surgeon

2 (9)

0 (0)

0 (0)

0 (0)

2 (29)

Genetic professional

1 (4.5)

1 (20)

0 (0)

0 (0)

0 (0)

Other / unknown

5 (23)

1 (20)

0 (0)

1 (20)

3 (43)

Internal lab

15 (68)

3 (60)

4 (80)

4 (80)

4 (57)

External lab (send out)

6 (27)

2 (40)

1 (20)

0 (0)

3 (43)

Part internal and part external

1 (4.5)

0 (0)

0 (0)

1 (20)

0 (0)

6 (27)

2 (40)

2 (40)

0 (0)

2 (29)

5 (23)

1 (20)

1 (20)

0 (0)

3 (43)

1 (4.5)

0 (0)

1 (20)

0 (0)

0 (0)

MSI then IHC with automatic reflex testing
Who orders screening
Nobody, automatic

Where screening is performed

Prescreening information, consent, “opt out”
Information on screening provided to patient
before results given (usually or always)
Patient informed consent obtained before
screening (verbal or written)
Option to “opt out” provided
a

Notes: One institution with no outcomes reported was still in the process of implementing UTS and
had not determined their protocol or procedures.
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Table II-7. Variability in Follow-up Procedures when Patients Screen Positive for Lynch Syndrome
All
institutions
a
( N=22)

H-R
(n=5)

M-R
(n=5)

L-R
(n=5)

Outcome
not
reported
(n=7)

Who discloses positive screen
Genetics professional only

9 (41)

4 (80)

1 (20)

0 (0)

4 (57)

Both genetics and non-genetics
Professionals

3 (14)

1 (20)

1 (20)

0 (0)

1 (14)

Non-genetics professional(s) only

10 (45)

0 (0)

3 (60)

5 (100)

2 (29)

Telephone call

8 (36)

3 (60)

1 (20)

0 (0)

4 (57)

At patient visit

6 (28)

2 (40)

2 (40)

1 (20)

1 (14)

Unknown / up to non-genetics
Professional

8 (36)

0 (0)

2 (40)

4 (80)

2 (29)

Patient contacted directly by GC

8 (36)

3 (60)

1 (20)

0 (0)

4 (57)

Physician refers patient
Genetic counselor calls physician to
get referral or permission and then
contacts patient directly

10 (45)

0 (0)

3 (60)

5 (100)

2 (29)

2 (40)

1 (20)

0 (0)

0 (0)

Unknown

1 (4.5)

0 (0)

0 (0)

0 (0)

1 (14)

18 (82)

5 (100)

4 (80)

5 (100)

5 (71)

3 (14)

0 (0)

1 (20)

0 (0)

2 (29)

How positive results are usually disclosed

Primary mechanism germline testing is
ordered

3 (14)

Who provides pretest discussion of
germline testing
Genetics professional
Both genetics and non-genetics
Professionals

1 (4.5)
0 (0)
0 (0)
0 (0)
0 (0)
Uncertain / not reported
a
Notes: One institution with no outcomes reported was still in the process of implementing UTS and
had not determined their protocol or procedures.
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Table II-8. Variability in Follow-up Procedures when Patients Screen Negative
All
institutions
a
( N=22)

H-R
(n=5)

M-R
(n=5)

L-R
(n=5)

Outcome
not
reported
(n=7)

3 (14)

1 (20)

1 (20)

0 (0)

1 (14)

1 (4.5)

0 (0)

1 (20)

0 (0)

0 (0)

1 (4.5)

0 (0)

0 (0)

1 (20)

0 (0)

15 (68)

4 (80)

3 (60)

4 (80)

4 (50)

2 (9)

0 (0)

0 (0)

0 (0)

2 (25)

3 (14)

0 (0)

1 (20)

0 (0)

2 (25)

Some patients are NOT identified as high
risk

6 (27)

1 (20)

2 (40)

3 (60)

0 (0)

No formal protocol exists

5 (23)

0 (0)

1 (20)

1 (20)

3 (43)

According to physician

7 (32)

1 (20)

2 (40)

2 (40)

2 (25)

Depending on patient scenario

4 (18)

2 (40)

2 (40

0 (0)

0 (0)

Usually

6 (27)

1 (20)

1 (20)

0 (0)

4 (57)

Sometimes

11 (50)

4 (80)

3 (60)

3 (60)

1 (12.5)

1 (4.5)

0 (0)

0 (0)

0 (0)

1 (12.5)

4 (18)
9 (41)
0 (0)

1 (20)
4 (80)
0 (0)

1 (20)
2 (40)
0 (0)

0 (0)
3 (60)
0 (0)

2 (29)
0 (0)
0 (0)

How negative screening results are handled
Patients informed in a letter or follow-up
visit
Non-genetics professional informs patient
Up to ordering physician
Results included in pathology report or
chart but patient is not informed
Uncertain
Protocol for high risk patients with negative
b
screen
Uncertain

Protocol varies

Referred to genetics

Rarely
Additional genetic screening or testing is
considered
Often
Sometimes
Rarely

c
3 (14)
0 (0)
2 (40)
0 (0)
1 (12.5)
Other
a
Notes: One institution with no outcomes reported was still in the process of implementing UTS and
had not determined their protocol or procedures.
b
High risk patients typically have one or more of the following characteristics: cancer under age 40,
multiple colon polyps, previous history of colorectal cancer or other cancers, multiple family members
with colorectal or other cancers.
c
Other included the following: GC reviews pathology reports looking for other risk factors; The patient
is encouraged to contact genetics if they have other red flags that are listed in the patient letter that is
generated; addendum on path report re: IHC states to still refer pt to genetics if they are high risk.
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Table II-9. Barriers to Genetic Counseling or Germline Testing Following a Positive Screen for Lynch
Syndrome
All
institutions
a
( N=19)

H-R
(n=5)

M-R
(n=5)

L-R
(n=5)

Outcome
not
reported
(n=4)

15 (79)

5 (100)

3 (60)

4 (80)

2 (50)

12 (63)

1 (20)

3 (60)

5 (100)

3 (75)

Healthcare provider fails to see
b
importance of counseling/testing

11 (58)

0 (0)

3 (60)

5 (100)

3 (75)

Patients fail to see importance of
b
counseling/testing

13 (68)

4 (80)

3 (60)

2 (40)

4 (100)

Inconvenient for patients to arrange a
separate counseling appointment

6 (32)

2 (40)

3 (60)

1 (20)

0 (0)

Inconvenient for patients to provide
blood or saliva sample for testing

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

4 (21)

0 (0)

3 (60)

0 (0)

1 (25)

Patients dealing with too many issues at
b
initial diagnosis

15 (79)

4 (80)

4 (80)

3 (60)

4 (100)

Patients don't want to face possibility of
b
risks to family

8 (42)

0 (0)

3 (60)

3 (60)

2 (50)

Patient lacks insurance / financial
b
difficulties
Patient never referred

b

Difficulty contacting patients

b

Patients are concerned about genetic
2 (10.5)
1 (20)
0 (0)
0 (0)
1 (25)
b
discrimination
a
Notes: Three institutions have not started screening and one institution has had no positive screens.
b
Two questions were combined so that centers are counted as yes if the representative indicated that the
item was a barrier to germline testing OR was a barrier to genetic counseling.
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Table II-10. Data Matrix Depicting Patient Reach Scores and Conditions
Patient
reach
a
score
Institution

# of
barriers > #
of
b
facilitators

Automatic
reflex
b
testing

Genetics
usually
receives
copy of all
positive
screening
b
results

Genetics
professional
usually
discloses
positive
screen
b
result

Difficulty
contacting
patients to
arrange GC
or germline
b
testing

Physician
refers
patient for
germline
b
testing

High
reach
centers
(H-R)
H1

6

X

X

X

H2

5.5
5
5
5

X
X
X
X

X
X
X
X

X
X
X
X

X
X
X
X
X

X

H3
H4
H5

X

Mid reach
centers
(M-R)

4
3.5
3
3
2.5

M1
M2
M3
M4
M5

X
X
X

X

X
X
X

X
X
X

Low reach
centers
(L-R)

1.5
1
1
1
1

L1
L2
L3
L4
L5

X

X
X

X
X

X
X

X

a

X
X
X
X
X

Notes: Patient reach was calculated by averaging the ordinal response options from two
questions estimating the percentage of patients who follow-through with genetic counseling and
percentage who follow-though with germline testing after a positive screen.
b
The presence of each condition is indicated with a “X”.
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Table II-11. Overall Findings from Applying the RE-AIM Framework
RE-AIM
Dimension
Description
Reach
Percentage of
screen positive
patients who
follow-through
with germline
testing and
genetic
counseling

General Findings

• Patient Reach was highly
variable across centers
(ranging from <10% to
>85%)
• High and Low Patient
Reach were consistently
associated with specific
combinations of
conditions related to
Implementation

Findings specific to HighReach (H-R)
Institutions

Findings specific to LowReach (L-R)
Institutions

• Patient reach
(>56-70%)
• H-R centers have all of
the following unique
conditions based on
results from QCA:

• Patient reach
(< 25%)
• L-R centers have either of
the following unique
conditions based on QCA
results:

1)

GC does NOT disclose
results AND implementation
barriers > facilitators

2)
3)
4)

Automatic reflex testing
is performed on subset
of screen positive
tumors
genetic counselor (GC)
discloses positive
results
contacting patients is
NOT a major barrier
obtaining a referral from
physician is NOT a
barrier

Effectiveness
• Institutional
• H-R centers adapted to
The impact of an
compensate when faced
representatives report
intervention on
patients rarely or never
with challenges
outcomes
have expressed concerns • Early on or prior to UTS,
(including
related to UTS
two H-R centers
potential
recognized that
• Challenges have been
negative effects)
encountered at both H-R
pathologists were doing
screening on subset of
and L-R institutions
patients, but physicians
• Only two centers reported
were neither reporting out
rarely experiencing
the result to patients nor
difficulties with
referring patients for
reimbursement for tumor
genetic counseling
screening; others did not
know or reported no
reimbursement issues
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OR
GC does NOT receive
screening results

• L-R centers reported
difficulties with patient
reach, and many reported
challenges to making
changes
•
Potential negative
outcomes included:
• Concern that failure to
disclose results, refer to
genetic counseling, or
order germline testing is a
liability for institutions
and/or physicians
• Concerns raised by one
L-R center that reflex
tests are interpreted
incorrectly or not seen on
pathology addendum

Table II-11 (continued).
Adoption
• All but one of the five H-R • Two of the five L-R
• Academic centers have
The absolute
institutions are academic
centers are academic
previously been found to
number,
be more likely to adopt
/research institutions
institutions
proportion, and
UTS (Beamer et al., 2012)
representativene • At most centers genetic
ss of institutions
counselors were the
and staff who
source of the idea for
currently offer a
UTS, but multiple
program
stakeholders were often
involved in making the
Characteristics
decision to adopt UTS.
of intervention
may increase the
likelihood of
• Common reason for UTS
adoption
adoption are to improve
identification of Lynch
syndrome patients and
benefit family members
• Cost was a key
characteristic in the
decision to adopt UTS
Implementation • Successful
Consistency of
implementation required
delivery, time
buy in from others
and cost of the
besides genetic
program, and
counselors.
what adaptations • Substantial heterogeneity
to the program
in UTS implementation
are made in
exists across institutions
various settings. • Several of the differences
are NOT consistently
associated with patient
reach including method of
screening IHC versus
MSI, and whether results
are disclosed by phone or
in person.
• Common barriers and
facilitators to
implementation were
identified (Table II-5)

Several adaptations have
been made to streamline the
process and overcome
barriers:
• Automate reflex testing to
reduce the number of
patients needing
counseling and germline
testing
• GCs disclose results
• Eliminate the need for a
referral from another
health care provider
entirely
• Lack of referral overcome
at a couple of H-R centers
by GC actively contacting
physicians to obtain
permission to contact
patient directly and log in
the referral if needed
• At least 3 H-R centers
found that meeting the
patient at a follow-up
appointment was
successful because it
removes additional
barriers.
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• The number of
implementation barriers
was greater than or equal
to the number of
facilitators for three of the
L-R centers
• L-R center
representatives want the
ability to contact patients
directly, but physicians are
resistant.
• L-R centers where GC
actively solicits a referral
from physicians are reliant
on physician believing
and expressing the
importance of genetic
counseling and germline
testing to the patient.
• Not logistically feasible for
GCs to meet patients at
follow-up appointments at
some institutions.

Table II-11 (continued).
Maintenance
How the
intervention and
its effects
changed over
time.

• Some centers have
• At least 3 H-R centers
• Several L-R centers have
modified their protocol
report having changed
run into barriers in trying
over time such as making
their procedures over time
to change their protocols
BRAF or
to streamline the process
or procedures
hypermethylation testing
and increase involvement • At least one L-R center
automatic in a subset of
of GCs, which resulted in
has since changed their
tumors.
higher patient reach
procedures as a result of
• Centers have also
the current study
changed their follow-up
procedures over time.
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SECTION III: QUALITATIVE COMPARATIVE ANALYSIS (QCA): A HYBRID
METHOD FOR IDENTIFYING KEYS TO SUCCESSFUL PROGRAM
IMPLEMENTATION
Abstract
Qualitative comparative analysis (QCA) is a hybrid analytic technique that
combines elements of quantitative and qualitative research. Despite several
relative advantages of QCA, this article illustrates that it has not been widely
adopted by mixed methods researchers and has been slow to diffuse through
health research channels. Applying the Diffusion of Innovations Theory, potential
reasons for limited diffusion and adoption of QCA are explored. Finally, to reduce
perceived complexity of QCA, data obtained as part of a multiple-case study is
used to demonstrate how to perform QCA and illustrate several associated
limitations and benefits.
Introduction
Use of what is still sometimes dichotomized into qualitative and
quantitative research methods in complimentary or comparative ways has
become widely accepted in several social science disciplines (Bazeley, 2009). In
contrast, analytic techniques that fuse or blend qualitative and quantitative
methods are not routinely utilized (Ragin, 1999). Qualitative comparative analysis
(QCA) is a method developed by Charles Ragin over 25 years ago (Ragin, 1989)
to bridge the qualitative and quantitative research gap. Although rooted within a
qualitative research paradigm (Ragin, 1989), QCA takes a practical approach to
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understanding complex, real-world situations and therefore may more accurately
fall within what Morgan (2007) promotes as a pragmatic paradigm. QCA is a
hybrid technique that cannot easily be dichotomized as either “qualitative” or
“quantitative”, yet many criticisms that researchers have leveled at QCA originate
from what researchers have referred to as the “paradigm wars” (Morgan,
2007).Other criticisms are based on the perceived complexity or lack of relative
advantage of QCA over other methods (Hawley, 2007).
Despite criticisms QCA is extremely versatile. For example, researchers
have used QCA to analyze both unstructured data (e.g., interview transcripts)
and structured data (e.g., responses to closed-ended survey questions) (Kahwati
et al., 2011; Shanahan, Vaisey, Erickson, & Smolen, 2008; Weiner, Jacobs,
Minasian, & Good, 2012). In addition, QCA can be used to analyze small,
medium, and large sample sizes. Furthermore, QCA has been used in
conjunction with various types of research designs.
Although QCA has many applications, it was initially developed for case
study research in order to derive solutions that contain a list of one or more
factors that when present or absent are uniquely associated with the presence or
absence of an outcome. Other methods of performing multiple cross-case
comparisons exist, but as the number of cases increases, systematic
comparisons across multiple cases may not be logistically feasible without using
QCA software. Additionally, journals that publish primarily “quantitative” research
may look more favorably on QCA due to its mathematical approach and ability to
quantitatively assess the overall merit of the solutions.
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QCA may also be particularly useful in theory development and model
building by determining which combinations of conditions are likely to be
'necessary' and/or 'sufficient' for a particular outcome of interest to occur. For
example, knowledge about a positive health behavior may be necessary, but it is
rarely sufficient to ensure that individuals will perform the health behavior.
According to the Health Belief Model (Janz & Becker, 1984), individuals often
require a combination of the following factors in order to perform a positive health
behavior: 1) knowledge about the behavior; 2) high level of perceived threat to
their health if they fail to perform the behavior; 3) high-level of perceived benefits
to performing the behavior; and 4) low-level of perceived barriers to performing
the behavior. The ability to identify this type of “causal complexity” is one reason
why QCA can be useful when generating or testing theoretical models (Ragin,
1989).
Structural equation modeling (SEM) is a more commonly used analytic
technique that also allows researchers to incorporate multiple variables and test
theoretical models. Although Hawley (2007) has argued that SEM would be
easier to use than QCA, SEM requires large samples and the results are
interpreted in a reductionist manner by considering the influence that one
variable has on the outcome while holding all other variables in the model
constant. Furthermore, unlike QCA, SEM and other inferential statistical analyses
typically fail to consider the possibility of equifinality, whereby different
combinations of factors can lead to the same outcome (Ragin, 1989; Rihoux &
Ragin, 2009). For example, the combination of knowledge about how to perform
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a behavior and a high level of perceived benefits may be sufficient to elicit a
positive health behavior among a subset of women who do not face a particular
barrier; however, additional or different factors may be needed to elicit the
behavior among other individuals. If a key factor is relevant to the outcome for
only a subset of individuals, the correlation between the factor and outcome is
weakened, potentially causing what may be a key factor to be deemed
insignificant if inferential statistics are used. Additionally, inferential statistics
assume that the influence of variables is symmetrical even though factors that
lead to the consistent performance of a health behavior may be different from
factors that cause poor adherence to the behavior.
Despite several relative advantages to QCA it remains unclear why this
hybrid analytic technique has not diffused more widely across academic
disciplines. In addition, the extent to which QCA has been adopted among
various populations is not well documented. Thus, the first objective of this article
is to describe QCA’s lack of both widespread diffusion through health research
channels and adoption among mixed methods researchers. To achieve this
objective, results are presented from a literature search of articles indexed by
PubMed and articles published in the Journal of Mixed Methods Research. The
second objective is to discuss several potential reasons for the slow diffusion and
adoption rates of QCA. Subsequently, to promote the broader goal of active QCA
dissemination, the final objective is to increase knowledge of QCA. To achieve
the final objective we demonstrate how to perform QCA and illustrate several
limitations and benefits of QCA using data obtained as part of a multiple-case
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study.
Diffusion and Adoption of QCA
The index term “qualitative comparative analysis” was used for online
searches of articles indexed by both PubMed and the Journal of Mixed Methods
Research (JMMR). The abstracts of all articles that were retrieved after typing in
the search term were reviewed. Several of the complete articles identified in
PubMed and all of the articles identified in JMMR were reviewed. Articles were
initially counted if the authors employed QCA in an original research study or
illustrated the use of QCA using hypothetical data. However, to be more inclusive
the literature search was extended to include any articles where the author(s)
described or mentioned QCA.
Only 25 articles meeting the original criteria had been indexed by PubMed
as of March 2013. Of these, all but one reported data from an original study. After
extending the criteria, an additional PubMed article was included. This article
described QCA and other methods of synthesizing qualitative and quantitative
evidence. No articles published in the Journal of Mixed Methods Research
(JMMR) met the initial search criteria, but 7 met the expanded criteria. The single
article in JMMR to focus solely on QCA was a book review by Hawley (2007). An
additional six articles mentioned QCA during discussions on various topics
including: integration in mixed methods research (Bazeley, 2009; Bazeley &
Kemp, 2012); mixed research synthesis (Sandelowski, Voils, Leeman, &
Crandell, 2012); triangulation strategies in Comparative Public Policy Research
(Wolf, 2010); qualitative data analysis tools (Onwuegbuzie, Bustamante, &
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Nelson, 2010); or data analysis as a process of interpretation (Van Ness, Fried, &
Gill, 2011).
Although limited in scope, this literature search substantiates the assertion
that QCA has been slow to diffuse into health research. The findings also suggest
that the rate at which QCA is being used in health research may be increasing
over time. Support for this latter assertion comes from the finding that half of the
QCA articles identified in PubMed were published between the years 2010
through 2012; and nine of these articles were published after 2011.
Diffusion of Innovations Theory (Rogers, 2003) provides several possible
explanations for these findings. First, an innovation takes time to diffuse within
and across social groups and the rate of diffusion is dependent on
communication channels. QCA was developed in the late 1980's by Charles
Ragin, a Sociologist who studies politics (Ragin, 1989). QCA therefore had to
spread across members of those disciplines through a limited number of
communication channels into other disciplines. Second, QCA is viewed by some
researchers as being incompatible with the methodological paradigm to which
they may still subscribe (Barbour, 1998). “Qualitative” researchers might view
QCA as incompatible because it is based on Boolean algebra and a computer
program is typically used to aid the researcher in identifying solutions which are
then evaluated using quantitative measures of solution consistency and
coverage. Whereas “quantitative” researchers may view QCA as incompatible
because it entails an iterative process of evaluating data, typically from a nonrandom sample, and requires researchers to use their substantive knowledge of
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the cases to make several 'subjective or interpretive' decisions at multiple points
during the analysis (Rihoux & Ragin, 2009). Third, knowledge about how QCA
works may be limited as there appear to be a relatively small number of
researchers who have been trained to conduct QCA. Fourth, performing QCA
was complex until computer software became widely available and automated
much of the process. Nevertheless, Hawley (2007) has pointed out that the
unique terminology used in QCA also makes learning this technique inherently
difficult. Furthermore, additional complexities have arisen as researchers have
developed several different types of QCA or other related configurational
comparative techniques since QCA was first introduced (Rihoux & Ragin, 2009).
Given that mixed methods researchers generally take a pragmatic approach
that transcends the positivist/constructivist or quantitative/qualitative “paradigm
wars” (Morgan, 2007), findings which suggested that few mixed methods
researchers have adopted QCA were somewhat surprising. Hawley’s (2007)
description of QCA in the book review published in JMMR suggests that high
perceived complexity and lack of relative advantage over other techniques may
explain the slow diffusion and low adoption rates. Therefore, to reduce
complexity, the following section provides a stepwise account of how QCA was
instrumental as an initial step in a multiple-case study designed to evaluate the
implementation processes and effectiveness of universal tumor screening
programs at several hospitals and cancer centers.
Background on Universal Tumor Screening (UTS) for Lynch syndrome
Occurring in approximately 1 out of every 35 patients with colorectal cancer
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(Hampel et. al., 2008), Lynch syndrome is the most common cause of hereditary
colorectal cancer (CRC). The identification of Lynch syndrome among CRC
patients and subsequently their family members is critical as Lynch syndrome
confers a 50-70% lifetime risk of colorectal cancer (CRC) (Barrow et al., 2008;
Hampel, Stephens, et al., 2005; E. Stoffel et al., 2009) as well as increased risks
for secondary cancers and several other types of malignancies (Barrow et al.,
2009; Hampel, Stephens, et al., 2005; Stoffel et al., 2009; Watson et al., 2008).
Universal tumor screening (UTS) is the process whereby tumors from all
newly diagnosed CRC patients are screened to identify those patients who may
have Lynch syndrome. Details about UTS have been described elsewhere
(Bellcross et al., 2011). Over 35 cancer centers and hospitals across the U.S
have implemented UTS, but substantial variability in protocols and procedures
exist across institutions (Beamer et al., 2012; Cohen, 2013). Outcomes also vary
across institutions as noted by large differences in patient reach, which is defined
here as the percentage of patients with a positive screen who follow-through with
genetic counseling and germline testing (Beamer et al., 2012; Lynch, 2011; South
et al., 2009). In view of the fact that patient reach is critical to the successful
identification of family members with Lynch syndrome and the prevention or early
detection of cancers, a multiple-case study was initiated to identify institutionlevel factors that might contribute to the wide variability in patient reach.
Methods
Study Design
A multiple-case study was initiated during the fall of 2012. The rationale
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for employing a multiple-case study design was based on the following (adapted
from Yin, 2008): (a) the key objective was to provide a detailed understanding of
a complex phenomenon (i.e. UTS program implementation and patient reach) for
which there is limited data; (b) the purpose was to answer how and why
questions; (c) the behavior of those involved could not be manipulated; and, (d) it
was hypothesized that contextual conditions would be relevant to variations in
patient outcome .
Conceptual Framework
The conceptual framework for the multiple-case study was based on the
RE-AIM evaluation framework and the Consolidated Framework for
Implementation Research (CFIR) (Damschroder et al., 2009; Glasgow et al.,
1999). The RE-AIM evaluation framework is comprised of five evaluation
dimensions (Reach, Effectiveness, Adoption, Implementation, and Maintenance)
that assist with identifying factors for multi-level comprehensive evaluations
(Glasgow, Klesges, et al., 2006). In the current study the RE-AIM evaluation
dimensions were defined as follows:
•

Reach: the percentage of patients with a positive tumor screen who followthrough with genetic counseling and germline genetic testing.

•

Effectiveness: the impact of UTS on outcomes (including potential negative
effects).

•

Adoption: the absolute number, proportion, and representativeness of
institutions and staff who implement UTS.
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•

Implementation: the consistency of delivery, time and cost of the UTS
program and what adaptations are made in various settings

•

Maintenance: the effects of UTS over time with regard to both the institution
and patients.
RE-AIM was selected based on the expectation that it would increase the

quality, speed, and impact of stakeholder efforts to more effectively translate
universal tumor screening for Lynch syndrome into practice. The CFIR provided a
framework for exploring factors within the Implementation dimension of RE-AIM
in order to gain a detailed understanding of UTS implementation and identify
factors that might influence patient reach. Table III-1 lists the five CFIR
dimensions and several constructs within each (Damschroder et al., 2009).
Study Participants
Fifteen representatives for the Lynch Syndrome Screening Network
(LSSN) who worked at institutions that perform UTS were recruited through the
LSSN listserv. These participants completed an initial survey and met the
minimum a priori inclusion criteria as follows: 1) institutions must have been
performing Lynch syndrome screening on tumors from all newly diagnosed
colorectal cancer (CRC) patients for at least six months; and 2) institutional data
on patient follow-through with genetic counseling and genetic testing was shared
by the institutional representative.
Measures
The initial online survey was developed using the RE-AIM and CFIR
frameworks as well as the researchers’ knowledge of institutional variations in
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UTS protocols. Information collected included: a) length of time UTS had been
performed at the institution; b) details on the implementation process, protocol,
and procedures (e.g., facilitators and barriers to implementation; method of
screening; who receives and/or discloses positive screening results; who
discusses germline testing with the patient; and when, where and how screening
results are disclosed and germline testing is discussed); c) percentage of patients
who undergo genetic counseling and percentage who undergo germline testing
that were used to calculate the outcome (i.e., patient reach); and, d) additional
factors within CFIR domains that may have helped facilitate or impede
implementation or patient reach.
Crisp-Set Qualitative Comparative Analysis (csQCA)
In the current study QCA was used to identify facilitators, barriers or other
institution-level conditions that were unique to centers with high patient reach and
those that were unique to centers that did not report high patient reach. Crisp-set
QCA (csQCA) was chosen for two main reasons: 1) the conditions assessed as
part of the survey were dichotomous; and 2) csQCA is simpler to perform and
interpret than other QCA methods. Steps used to perform csQCA are
summarized in Table III-2. These steps are somewhat fluid because QCA is an
iterative process that allows for modifications as researchers gain additional
information and insights into the cases. Briefly, steps 1-3 are needed to prepare
data for use in QCA. Step 4 involves deciding which type of analyses to perform
(i.e., necessary and/or sufficiency analyses). Steps 5-9 describe how to
determine which conditions are sufficient for the outcome. Step 10 is the step in
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which solutions are interpreted to propose “causal models”.
Step 1: Outcome operationalization and set membership scoring.
Patient reach was operationalized using two questions assessing the percentage
of patients who follow-through with genetic counseling and percentage who
follow-through with genetic testing. Response options were the same for both
questions: 1 = <10%; 2 = 11-25%; 3 = 26-40%; 4 = 41-55%; 5 = 56-70%; 6 = 7185%; and 7 =>85%. The ordered categorical response options for the two
questions were averaged to create a “patient reach” score ranging from 1-7. After
arranging cases in descending order by patient reach, two natural breaks in
patient reach scores were identified (Table III-3, column 1). The first 5 cases were
grouped into a “high-reach” set (H-R), the second 5 cases into a “mid-reach” set
(M-R) and the last 5 into a “low-reach” set (L-R). Natural breaks were chosen to
ensure that cases with very similar values were grouped together in the H-R and
L-R groups, as has been recommended (Rihoux & De Meur, 2009)
One key limitation of cs-QCA is that all variables, including the outcome,
need to be dichotomized so that the case either belongs to the set (dummy
code=1) or does not belong to the set (dummy code=0). In the current study the
threshold for inclusion in the H-R set was a patient reach score >5. All other
cases did not belong in the H-R set. In QCA cases not in a set are referred to by
placing a tilde before the abbreviation (i.e., ~H-R).
Step 2: Case selection. Although QCA has been used to analyze data from
random samples, it was developed to compare cases that are carefully selected
using one of a number of different selection procedures (Gerring, 2007). In the
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current study at least a few institutions with high patient reach and a few
institutions with low patient reach were needed to determine why large
discrepancies in patient reach might exist across institutions. To maximize both
sample size and diversity in contextual variables, all cases that met minimal
inclusion criteria were included and dichotomized according to membership in the
H-R set.
Step 3: Selection of key conditions. Although many CFIR constructs were
measured to assist in gaining an in-depth understanding of each case, only a
relatively small number of key factors could be used in QCA for two main
reasons. First, the number of possible configurations increases exponentially
according to an increase in the number of contextual variables; and this
increases the likelihood that there will be a number of configurations for which
there are no cases (i.e.,remainders). Second, when the ratio of conditions to
cases is high, the probability of getting a solution that just by chance appears
sound even when the model is misspecified increases (Marx & Dusa, 2011).
Guidelines from a simulation study by Marx and Dusa (2011) were therefore
followed by limiting analyses to no more than 4 conditions so that
misspecification of the model would most likely lead to contradictory cases (i.e.,
cases with the same configuration of conditions, but different outcomes).
In the current study, processes related to results disclosure and discussion of
germline testing as well as the individuals involved with these processes were
hypothesized to have the most direct influence on patient reach. As a first step in
narrowing down the number of conditions to consider for QCA, a computer
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spreadsheet of responses from each institutional representative was created by
the researchers with cases organized from highest to lowest patient reach.
Frequencies of responses were then generated for each reach category (i.e., HR, M-R, L-R). Each contextual factor was evaluated by the researchers in terms
of how it might relate to patient reach independently or in combination with other
factors. During the selection process the researchers created a data matrix
(Table III-3) of membership scores for the factors considered for inclusion in
QCA. The data matrix was then reviewed by the researchers to narrow down the
list of conditions. This process consisted of a series of decisions described in
more detail below whereby similar pairs of conditions were combined to create
composite conditions (presented in Table III-3); and several conditions were then
deleted from Table III-3.
General differences between patient reach groups were found with regard to
who discloses abnormal (positive) screening results to patients. All
representatives of the H-R institutions reported that a genetics professional
discloses abnormal screening results to patients. There were also two M-R
institutions where a genetics professional discloses positive results. This
condition was included in QCA and is referred to as (gen_prof_disclose_screen).
How positive results were disclosed (i.e., by phone or at a follow-up visit) was
mixed across the patient reach groups; and was subsequently deleted from the
data matrix.
Several conditions that could act as barriers to follow-through with genetic
counseling and germline testing were also considered (Table III-3). Obtaining a
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referral from a healthcare provider as the primary mechanism for the patient to
receive germline testing was reported by most ~H-R institutions and was coded
as (referral_barrier) for use in QCA. Similarities were noted in the pattern of
responses for other barriers to genetic counseling and barriers to germline
testing. Therefore analogous pairs of barriers were combined using the Boolean
operator “OR”, which indicates Boolean addition. As an example, the new
composite condition (difficulty_contact_pt) was “present” if (1) the institutional
representatives indicated that difficulty contacting patients to set up genetic
counseling was a barrier “OR” (2) that difficulty contacting patients to set up
germline testing was a barrier. Whereas if neither of these barriers were reported,
then the new composite condition was considered absent. Conditions used to
create the composite barriers were maintained in the data matrix for possible
inclusion in QCA.
Nearly all institutions have genetics professionals provide pretest counseling
prior to germline testing. Consequently, this condition was deleted from the data
matrix because unless a condition varies, it cannot be associated with the
outcome (Rioux ch 3). The revised data matrix contained three conditions
selected for inclusion in QCA (gen_prof_disclose_screen, referral_barrier, and
gen_directly_contacts_pt) as well as several additional barriers to consider
including. Once complete, the principal investigator saved the data matrix (which
was in an Excel spreadsheet) as a .csv file because this type of file can be
opened and read by fsQCA2.0 software using the point and click FILE menu
(“Citing fs/QCA,” n.d.).
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Step 4: Decide which analyses to run. While the focus of QCA is often on
identifying conditions that are sufficient for the presence of an outcome,
researchers have suggested that sufficiency analysis be preceded by identifying
potential necessary conditions (Schneider & Wagemann, 2010). A necessary
condition is one that occurs in all cases that demonstrate the presence of the
outcome. There are many instances where a theory or previous empirical
observations would lead researchers to hypothesize that certain conditions may
be either 1) necessary and sufficient for an outcome or 2) necessary but
insufficient for an outcome. However, in the current study, none of the conditions
were originally hypothesized to be necessary in all cases. Therefore, only
analyses to determine sufficiency were performed.
FsQCA 2.0 software developed by Charles Ragin was chosen to run the
sufficiency analyses as it is freely available for download online at
http://www.u.arizona.edu/~cragin/fsQCA. A manual detailing how to use this
software is also available at the same website. However, to help decrease
perceived complexity, basic steps performed in the current study are described
below. Also, to reduce complexity, key terms are defined and illustrated
throughout the step-by-step description, but QCA jargon is used sparingly.
Step 5: Determine if conditions are sufficient. Using fsQCA software,
“Truth Table Algorithm” was selected under the ANALYSE > Crisp sets menu. The
outcome and conditions were chosen as prompted in the pop-up window before
clicking the “run” button. The software then created a truth table similar to the
replica in Table III-4. Each row of the truth table shows a configuration of
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conditions and lists the number of cases that share that configuration. As is often
the case, several configurations had no case examples (rows E-H); and these
are called remainders (Rihoux & Ragin, 2009).
Step 6: Examine the truth table and resolve contradictions. The objective
when creating a truth table is to ensure that all cases that share a configuration
also share the same outcome. The consistency score for each row indicates the
proportion of cases in the respective configuration that belong to the H-R set (i.e.,
outcome is present). When the consistency is above .9 it indicates that the
configuration of conditions is almost always associated with the presence of the
outcome (Rihoux & Ragin, 2009). In the initial truth table (Table III-4) generated
for the current study, rows A and B have consistency scores of 0.8 and 0.5,
respectively. This suggests that these rows represent configurations where the
outcome is inconsistent. Specifically, row A represents a configuration that is
shared by 4 H-R cases and 1 M-R case; and row B represents a configuration
that is shared by 1 H-R case and 1 M-R case. The need to resolve such
contradictions often occurs in QCA (Marx & Dusa, 2011). Contradictions provide
researchers an opportunity to gain additional understanding of the cases and
serves as a mechanism for building models (Ragin, 2004). For example,
contradictions could indicate that a key condition is missing from the model.
To resolve the contradictions, the research team went back to the reduced
data matrix to examine the cases and select another key barrier. Logic dictated
that difficulty contacting patients after a positive screen (difficulty_contact_pt)
would directly lower patient reach. Once this condition was added, the new truth
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table contained no contradictions (Table III-5). The consistency scores for the first
two configurations (rows A-B) were 1 and the consistency scores for the other
configurations (rows C-F) were 0. Thus, the outcomes of the first two
configurations (rows A-B) were coded 1 by the researchers and the outcomes of
all the other configurations for which there were cases (rows C-F) were coded 0.
Table III-5 does not show configurations (rows) for which there were no cases
(i.e., remainders), as these configurations were deleted before running a
standard analysis.
Step 7: Use software to generate solutions. Although the final truth table
(Table III-5) is quite revealing in terms of which contextual conditions are
associated with high patient reach, it can be helpful to have the computer
software generate three solutions (complex, parsimonious, and intermediate),
particularly when truth tables are large, multiple different configurations are
associated with the same outcome, or fuzzy-set QCA (in which outcomes and/or
conditions are not dichotomized) is used instead of crisp-set QCA. As part of the
current study, the researchers ran a “Standard Analysis” by clicking this option in
the menu at the bottom of the window. The computer software used the QuineMcCluskey algorithm (which is based on Boolean simplification) to make multiple
comparisons of case configurations and logically simplify the data ("Citing fs/QCA
2.0," ; Rihoux & Ragin, 2009). The idea behind this minimization procedure is
that if two configurations differ in only one condition, yet produce the same
outcome, then the condition that distinguishes the two configurations can be
considered irrelevant to the outcome and removed to create a simpler
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expression.
The fsQCA2.0 software determines three solutions with input from the
researchers. The first is the complex solution, which is determined by the
computer through minimizing only those configurations for which cases are
available (i.e., remainders are not used to make simplifying assumptions). When
there are multiple conditions or multiple configurations leading to the presence of
the outcome, this solution may be so complex that it is not very useful. This is
why the software generates a parsimonious and intermediate solution with input
from the researchers.
To determine the parsimonious solution, the software makes assumptions
about what the outcome might be for the configurations that do not have cases
(i.e., remainders) and uses these remainders to further simplify the expression.
During the minimization process in the current study, a “prime implicant chart”
appeared on the screen. A prime implicant chart appears when there are multiple
ways of simplifying a solution. In order to obtain the most parsimonious solution,
researchers must choose one prime implicant to cover each configuration in the
chart. In the notation for prime implicants, the tilde (~) indicates the condition is
absent. An asterisk (*) indicates Boolean “AND” (meaning that the conditions
joined by * must both be present). The prime implicant chart in the current study
showed that the configurations for the H-R cases could be simplified in two
different ways: (a) ~referral_barrier * ~difficulty_contact_pt; or (b)
gen_prof_disclose_screen * ~difficulty_contact_pt. Despite an inability to make a
compelling argument for choosing one prime implicant over the other, in the
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current study the researchers chose the first prime implicant so that the software
would continue the analysis. In some instances (such as the current study) the
prime implicant chosen to create the parsimonious solution does not influence
the researchers’ final interpretation because they will reject the parsimonious
solution if they cannot use logic and knowledge of the topic to substantiate all of
the simplifying assumptions upon which the parsimonious solution is based.
Even though it is often the case that assumptions underlying the
parsimonious solution cannot all be reasonably justified by the researchers,
certain assumptions might be easy for the researchers to substantiate to create
an intermediate solution; these are referred to as “easy counterfactuals”(Ragin,
2004). As part of the analytic process, the computer software automatically opens
another window so that researchers can decide which simplifying assumptions
are reasonable. In order for the software to generate the intermediate solution in
the current study, the following logic-based assumptions were selected:
1. Absence of each barrier (i.e., ~difficulty_contact_pt and
~referral_barrier) will contribute to high patient reach (H-R), but the
presence of each barrier will not contribute to H-R.
2. Involvement of a genetic professional in the disclosure of screening
results (gen_prof_disclose_screen) and in directly contacting the
patient to arrange genetic counseling and testing
(gen_directly_contacts_pt) will contribute to high patient reach, while
lack of involvement by genetics professionals will not be associated
with H-R.
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Step 8: Determine if the influence of conditions is symmetrical. The
combinations of factors that are associated with high patient reach may differ
from those associated with less successful outcomes. In the real world there are
often more pathways that lead to the failure of a health program than there are
leading to successful programs. Because QCA is not based on correlations, it
does not assume that conditions will have a symmetrical influence. To illustrate
this point, QCA steps 4-6 were repeated using the absence of high patient reach
(~HR) as the outcome. During this analytic process the latter of the following two
prime implicants was chosen to be consistent with the initial analysis: (a)
~gen_prof_disclose_screen or (b) referral_barrier. Assumptions made to
generate the intermediate solution were the inverse of the assumptions chosen
for the first analysis (i.e., presence of barriers would contribute to ~H-R, and
absence of involvement by genetics professionals would contribute to ~H-R).
Step 9: Evaluate consistency and coverage scores for the solutions.
Consistency and coverage are interpreted differently when determining whether
conditions are necessary versus when determining if they are sufficient. When
performing sufficiency analyses, solution consistency should be close to 1 in
order for researchers to conclude that the combination(s) of conditions in the
solution is(are) almost always associated with the outcome of interest (Ragin,
2004). A solution coverage of 1 indicates that all cases with the outcome of
interest are represented or covered by at least one of the combinations of
conditions in the solution. When there are multiple combinations of conditions
within a solution, raw and unique coverage can be used by the researcher to
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assess the importance of each combination of conditions and the extent to which
a case is covered by more than one combination of conditions.
Step 10: Interpret the resulting solutions and create causal models.
Even if conditions are consistently associated with an outcome, it does not mean
they cause the outcome. However, researchers can use solutions in conjunction
with theory, conceptual frameworks, and detailed knowledge about the cases to
develop causal models that help unpack potential mechanisms leading to the
outcome (Ragin, 2004). In the current study the researchers used their
substantive knowledge of UTS and theoretical framework (CFIR) to interpret the
solutions and piece together key conditions to create tentative models that were
intended to be modified as additional details about the cases were obtained.
Results
Table III-6 lists the complex, parsimonious, and intermediate solutions
from the first csQCA analysis performed to determine institutional and
implementation conditions associated with high patient reach (H-R). The
parsimonious solution was rejected because all of the simplifying assumptions
could not be substantiated. The model was based on the intermediate solution,
which in this case, happened to be the same as the complex solution. This
intermediate solution is interpreted as meaning that all of the following three
conditions are together sufficient for high patient reach: 1) a genetics
professional discloses the results of positive tumor screening to patients; AND 2)
a referral from another health care provider is not the primary mechanism for the
patient to receive testing; AND 3) difficulty contacting patients is not a barrier.
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This combination of three conditions is unique only to the H-R cases, which is
why the consistency score is 1. The coverage score of 1 verifies that that this
combination of three conditions characterizes (covers) all 5 cases that belong to
the H-R set.
The bottom of Table III-7 presents all three solutions for the absence of the
outcome (i.e.,~H-R). The three solutions were all different; thus, the causal model
was based on the intermediate solution because it was not too simple, but made
more logical sense than the complex solution. The intermediate solution for
absence of high reach (~H-R) revealed two distinct sets of conditions that were
both associated with the absence of the outcome (Table III-6). The intermediate
solution can be interpreted as meaning that difficulty contacting patients who
screen positive is sufficient but not necessary to prevent high patient reach.
Alternatively the following three conditions are together sufficient to prevent high
patient reach: genetic professionals do not disclose positive screening results,
AND genetic counselors do not contact patients directly to arrange genetic
counseling and testing, AND health care provider referral is the key mechanism
for patients to receive genetic testing. The consistency of the intermediate
solution was 1, indicating there were no contradictory cases. The coverage score
of 1 indicates that all cases without high-reach (~H-R ) fit one or both of the
combinations in the solution. The raw coverage for the first configuration (i.e.,
difficulty contacting patients) was 0.3, indicating that the presence of this barrier
distinguished 3 of the 10 ~H-R cases from the H-R cases. The unique coverage
for this configuration was lower (0.2) because 1 of the 3 institutions with difficulty
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contacting patients also shared the second combination of conditions that
uniquely covered the other ~H-R cases (Table III-6).
Discussion
QCA was used as part of a multiple-case study to formulate tentative
causal models explaining high variability in patient reach across institutions that
have implemented a universal tumor screening program. Nevertheless, models
may be overly simplistic; and findings do not preclude the possibility that other
combinations of factors could lead to high patient reach at institutions that were
not part of the current study. Indeed one advantage of QCA is that it can identify
multiple different “recipes” for success. Subsequently, as more information about
each institution is obtained and additional cases are identified it is likely that the
model will be expanded and modified.
QCA was also useful in identifying additional research questions to be
explored as part of the ongoing multiple-case study. For example, why did
representatives from the five high-reach centers report no difficulty contacting
patients or obtaining a referral from a health care provider? In addition, what may
prevent stakeholders at low or mid-reach centers from: (a) altering the UTS
procedures so that genetics professionals contact patients to disclose positive
screening results; and (b) eliminating the need for a referral? Insights gained
from QCA have informed the creation of semi-structured interview guides and
follow-up surveys to answer further questions that were identified during the
process of QCA, obtain information on the nuanced differences between UTS
programs at different institutions, and possibly reveal other key conditions that
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may contribute to patient reach as part of a continuing iterative process to better
understand how implementation factors influence patient reach.
Many criticisms that researchers have leveled at QCA originate from what
Morgan (2007) referred to as the “paradigm wars”. For instance, researchers who
view QCA using a “quantitative” lens might consider performing multiple analyses
on the same data to be problematic. However, multiple analyses are consistent
with the iterative nature of QCA. Furthermore, determining which factors are
associated with both the presence and absence of the outcome is considered
good practice by QCA researchers (Schneider & Wagemann, 2010) as it can
provide broader or more in depth insights into the underlying mechanisms and
can add to the credibility of the proposed models. Several other concerns that
critics raise such as the use of purposive sampling and the iterative nature of
QCA are also unproductive from a pragmatic perspective. Nevertheless, several
more practical limitations are worth mentioning.
One limitation of QCA is the potential for measurement error and case
misclassification. The current study was based on data that were self-reported by
a single individual from each institution and may contain inaccuracies or bias.
Furthermore, the use of natural breaks for set membership scoring does not
prevent the possibility of misclassification. For example, an open-ended survey
response from the institutional representative of a mid-reach (M-R) center
revealed that this institution may instead belong in the high-reach (H-R) set due
to a unique difference in this institution’s protocol that may have led to an
underestimation of patient reach. This institution had the highest patient reach
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among the M-R set and was similar to H-R institutions in several ways. However,
the representative reported difficulty contacting patients as a barrier. Given that
difficulty contacting patients was sufficient to prevent H-R under the current
model, reclassification of this institution into the H-R set would unveil a
contradiction that would need to be resolved through modifications to the model
based on additional information. For instance, it is possible that the genetic
professional at this M-R institution has relatively few difficulties contacting
patients. Unfortunately, the extent to which patient contact is difficult was not
captured in the survey measure.
The measurement issue described above illustrates a limitation of crispset QCA, whereby conditions and outcomes must be dichotomized. In contrast,
fuzzy-set QCA overcomes this limitation by allowing the researcher to code the
outcome and/or conditions on a calibrated scale from 0 to 1. This fuzzy-score
represents the extent to which a case falls within the set rather than being fully in
or fully out of a set (Rihoux & Ragin, 2009). The resulting advantages of fsQCA
over csQCA include the ability to maintain variation and to more accurately
represent social reality when outcomes and/or conditions are not truly
dichotomous. Although bias and measurement error may remain a concern,
using fsQCA may lead the researcher to assign a set membership score that is
off by only a small degree rather than misclassifying it into the opposing set; and
this is expected to have a smaller impact on the results. Unfortunately, the
advantages of fsQCA also make it more complicated than csQCA.
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Conclusion
Although rooted in a qualitative paradigm, QCA may appeal to researchers
or journal editors that prefer “quantitative” methods because QCA: (a) takes a
logical and mathematical approach; (b) can be used to analyze small, medium,
and large data sets; (c) provides a tool for identifying causal complexity and
equifinality; (d) allows the researcher to generate solutions (with the aid of a
computer program); and (e) calculates measures to evaluate the merit of the
solutions (i.e., solution consistency and coverage). Given that QCA confers
several advantages over other techniques, one of the purposes of this article is to
encourage its active diffusion across mixed methods research channels. This
article has attempted to reduce perceived complexity of QCA by illustrating how
to perform the simplest type of QCA (i.e., crisp-set QCA). The example presented
here demonstrated how QCA aids in systematically identifying and simplifying
key factors (i.e., conditions) that are uniquely associated with an outcome of
interest. Although the use of cross-sectional data inhibits the ability to
demonstrate causation, QCA provides solutions that researchers can use to
propose logical mechanisms by which key factors may act together to facilitate or
impede outcomes. The iterative nature of QCA allows the researcher to gain an
in-depth understanding of multiple cases and alter “causal” models as additional
information is discovered.
QCA and other techniques that fuse qualitative and quantitative methods
(Bazeley, 1999) provide an opportunity to help in bridging the gap that “paradigm
wars” have created. Ultimately, we believe researchers should first consider how
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resources or other factors may limit the type of data they can feasibly obtain to
answer their research questions and then choose one or more of a wide variety
of analytic tools based on how well-suited the tools are for answering their
specific research questions. To that end, QCA is another tool that mixed methods
researchers may find useful.
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Table III-1. Five Domains of the Consolidated Framework for Implementation Research
(CFIR)
CFIR Domain

Description and Examples of Associated Constructs

Intervention

Characteristics of the intervention such as complexity, cost, and relative
advantage.

Inner setting

Structural, political, and cultural contexts through which implementation
proceeds. Includes organizational structure, social architecture,
communication/networks, and implementation climate & readiness.

Outer Setting

Economic, political, and social context in which an organization resides.
Includes the extent to which the organization has an accurate knowledge
of patient needs, billing & reimbursement, funding constraints, and ties to
external organizations.

Individuals
involved

Individuals in the inner or outer setting can promote the implementation
process and alter program effectiveness via their actions which are
influenced by motivations, attitudes, etc.

Implementation
Process

Processes include actions that lead to implementation, protocol and
procedures, and ongoing reflection.
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Table III-2. Summary of Steps Used to Perform Crisp-set Qualitative Comparative Analysis
(csQCA)
csQCA steps

Application of QCA steps in the current study

Step 1:
(a) Determine, define,
and operationalize the
outcome of interest
(b) Assign
dichotomous set
membership scores for
the outcome

(a) Outcome =patient reach
Defined as the percentage of patients who follow-through with genetic
counseling and germline testing following an abnormal tumor screen at
each institution. Operationalized based on two survey questions as
described in the manuscript text.
(b) Cases naturally fell into three groups or sets: high-reach (H-R); midreach (M-R); and low-reach (L-R). Cases with a patient reach score >5
were included in the H-R set (coded as H-R=1). All other cases were
coded H-R=0 and are referred to with a tilde to indicate they are not in
the high-reach set (i.e., ~H-R).

Step 2: Select Cases

Several high-reach and several low-reach institutions were needed.
However, to maximize both sample size and diversity in contextual
variables, all available cases that met the minimum a priori inclusion
criteria were used in the analysis.

Step 3:
(a) Identify key
conditions
(b) Assign
dichotomous set
membership scores for
each condition
(c) Create a data
matrix of scores for
conditions

(a) As part of the multiple-case study data on many contextual factors
were collected to gain an in-depth understanding of the cases. Based
on theory and careful review of the cases, factors (i.e., conditions) for
possible inclusion in QCA were selected as detailed in the manuscript
text.
(b) Although this is often not the case, all of the conditions were already
dichotomized as either present=1 or absent=0 based on how they were
asked as part of the survey.
(c) A data matrix (Table III-3) was created by listing membership scores
for the outcome and key conditions for each case.

Step 4: Determine
which analyses to run

To determine whether conditions are necessary for the presence of an
outcome, a separate analysis is recommended. However, none of our
conditions were hypothesized to be necessary in all cases of high or
low patient reach. Thus, only sufficiency analyses were conducted.

Step 5: Determine if
certain conditions are
sufficient for the
outcome using the
“truth table” approach

Although not necessary for the presence of high patient reach,
conditions may be sufficient for the outcome (i.e. H-R) either when
occurring alone or in combination with other conditions. Using freely
available software (fsQCA 2.0), a truth table was created showing all
possible configurations of conditions (Table III-4).

Step 6: Examine the
truth table and resolve
contradictions

The first row of the truth table (Table III-4) shows the configuration that
contains 4 H-R cases as well as 1 M-R case (consistency =.8). The
second row contains 1 H-R and 1 M-R case (consistency = .5) To
resolve these contradictions, an additional condition (diff_contact_pt)
was added to create a revised the truth table (shown in abridged form
in Table III-5).
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Table III-2 (continued).
Step 7: Use computer
software to generate
solutions through
multiple comparisons
of case configurations
in the truth table

Using fsQCA 2.0 software, a “Standard Analysis” was performed to
identify conditions associated with H-R. This software uses the QuineMcCluskey algorithm (which is based on Boolean simplification) to
make multiple comparisons of case configurations represented in the
truth table and logically simplify the data. During this process input from
the researchers was required to select prime implicants and determine
which simplifying assumptions were tenable. The software then used
this information to generate three solutions (complex, parsimonious,
and intermediate) for H-R.

Step 8: Determine if
the influence of
conditions is
symmetrical

To determine if conditions associated with H-R are the same as those
associated with the absence of the outcome (~H-R), steps 4-6 were
repeated using ~H-R as the outcome.

Step 9: Evaluate the
consistency and
coverage of the
solutions

The overall solution consistencies were 1 for each of the two outcomes
evaluated (H-R and ~H-R), indicating that the respective combination of
conditions were consistently associated with the respective outcome.
The overall coverage for each solution was 1; indicating that all of the
cases with the presence (or absence) of the outcome were explained
(covered) by the respective solution.

Step 10: Interpret the
resulting solutions and
create causal models

Even when conditions are uniquely and consistently associated with an
outcome, it does not necessarily mean they cause the outcome.
However, these solutions in conjunction with theories, frameworks, and
details about the cases can be used to develop a causal theoretical
model that describes how the conditions might lead to the outcome.
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Table III-3. Data Matrix of Conditions Considered for Inclusion in QCA
Patient
Set
Outreach member come
a
b
score
-ship
c
(H-R)

Conditions
d

e

F

G

h

i

j

k

l

m

n

o

6

H-R

1

1

0

1

0

0

0

0

0

0

0

1

1

5.5

H-R

1

1

0

1

0

0

0

0

0

0

0

1

0

5

H-R

1

1

1

0

0

0

0

0

0

0

0

1

1

5

H-R

1

1

1

0

0

0

0

0

0

0

0

1

1

5

H-R

1

1

1

0

0

0

0

0

0

0

0

1

1

4

M-R

0

1

0

1

0

0

0

0

1

1

1

1

0

3.5

M-R

0

0

-

-

1

1

0

1

1

1

1

1

0

3

M-R

0

1

1

0

0

0

0

0

1

1

1

1

1

3

M-R

0

0

-

-

1

1

0

0

0

0

0

1

0

2.5

M-R

0

0

0

1

1

1

0

1

0

0

0

1

0

1.5

L-R

0

0

0

1

1

1

1

1

0

0

0

1

0

1

L-R

0

0

-

0

1

0

1

1

0

0

0

1

0

1

L-R

0

0

1

0

1

1

1

1

0

0

0

1

0

1

L-R

0

0

-

-

1

0

1

1

0

0

0

0

0

1
L-R
0
0
1
1
1
1
0
0
0
1
0
a
Notes: Patient reach was calculated by averaging the ordinal response options from two
questions estimating the percentage of patients who follow-through with genetic counseling and
percentage who follow-though with germline testing after a positive screen.
b
Natural break points were used to initially categorize institutions into three sets based on patient
reach score (H-R=high reach; M-R=medium reach; L-R=low reach).
c
The outcome for the initial QCA was high patient reach (presence=1, absence=0).
d
Genetic professional discloses positive screening results (presence=1, absence=0, ).
e
Positive screening results disclosed by telephone (presence=1, absence=0, don’t know = “-“).
f
Positive screening results disclosed at follow-up visit (presence=1, absence=0, don’t know = “-“).
g
Obtaining/receiving a referral from a non-genetics health care provider is primary mechanism for
genetic testing (presence=1, absence=0)
h
Health care providers often fail to see the importance of genetic counseling after a positive
screen (presence=1, absence=0).
i
Health care providers often fail to see the importance of germline testing after a positive screen
(presence=1, absence=0).
j
Combined condition based on Boolean addition “OR” (presence of condition “h” OR condition
“i”=1, absence of both conditions=0).
k
Difficulty contacting patients to set up genetic counseling after a positive tumor screen
(presence=1, absence=0).
l
Difficulty contacting patients to arrange germline genetic testing after a positive screen
(presence=1, absence=0).
m
Combined condition based on Boolean addition (presence of condition “k” OR condition “l”=1,
absence of both=0).
n
Genetic professional is responsible for pre-test discussion of germline testing with the patient
(presence=1, absence=0).
o
Genetic professional contacts patient directly to set up pre-test counseling and germline testing
(presence=1, absence=0).
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Table III-4. Initial Truth Table of All Potential Conditional Configurations
a

e

Row

gen_prof_
disclose_
b
screen

referral_
c
barrier

gen_directly_
d
contacts_pt

# cases fitting
configuration

H-R
(outcome)

Raw
consistency

A

1

0

1

5

0.8

B

1

0

0

2

0.5

C

0

1

0

8

0

D

0

1

1

(remainder)

h

E

0

0

0

(remainder)

h

F

0

0

1

(remainder)

h

G

1

1

0

(remainder)

h

f
f

g

h

H
1
1
1
(remainder)
Notes: This is a replica of the initial truth table generated using fsQCA 2.0 software. However, the
first column was added to label configurations and several descriptors were added in
parentheses.
a
Each potential configuration of conditions is represented by a row. Since there are 3 conditions
3
there are 2 (8) possible configurations.
b
Genetics professional discloses positive screening results (presence=1, absence=0)
c
Referral is primary mechanism for patient to receive genetic testing (presence=1, absence=0)
d
Genetic professional contacts patient to set up counseling and testing (presence=1, absence=0)
e
The outcome column is blank because the software requires the researchers to fill in a 0 or 1 for
each configuration (row) based on whether or not the cases that share that configuration have the
outcome of interest (i.e., high patient reach; H-R).
f
These configurations contain contradictions (as indicated by consistency scores). Consistency
for row A is 0.8 because 4 of the 5 cases with this configuration have high patient reach (H-R=1).
Consistency for row B is 0.5 because only one of the two cases in this configuration belongs to
the H-R set. Contradictions must be resolved before assigning outcome scores.
g
The consistency score for row C is 0 because none of the cases with this configuration have
high patient reach.
h
There are no consistency scores for rows D-H because there are no cases in this sample that fit
these configurations. These are called remainders.
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Table III-5. Revised Truth Table
a

Row

gen_prof_ referral_ gen_directly_ difficulty_
# cases
H-R
c
d
e
disclose_ barrier
contacts_pt contact_pt
fitting
(outcome)
b
screen
configuration

Raw
consistency
f

A

1

0

1

0

4

1

1

B

1

0

0

0

1

1

1

C

0

1

0

0

7

0

0

D

0

1

0

1

1

0

0

E

1

0

1

1

1

0

0

f

g
g
g
g

F
1
0
0
1
1
0
0
Notes: The revised truth table was created using fsQCA 2.0 software by adding a fourth condition
to the original truth table, assigning outcome scores for each configuration, and deleting
configurations with no cases (remainders).
a
4
Each row represents a configuration of conditions. Although there are 2 (16) possible
configurations, but only those configurations for which there are cases are shown.
b
Genetics professional discloses positive screening results (presence=1, absence=0)
c
Referral is primary mechanism for patient to receive genetic testing (presence=1, absence=0)
d
Genetic professional contacts patient directly to set up counseling and testing (presence=1,
absence=0)
e
Difficulty contacting patients after a positive tumor screen (presence=1, absence=0)
f
The consistency scores for rows A-B are 1 because all cases with these configurations have high
patient reach (H-R=1).
g
The consistency scores for rows C-F are 0 because none of the cases in those configurations
have high patient reach (H-R=0)
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Table III-6. QCA Solutions, Consistency and Coverage
Outcome

High
Patient
Reach
(H-R)

Solutions

Consisten
cy

Raw
Coverage

Unique
Coverage

Complex:

gen_prof_disclose_screen *
~referral_barrier *
~difficulty_contact_pt

1.0

1.0

1.0

Parsimonious:

~referral_barrier *
~difficulty_contact_pt

1.0

1.0

1.0

gen_prof_disclose_screen *
~referral_barrier *
~difficulty_contact_pt

1.0

1.0

1.0

Intermediate:

a

Overall consistency = 1.0
Overall coverage = 1.0
Complex:
Absence
of High
Patient
Reach
(~H-R)
Parsimonious:

Intermediate:

b

gen_prof_disclose_screen *
~referral_barrier*
difficulty_contact_pt
+
~gen_prof_disclose_screen *
referral_barrier *
~gen_directly_contacts_pt

1.0

0.2

0.2

1.0

0.8

0.8

difficulty_contact_pt
+
referral_barrier

1.0

0.3

0.2

1.0

0.8

0.7

difficulty_contact_pt
+
~gen_prof_disclose_screen *
referral_barrier *
~gen_directly_contacts_pt

1.0

0.3

0.2

1.0

0.8

0.7

Overall consistency = 1.0
Overall coverage = 1.0
Notes: A tilde (~) indicates the absence of the outcome or condition.
The intermediate solutions are bolded because they were determined to be the most theoretically
sound and not overly simple or complex.
* The asterisk indicates Boolean multiplication (i.e. logical “AND”)
+The plus sign indicates Boolean addition (i.e. logical “OR”)
a
The following three conditions are sufficient for high patient reach: 1) a genetics professional
discloses the results of positive tumor screening; AND 2) obtaining a referral from another health
care provider for the patient to receive genetic counseling and testing is not a barrier; AND 3)
difficulty contacting patients is not a barrier.
b
Two distinct sets of conditions could both explain the absence of the outcome (Table III-6).
Difficulty contacting patients who screen positive is sufficient but not necessary to prevent high
patient reach. Alternatively, the following three conditions are together sufficient but not necessary
to prevent high patient reach: 1) genetic professionals do not disclose positive screening; AND 2)
genetic counselors do not contact patients directly to arrange genetic counseling and testing ;
AND 3) the need for a health care provider to refer the patient for genetic counseling and testing
is a barrier.
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SECTION IV: CONCLUSIONS AND RECOMMENDATIONS
Public Health Significance and Practical Implications
Screening tumors from all newly diagnosed colorectal cancer patients (i.e.,
universal tumor screening; UTS) is a promising method to achieve the Healthy
People 2020 provisional objective: “Increase the proportion of persons with newly
diagnosed colorectal cancer [CRC] who receive genetic testing to identify Lynch
syndrome (LS)”. (“Genomics - Healthy People”). Diagnosing LS allows for the
prevention or early detection of colorectal and other types of cancer among
patients and their relatives; thereby reducing associated morbidity and mortality.
However, the health benefits of tumor screening will only be realized if patient
reach is high (i.e., a large percentage of patients who screen positive follow
through with germline testing and genetic counseling.)
Given that the RE-AIM evaluation framework was designed to increase the
public health impact of evidence-based programs (Glasgow et al., 1999), this
framework was used in the current study. Results add to the current literature by
confirming that centers vary substantially in terms of patient reach. Even more
importantly the current study identified several key implementation factors that
characterized institutions with high and low patient reach. These factors included:
1) streamlining UTS procedures by making BRAF or hypermethylation testing
automatic in order to rule out a subset of individuals who screen positive but do
not need to follow-up with genetic counseling and germline testing and by
eliminating the requirement for referral or systematizing the process of obtaining
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a referral so that the need for referral is not a barrier); 2) incorporating a high
level of involvement of genetics professionals in receiving screening results,
disclosing positive tumor screening results to patients, and initiating genetic
counseling and germline testing; 3) reducing barriers to patient contact and
follow-up (i.e., meet patients at post-op appointments, arrange appointments at
convenient times to coincide with other follow-up appointments, etc).
Study findings can serve as key leverage points to inform policy decisions
among stakeholders. Implementing UTS practices and procedures that
consistently led to high patient reach in this multiple-case study is expected to
ultimately contribute to the long-term goal of reducing high levels of morbidity and
mortality associated with hereditary cancer. Indeed the results of this study have
already prompted one L-R institution to change their follow-up procedures.
Unfortunately, some centers may be unable to alter their practices; and ways to
work around barriers may be necessary. Interviews conducted as part of the
current study for member checks identified additional information that may help
centers that are implementing UTS and it is expected that much of this
information will be consolidated and shared on the Lynch Syndrome Tumor
Screening (LSSN) website. Nevertheless, additional implementation and
dissemination efforts in conjunction with research studies will be required before
the provisional Healthy People 2020 objective can be achieved and before UTS
will have a substantive public health impact.
Implications for Future Research
Given that the current study did not comprehensively evaluate all
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dimensions of RE-AIM, several unanswered research questions remain and are
listed in Table IV-1. For example, future studies should extend the definition of
Reach to include the number of family members that are diagnosed as a result of
UTS programs, particularly because prevention of cancers in family members
determine a large portion of the public health benefit of UTS programs.
Interviews with a few institutional representatives suggest that some centers
have diagnosed several family members as the result of UTS, but systematic
methods of tracking family members over time will be necessary to more
thoroughly answer questions pertaining to patient Reach and Maintenance.
Additionally, widespread Adoption of UTS screening by hospitals and
cancer centers is critical for UTS to have a large public health impact. Given that
academic/research institutions appear to have been quicker to adopt UTS
(Beamer et al., 2012; Cohen et al., 2013), health disparities could increase in
rural areas or among minority populations that may be less likely to be treated at
academic/research centers. Smaller, non-academic centers may have fewer
resources or expertise needed for implementation and may face a greater
number of barriers. Therefore to help actively disseminate UTS, summaries of
the current study findings related to overcoming barriers and strategies for
successful UTS implementation are expected to be posted on the Lynch
Syndrome Screening Network (LSSN) website (www.lynchscreening.net) where
several other useful documents and information on UTS are currently housed.
Additional research is needed to evaluate other UTS programs,
particularly those implemented in non-academic centers or institutions that do not
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employ genetics professionals. Evaluating programs that have been able to
achieve high patient reach but do not conform to the key conditions identified in
the current study may help to better understand other implementation strategies
that fit better within certain institutions and are therefore more feasible. Although
the current study found only a single model leading to successful UTS
implementation, different recipes to achieve high patient reach are possible.
Therefore future research is expected to confirm, add to, or refine the institutionlevel mechanisms that appeared to consistently lead to effective program
implementation in the current study.
By demonstrating the importance of institution-level factors for patient
outcomes, the current study data has already informed further evaluations of
UTS. Specifically, LSSN now plans to include institution-level data in addition to
individual-level patient data in the database that is being developed. Given the
clustered nature of the data, with patients nested within institutions, multilevel
modeling (MLM) is necessary when analyzing individual-level data (as opposed
to aggregated data used in the current study) in order to reduce the type I error
rate (Kreft, 1996) and prevent any unanalyzed institution-level effects from
obscuring or exaggerating pooled findings (Seltzer, 1994). A major advantage of
MLM is that it allows both random (institution-level) effects and fixed (patientlevel) effects to be examined (Seltzer, 1994). In other words, MLM could be used
to determine the extent to which differences in patient reach across sites are the
result of institution-level effects versus patient-level characteristics (such as stage
of cancer, age, gender, or insurance status). MLM will also ensure that individual-
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level factors do not confound institution-level findings and thereby overcome a
key limitation of the current study.
Implications for Theory
Integrating the RE-AIM and CFIR Frameworks
Given that relatively few implementation studies have employed theoretical
models (Damschroder & Hagedorn, 2011), results from the current research
could contribute more broadly to the theoretical underpinnings of implementation
science. Since its development in 1999 by Glasgow, RE-AIM has been used to
evaluate the public health impact of many different evidence-based programs
and is a useful conceptual model. However, RE-AIM does not provide enough
detail to comprehensively characterize the Implementation dimension or define
key constructs that are important for Implementation. The Consolidated
Framework for Implementation Research (CFIR) was developed in 2009 to open
the “black box of the RE-AIM framework” (Damschroder et al., 2009). Employing
the RE-AIM evaluation framework together with the CFIR can help to better
determine how Reach, Effectiveness, Adoption, Implementation, and
Maintenance interact. In particular, the current study results lend support for the
critical influence implementation processes have on outcomes, specifically
patient reach. Using qualitative comparative analysis (QCA), several
Implementation processes were determined to be key conditions associated with
patient Reach in the current study. Additionally, interviews performed as part of
the current study revealed the importance of several other CFIR constructs in the
decision making process to Adopt UTS and in determining how to Implement
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UTS. Themes from interviews are now being categorized according to various
CFIR constructs as shown in Table IV-2 and then will be integrated within the
broader RE-AIM framework to further illustrate the interactions between RE-AIM
dimensions.
Quantitative Measures of CFIR Constructs
Lack of validated tools is currently a weakness identified in implementation
and dissemination research (Damschroder et al., 2009). Despite the small
sample size, the current study provides pilot data to help evaluate the new
survey tools that were designed to include measures of several CFIR constructs
that are not specific to the processes of UTS. Further analysis of the current data
can aid in the refinement of these survey instruments for use in evaluating the
adoption and implementation of other evidence-based programs or practices.
Additional Manuscripts
Development of Quantitative Measures for CFIR Constructs
A manuscript describing the development and pilot testing of quantitative
CFIR measures is planned. This will include a discussion of the many problems
or challenges inherent in developing this type of measure, particularly those
related to measuring institutional constructs using survey data from individuals.
The paper will also triangulate findings from interviews with findings from the
survey measures to determine whether qualitative and quantitative methods of
identifying key CFIR constructs are consistent. The article will conclude with
lessons learned during the development and pilot of the instruments as well as
recommendations going forward that may help improve upon the newly
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developed measures.
Policy Implications for Lynch Syndrome Universal Tumor Screening
Another manuscript will focus on several policy and practical implications of
the research findings. This will include a more detailed discussion of the barriers
to implementation and possible challenges to effective implementation and
dissemination of UTS on a broader scale. For example, during interviews with a
few individuals who are not genetic counselors, they reported that their institution
would not have implemented UTS without a genetic counselor on site (and many
hospitals do not have genetic counselors). Furthermore, disparities in at least
four cities or large geographical regions became apparent during the interviews.
Lastly, follow-up on positive tumor screens is not being performed in any
systematic fashion at some centers; and patients are definitely falling through the
cracks, whereas other institutions have even begun implementing methods to
check or ensure that all patients are screened and either follow-through or
provide informed refusal of follow-up counseling and testing.
Implementation of Genomic Technologies: Practical & Ethical
Considerations
Another potential manuscript could describe ethical considerations and
practical issues of widespread implementation of genomic technologies and
illustrate how UTS can be used as a model for implementation of these other
technologies. Specifically, sequencing the genome of tumors to help determine
treatment options is expected to become a common practice in the future. Similar
to UTS where an abnormal screen must be verified with germline testing, there
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are likely to be cases where tumor sequencing suggests the potential of a
germline mutation. These individuals will require genetic counseling so they can
be informed of the implications that identifying a germline mutation may have for
themselves and for their family members. Although a couple of key differences
exist between tumor sequencing and UTS, lessons learned from UTS
implementation may be useful in preparing for and identifying best methods for
implementing future genomic technologies.
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Table IV-1. Future Directions for Applying RE-AIM and Consolidated Framework for
Implementation Research (CFIR)
RE-AIM Dimension
Description

Relevant Study Result

Future Research

Reach
Absolute number,
proportion, and
representativeness
of individuals who
participate.

• Patient Reach (i.e., proportion of screen
positive patients who receive information
on germline testing and follow-through
with germline testing and genetic
counseling) is highly variable across
centers (ranging from <10% to >85%).

• Determine
characteristics of
patients who followthrough
• Identify the number of
family members who
are diagnosed with LS
as a result of patient
diagnosis

Effectiveness
The impact of an
intervention on
outcomes (including
potential negative
effects).

• Institutional representatives report few
negative effects associated with
screening.
• Potential liability was identified by a few
centers where patient reach is low and
several expressed concerns that patients
may not always be referred after a
positive screen.

• Do patients perceive
UTS to have a positive
or negative impact? In
what ways?

Adoption
The absolute
number, proportion,
and
representativeness
of settings and staff
who currently offer a
program.
Characteristics of
intervention may
increase the
likelihood of
adoption.

• Centers report a variety of reasons for
adopting UTS, but most common reasons
are the EGAPP recommendation and to
benefit patients and their families.
• Multiple stakeholders are typically
involved in making the decision to adopt
UTS and changes to the procedures.
• Projected cost was a common factor in
weighing the decision to adopt UTS at
most participating institutions.

• Overall in the U.S.
what
centers/institutions
have adopted UTS
and how do they
compare to others that
have not adopted
UTS?

Implementation
Consistency of
delivery, time and
cost of the program,
and what
adaptations to the
program are made
in various settings.

• Centers with direct and high level of
involvement of genetic counselors in
disclosing results and follow-up
procedures is sufficient for high patient
reach in the absence of two barriers
including lack of referral from another
healthcare provider for patient to undergo
genetic counseling and difficulty
contacting patients.
• The number of implementation barriers
was greater than or equal to the number
of facilitators for most low-reach centers,
but only 1 H-R center.
• Recurring themes and a few unique
responses were identified regarding how
centers can facilitate implementation and
overcome barriers/challenges.

• Are there other
procedures that can
lead to high patient
reach particularly at
centers that do not
have genetics
professionals?
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Table IV-1 (continued).
Maintenance
Extent to which the
program is
institutionalized and
maintained or
altered over time.

A few centers have changed their screening
protocol so that genetic professionals disclose
positive screening results and meet patients at
a follow-up appointment to discuss germline
testing. These centers saw improvement in
patient follow-through and under their current
protocol they were achieving high patient
reach.

At the individual
level, maintenance
is the long-term
A few other centers are now in the process of
effects of a program changing their procedures.
on outcomes after 6
or more months.
One low-reach center used to let the genetic
counselor see all positive screening results
and follow-up to ensure she received a
referral for all of these patients. She reported
that since she could no longer do this it
reduced the percentages who followed
through.
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Do other centers that alter
their procedures to
resemble those of highreach centers in our study
see improved patient
reach?
What prevents programs
from changing to try and
improve patient reach?
Are patients who have
been diagnosed with
Lynch syndrome through
UTS or as a result of
cascade testing of at-risk
relatives undergoing
recommended cancer
screening?

Table IV-2. Study Themes Consistent with the Consolidated Framework for Implementation
Research (CFIR)
CFIR
Construct

Description

Relevant Findings from
Current Study

Intervention
source

Perception of key stakeholders about whether
the intervention is externally or internally
developed to solve a local problem and the
legitimacy of the source (Greenhalgh, Robert,
Macfarlane, Bate, & Kyriakidou, 2004).
Externally developed interventions and lack of
user input can lead to ineffective implementation
(Helfrich, Weiner, McKinney, & Minasian, 2007;
Kitson et al., 2008; Katherine J. Klein, Conn, &
Sorra, 2001).

A few GCs cite that if it is simply
coming from them other
physicians won’t listen. So need
to get a pathologist and a
surgeon on board early on in
the process.

Relative
advantage

Stakeholder beliefs about the benefits of UTS
compared with the status quo or an alternative
(Rogers & Rogers, 2003). Relative advantage
and observability are constructs from Diffusion
of Innovations (Rogers & Rogers, 2003). They
are combined because benefits, if visible to the
stakeholders, aid adoption and implementation
(Denis et al., 2002; Feldstein & Glasgow, 2008;
Greenhalgh et al., 2004; Grol, Bosch, Hulscher,
Eccles, & Wensing, 2007).

One GC indicated that once the
physicians started seeing how
family members were
diagnosed and that they were
using the information to be
proactive in screening they
would get on board.

Perceptions about whether and how an
intervention can be tailored to meet specific
needs or characteristics of an institution (Rogers
& Rogers, 2003). There are generally 'core
components' that are necessary elements of the
intervention and an 'adaptable periphery'
(Greenhalgh et al., 2004). According to Diffusion
of Innovations, programs that can easily be
modified to are more likely to be adopted
(Rogers & Rogers, 2003).

Whether or not they do IHC or
MSI does not appear to be
necessary for success.

Ability to test an intervention on a small scale
and reverse implementation if warranted
(Rogers & Rogers, 2003). According to Diffusion
of Innovations, trialability has a strong positive
association with adoption (Greenhalgh et al.,
2004; Rogers & Rogers, 2003). It also increases
the likelihood of effective implementation
because piloting provides experience that can
be used to improve full scale implementation
(Kitson et al., 2008; Rycroft-Malone et al.,
2002).

Some centers were already
screening a sub-set of tumors
before going to universal
screening and they reported
that this helped because
systems were already in place.

Intervention Characteristics

Adaptability

Trialability
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Observing how patients were
being missed without UTS
helped some centers get it
implemented.

Some centers only do IHC in
house and that was one reason
for selecting IHC.

Table IV-2 (continued).
Complexity

Perceived difficulty of implementation (duration,
scope, radicalness, disruptiveness, centrality
and number of steps required) (Rogers &
Rogers, 2003). According to Diffusion of
Innovations complexity plays a critical role in the
decision to adopt an innovation. In addition,
simple interventions are more likely to be
effective (Greenhalgh et al., 2004). Assessing
complexity can also help in understanding and
avoiding unintended consequences (Kochevar &
Yano, 2006).

Perceived difficulty of
implementation did not appear
to be consistently associated
with patient reach but those with
low-reach reported more
barriers than facilitators.
GCs expressed how complex it
is to implement in a hospital or
hospital system where the
physicians are private and NOT
employed by the hospital.
Reduction in complexity of
follow-up procedures following a
positive screen appears to be a
key to success of high reach
institutions.

Costs

Costs of the intervention as well as
implementation costs (Rogers & Rogers, 2003).
Cost is a characteristic from Diffusion of
Innovations and is negatively associated with
adoption (Rogers & Rogers, 2003; Teplensky,
Pauly, Kimberly, Hillman, & Schwartz, 1995).
Cost is also likely to influence how the
intervention is implemented and its overall
effectiveness.

Costs are a common concern in
deciding whether to adopt
universal tumor screening.
Because it is part of DRG when
performed on resections the
hospital is essentially adding on
the screen without recouping
additional money.
Some centers are going to
biopsies in part because they
are outpatient procedures and
more likely to be reimbursed.

Outer setting
Patient
needs and
resources

The extent to which patient needs, barriers, and
facilitators are accurately known and prioritized.
(Feldstein & Glasgow, 2008; Graham & Logan,
2004; Rycroft-Malone et al., 2002). A number of
implementation theories postulate that taking
these issues into account will increase the
chance that the intervention will be effective
(Ferlie & Shortell, 2001; Kitson et al., 2008;
Rycroft-Malone et al., 2002). Quality
improvement initiatives have proven more
successful if there has been a strong focus on
the patients' needs (Ferlie & Shortell, 2001).
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Several programs changed their
protocol to better meet patient
needs by simplifying follow-up
procedures and removing
barriers.
Several centers considered
patient needs in their discussion
of whether or not informed
consent was necessary and
what information patients
should be provided.

Table IV-2 (continued).
Cosmopolitanism

Degree to which the organization is networked
with other external institutions (i.e., social capital
of the organization) (Greenhalgh et al., 2004).
The degree of external networking increases the
likelihood of implementing new practices quickly
once advantages become apparent
(Greenhalgh et al., 2004).

“You need to keep up to date
with the literature and use other
centers that have been doing
UTS as a resource!” quote
Some centers indicated that
they modeled their program
after another one, such as Ohio
State. This was even one
reason why they chose IHC.
One GC recommended that
people should join LSSN if they
want to implement UTS.

Peer
pressure

External
policies and
incentives

Competitive pressure to implement an
intervention (to either obtain a competitive edge
or because other organizations already have
implemented it) (Greenhalgh et al., 2004). There
is strong evidence that peer pressure influences
organizational adoption or programs /
interventions / technologies (Greenhalgh et al.,
2004).

Several centers reported this as
a reason for implementation as
follows:

External strategies to spread interventions (e.g.,
mandates, pay-for-performance, political
directives, recommendations, collaboratives)
(Greenhalgh et al., 2004; Mendel, Meredith,
Schoenbaum, Sherbourne, & Wells, 2008).
Many times these strategies lead to adoption
and increase effective implementation, but there
are some exceptions (Greenhalgh et al., 2004;
Grol et al., 2007; Katherine J. Klein & Sorra,
1996).

One M-R center indicated that
they implemented UTS because
they believed it was “becoming
standard of care”
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Seeing competitor hospitals
doing it was a motivation.
Also, one center reported that
the fact they would be the first
to implement in their area was
helpful because administration
liked the idea of being ahead of
others.

Some implemented because of
EGAPP, but more often EGAPP
was used to support it and they
wanted to implement to improve
identification of patients.

Table IV-2 (continued).
Inner setting
Structural
Social architecture (i.e., how people are
characteristic clustered into smaller groups and how actions
are coordinated), age, maturity, and size of an
organization (Damanpour, 1991a; Greenhalgh et
al., 2004). Several structural characteristics
have been found to be significantly associated
with implementation effectiveness, often with
mixed results (Frambach & Schillewaert, 2002).
A greater number of departments involved in
decision making may slow down the process,
but generally increases successful
implementation (Damanpour, 1991b;
Greenhalgh et al., 2004).

Many of high reach centers are
NCCN designated academic
research focused.
If the physicians are not actually
employed by the hospital this
made it more challenging for
some to implement. Also, this
prevents GCs from being able
to follow-up at post op
appointments.
Even one center where GCs
could follow-up the physical
structure of having genetics so
far away required them to rely
on a nurse who is
knowledgeable about genetics
to meet patient at follow-up
appts.
The more physicians or
hospitals reported to be part of
the system the longer it seems
to have taken to get UTS
implemented one hospital
system took 3 years and even
after that not all came on board.
Also seen with the affiliate
hospitals of one center that
implemented UTS with no
problem, but affiliate has not
yet.

Networks
and
communication

Nature, quality, and extent of social networks
(social capital). Formal and informal
communications within an organization
(Greenhalgh et al., 2004; Helfrich et al., 2007).
Coordination and teamwork across departments
and specialties is typically important for effective
implementation of programs or initiatives
(Feldstein & Glasgow, 2008; Ferlie & Shortell,
2001). Clear role definitions and high quality
communication increase the likelihood of
success (Simpson & Dansereau, 2007).

Role definitions and quality
communication are cited as
critical to implementation.
Those centers where physicians
sometimes disclose and GCs
sometimes disclose tend to
have lower patient reach.
Teamwork among genetics,
pathology, and surgeons was
cited as a key to successful
implementation by many H-R
centers.
Lack of communication cited
among many L-R centers.
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Table IV-2 (continued).
ImplemenAbsorptive capacity for change, shared
tation climate receptivity of those involved, extent to which
involvement with the intervention is rewarded,
supported, or expected within the organization.
(Gershon et al., 2004; Greenhalgh et al., 2004;
Katherine J. Klein & Sorra, 1996).Climate
includes the following 6 sub-constructs:
Tension for change – degree to which
stakeholders perceive current situation as
needing change.
Compatibility – degree of fit between the
meaning and values of the intervention and
individual's and institution's values as well as fit
with work flow and systems. Greater perceived
fit = greater likelihood of adoption according to
Diffusion of Innovations and empirical research
(Greenhalgh et al., 2004; Katherine J. Klein &
Sorra, 1996; Rogers & Rogers, 2003).
Relative priority – shared perception of how
important implementation is. The higher the
priority the more likely it is to be successful
(Helfrich et al., 2007; Katherine J. Klein, Conn,
et al., 2001).
Organizational incentives/rewards – include but
are not limited to goal-sharing awards,
performance reviews, raises in salary, increased
stature or respect. Strong incentives increase
the likelihood of implementation success
(Helfrich et al., 2007; Katherine J. Klein, Conn,
et al., 2001). The number of different types of
incentives has been positively related to use of
best practices by healthcare organizations
(Shortell et al., 2001).
Goals and feedback – Goals that are specific,
incremental, and attainable increase effective
implementation. Feedback has been shown to
have small to moderate effects (Jamtvedt,
Young, Kristoffersen, O’Brien, & Oxman, 2006).
Learning climate – climate where leaders
recognize they are fallible and need input, and
team members feel their input is valued. This is
hypothesized to influence the ability of an
organization to fully assimilate an intervention
(Greenhalgh et al., 2004).
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Having gastroenterologists and
surgeons who were receptive
was necessary.
Preliminary analysis using scale
measure of implementation
climate those with higher scores
are the H-R centers.
H-R centers have set goals for
UTS and keeping track of
outcomes carefully

Table IV-2 (continued).
Readiness
for
implementation

Tangible and immediate indicators of
organizational commitment to its decision
(Greenhalgh et al., 2004; Kitson et al., 2008).
This includes 3 sub-constructs.
Leadership engagement – commitment,
involvement, and accountability of managers.
This is critical to successful implementation
(Meyer & Goes, 1988; Repenning, March). It
leads to a stronger implementation climate
(Helfrich et al., 2007; K J Klein, Conn, et al.,
2001).
Available resources – level of resources
implemented (i.e., money, time, space). The
level of resources is positively associated with
implementation, but does not guarantee
success (K J Klein, Conn, et al., 2001).

Not all centers had to have the
administration on board (tended
to be academic centers).
Community hospitals reported
the need for administration on
board for implementation.
Community hospitals may have
fewer resources and more
difficult to implement.
One hospital indicated if they
did not have a GC on site they
probably would not have
implemented it.

Access to information and knowledge – Access
to easy to use information about UTS and how
to incorporate it is essential for successful
implementation (Greenhalgh et al., 2004;
Helfrich et al., 2007; K J Klein, Conn, et al.,
2001). Timely, on the job training (particularly if
provided at a team level) contributes to success
(Greenhalgh et al., 2004). This is also critical to
get key stakeholders engaged (Grol et al.,
2007).
Characteristics of individuals
Knowledge
and beliefs
about the
intervention

Familiarity with principles related to the
intervention and how-to knowledge as well as
positive and negative attitudes about the
intervention and value placed on the
intervention (Katherine J. Klein & Sorra, 1996;
Rogers & Rogers, 2003). Principles and how-to
knowledge are constructs from Diffusion of
Innovations (Rogers & Rogers, 2003). Attitudes
are key constructs in some theories that explain
individual behavior change, specifically the
Theory of Reasoned Action (Fishbein & Ajzen,
2009).

Self-efficacy

Individual belief in capability to execute behavior Not measured here
needed to achieve implementation goals.
Perceived ability to perform a specific action
within a specific context (Bandura, 1977). This
construct is included in multiple theories of
behavior change (Glanz, Rimer, & Viswanath,
2008) However, self-efficacy is originally
attributed to Bandura and is a key construct in
Social Cognitive Theory (Bandura, 1977).
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Genetic professionals may be
more knowledgeable.
Lack of knowledge among
physicians more often cited as
barrier by L-R centers.

Table IV-2 (continued).
Individual
stage of
change

Progression toward use of the intervention.
NA
Stage depends on the specific model used (i.e.,
Prochaska's Transtheoretical model, Roger's
Diffusion of Innovations, etc) (Levesque,
Cummins, Prochaska, & Prochaska, 2006;
Prochaska & Velicer, 1997; Rogers & Rogers,
2003).

Individual
identification
with the
organization

How individuals perceive the organization and
their relationship and commitment to the
organization (“AHRQ Innovations Exchange |
Will It Work Here? A Decisionmaker’s Guide to
Adopting Innovations,” n.d.; Cropanzano, Rupp,
& Byrne, 2003). This can affect the willingness
of individuals to fully engage in implementation
efforts, but this construct has not been widely
studied in health care settings .

Not assessed, except for the
finding that those centers where
the physicians are not actually
hospital employees reported
more difficulty implementing.
Though actual commitment to
organization was not assessed.

Planning

Degree to which the methods and tasks for
implementation and evaluation are developed
(Damanpour, 1991b; Greenhalgh et al., 2004;
Rogers & Rogers, 2003). Although planning is
generally necessary for implementing
institutional programs (Greenhalgh et al., 2004),
additional research is needed into how planning
influences implementation effectiveness.

Level of planning may be
important in outcomes. One
hospital system worked on
implementation and planning for
3 years and are a H-R
institution.

Engaging

Attracting and involving appropriate people in
implementation using social marketing,
education, role modeling, training, and other
activities (“AHRQ Innovations Exchange | Will It
Work Here? A Decisionmaker’s Guide to
Adopting Innovations,” n.d.; Greenhalgh et al.,
2004; Kitson et al., 2008; Lukas et al., 2007;
Pronovost, Berenholtz, & Needham, 2008). If
implementation leaders are similar to intended
users they are more likely to adopt the
intervention (Greenhalgh et al., 2004). Chances
of success are greater if all stakeholders are
engaged early on in the process (Greenhalgh et
al., 2004).

Multiple stakeholders need to
be in agreement, upfront, to
implementing this screening.
More people "on board" from
the beginning means less
problems that arise after the
screening begins. (/Tia)

Process
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Having a champions that are
pathologists and GI / surgeons,
etc was helpful in getting others
on board.

Table IV-2 (continued).
Executing

Carrying out the implementation according to
plan (Carroll et al., 2007; Damanpour, 1991b;
Edmondson, Bohmer, & Pisano, 2001; Helfrich
et al., 2007). In cases where there is not a plan,
assessing execution is difficult. Execution quality
may be related to the following: level of fidelity
to the plan, intensity of implementation,
timeliness of task completion, and degree of
engagement of key stakeholders (Carroll et al.,
2007; Edmondson et al., 2001).

my institution used to allow me
to review all MSI/IHC results so
I could make sure a referral was
made. Because of HIPAA
concerns this was stopped. IF
we institute this again I believe
genetic counseling would
increase.
I also had a problem with
receiving the results for reflex
tests when I was screening,
specifically BRAF, so that I
couldn't determine if a patient
needed genetic counseling as
almost all of our abnormal
results were loss of expression
of MLH1 and PMS2. If the
reflex process and reporting
process were cleaned up this
would also assist in increaseing
genetic counseling referrals.
Have genetic counselors review
all pathology reports and follow
up with patients on their own
Need to get them in the door to
discuss testing

Reflecting
and
evaluating

Quantitative and qualitative feedback about the
progress and quality of implementation. Team
debriefing and reflection (“AHRQ Innovations
Exchange | Will It Work Here? A
Decisionmaker’s Guide to Adopting
Innovations,” n.d.).
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Actually getting the data has
helped some centers make
changes.
After talking to a pathologist he
said it got him thinking of ways
to better streamline the process
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Appendix A: Literature Review
Public Health and Hereditary Colorectal Cancer
Healthy People genomics objectives. According to the Healthy People
(HP) 2020 website, the addition of genomics as a topic area reflects “the
increasing scientific evidence supporting the health benefits of using genetic
tests and family health history in clinical and public health interventions”
(“Genomics - Healthy People,” n.d.). Two objectives have been included in the
HP 2020 genomics topic area. My focus will be on the following provisional
objective: “Increase the proportion of persons with newly diagnosed colorectal
cancer (CRC) who receive genetic testing to identify Lynch syndrome (or familial
CRC syndromes).”
Prevention of disease and death. Colorectal cancer (CRC) is the third
most common type of cancer and third leading cause of cancer-related deaths in
the United States (U.S.) (“Colorectal Cancer Facts & Figures 2011-2013,” n.d.).
In 2011, an estimated 141,210 people will be diagnosed with CRC and 49,380
people in the U.S. will die of the disease (“Colorectal Cancer Facts & Figures
2011-2013,” n.d.) Occurring in approximately 1 out of every 35 patients with CRC
(Hampel et al., 2008), Lynch syndrome (LS) is the most common cause of
hereditary CRC. LS confers a lifetime risk for CRC as high as 78%-80% (Aarnio,
Mecklin, Aaltonen, Nyström-Lahti, & Järvinen, 1995; H. F. Vasen et al., 1996).
However, due to probable ascertainment bias, more accurate CRC risks likely fall
in the range of 54-69% for men with LS and 43-52% for women with LS (Barrow
et al., 2008; Hampel, Stephens, et al., 2005; E. Stoffel et al., 2009). The average
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age of onset of CRC among individuals with LS ranges from 44-62 years
(Hampel, Stephens, et al., 2005). It is also important to note that risks of CRC
and age of onset appear to vary based on which gene is implicated as the cause
of LS (Bonadona et al., 2011; E. Stoffel et al., 2009).
LS is also referrred to as hereditary nonpolyposis colorectal cancer
(HNPCC) despite being associated with substantial increases in risk for several
other types of cancer including: endometrial, ovarian, gastric, small bowel,
pancreatic, hepatobiliary, brain, and urothelial cancers (Barrow et al., 2009;
Kastrinos et al., 2009; Watson et al., 2008). Notably, the second most common
malignancy associated with LS is endometrial cancer. Risks for women with LS
to develop endometrial cancer range from 32-54% (Barrow et al., 2009; Hampel,
Stephens, et al., 2005; E. Stoffel et al., 2009). Studies have found that
approximately 2% of patients with endometrial cancer have LS (Hampel et al.,
2006). In 2011, an estimated 46,470 women will be diagnosed with endometrial
cancer in the United States and approximatelyt 8,120 women will die of the
disease (“Cancer Facts & Figures 2011,” n.d.).
The greatest public health benefit of identifying LS among newly
diagnosed patients with CRC is the opportunity it provides to prevent cancer
among patients' at-risk relatives. Given the autosomal dominant inheritance
pattern of LS, first degree relatives of patients with LS have a 50% chance of
having inherited the same cancer-predisposing gene mutation. Furthermore,
depending on which side of the family the gene was inherited, second degree
relatives may have a 25% chance of having LS.

134

Fortunately for at-risk relatives, early identification of LS has been proven
to reduce cancer incidence, morbidity, and mortality through both primary and
secondary cancer prevention (Heikki J Järvinen et al., 2009; H J Järvinen et al.,
2000; “Recommendations from the EGAPP Working Group,” 2009; Schmeler et
al., 2006; Stupart, Goldberg, Algar, & Ramesar, 2009; H. F. A. Vasen et al.,
2010). With early and intensive surveillance, such as colonoscopy every one to
two years (beginning at age 20-25 years) (“NCCN Clinical Practice Guidelines in
Oncology,” n.d.), the incidence of CRC can be reduced by approximately 59-62%
(Heikki J Järvinen et al., 2009; H J Järvinen et al., 2000; Stupart et al., 2009) and
overall mortality can be decreased by at least 65% (H J Järvinen et al., 2000).
Furthermore, evidence suggests that genetic testing improves compliance with
screening procedures (“Hereditary Nonpolyposis Colorectal Cancer: Diagnostic
Strategies and Their Implications: Structured Abstract,” n.d.). Chemoprevention
may also become a routine prevention strategy in the future in light of recently
published results from a randomized trial demonstrating that among individuals
with LS, long-term use of aspirin reduces the risk of CRC by around 60%
compared to no aspirin use (Chan & Lippman, 2011). Evidence has also
demonstrated the efficacy of surgical options (i.e., hysterectomy and
salpingoophorectomy) for reducing risks of ovarian and endometrial cancers
(Auranen & Joutsiniemi, 2011; Koornstra et al., 2009; H. T. Lynch & Casey, 2007;
“NCCN Clinical Practice Guidelines in Oncology,” n.d.; Schmeler et al., 2006).
Although annual transvaginal ultrasound and endometrial sampling (biopsy) are
often recommended beginning at age 30-35, published evidence that these
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screening methods reduce mortality is insufficient (“NCCN Clinical Practice
Guidelines in Oncology,” n.d.; Auranen & Joutsiniemi, 2011; Koornstra et al.,
2009; Barrow et al., 2009). The utility of screening for other cancers among
patients with LS has not been established, but surveillance for gastric cancer has
been recommended for patients born before 1935 (Barrow et al., 2009) or for
families with more than one member affected by this type of cancer (Koornstra et
al., 2009). Additional surveillance measures have also been recommended for
individuals with more than one urinary tract cancer in the family (Koornstra et al.,
2009; “NCCN Clinical Practice Guidelines in Oncology,” n.d.).
The HP genomics objective clearly has the potential “to prevent disease,
disability, and premature death”, which is an overarching HP goal (“About Healthy
People - Healthy People 2020,” n.d.). This potential is greatest for family
members of patients with LS. Nevertheless, identifying LS in patients with CRC
may help to prevent secondary cancers and improve clinical treatment. More
specifically, a diagnosis of LS alters future cancer surveillance recommendations
and cancer prevention options due to increased risks for developing additional
cancers (Balmaña, Castells, & Cervantes, 2010; Rex et al., 2006). Given that one
in four women with CRC related to LS will go on to develop endometrial cancer
within 10 years (Obermair et al., 2010), diagnosing LS can be particularly
beneficial if these women choose to pursue hysterectomy and
salpingoophorectomy (Ladabaum et al., 2011). If LS is suspected based on
screening performed on a tumor biopsy, the diagnosis may help inform surgical
treatment options (i.e., subtotal colectomy versus segmental colectomy)
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(Natarajan, Watson, Silva-Lopez, & Lynch, 2010). There is also preliminary (yet
highly controversial) evidence to suggest that patients with LS respond differently
to adjuvant chemotherapy with 5-fluorouracil than other patients whose tumors
demonstrate microsattelite instability as a result of somatic mutations (Tejpar,
Saridaki, Delorenzi, Bosman, & Roth, 2011).
Screening and/or germline testing for LS has historically been offered to
certain patients who are at high risk for the syndrome based on their personal
and/or family medical histories (Park et al., 1999; Umar et al., 2004), yet many
cases remain unrecognized due, in part, to limitations in the collection and
interpretation of family history (De Bruin et al., 2006; Singh, Schiesser, Anand,
Richardson, & El-Serag, 2010; Sjursen et al., 2010). Screening all tumors from
newly diagnosed patients with CRC, a process referred to as universal tumor
screening (UTS) (Bellcross et al., 2011), has been shown to substantially improve
the identification of LS (Hampel, Frankel, et al., 2005; Hampel et al., 2008;
Ladabaum et al., 2011; Mvundura, Grosse, Hampel, & Palomaki, 2010;
“Recommendations from the EGAPP Working Group,” 2009; Tranø, Sjursen,
Wasmuth, Hofsli, & Vatten, 2010). UTS presents an opportunity to identify most
of the estimated 28% to 50% of individuals with LS who would not otherwise be
identified with the common practices of limiting tumor screening to patients who
fulfill family history or age criteria (Hampel et al., 2008; Mvundura et al., 2010).
Although not specifically stated in the provisional HP genomics objective,
UTS is a promising method of achieving this objective. Furthermore, if UTS is
successful, it could serve as a model for implementing other evidence-based

137

public health genomic applications. The potential population health impact if
screening were to be performed on all tumors from both newly diagnosed
patients with CRC and newly diagnosed patients with endometrial cancer (EC) in
the U.S. is detailed in a paper by Bellcross et al. (Bellcross et al., 2011).
Despite substantial clinical evidence demonstrating the feasibility and
efficacy of UTS for LS (Bellcross et al., 2011; Hampel et al., 2008; Palomaki,
McClain, Melillo, Hampel, & Thibodeau, 2009; “Recommendations from the
EGAPP Working Group,” 2009; Sjursen et al., 2010; Tranø et al., 2010), evidence
to support the real-life effectiveness of screening programs is limited (Hall, 2010)
and consensus or best practice measures for UTS have not been established
(“Recommendations from the EGAPP Working Group,” 2009).
Health care costs. Given limited health care resources, public health
genomic applications should not be implemented without first considering the
fiscal impact. Simulation and modeling of various different CRC tumor screening
protocols have demonstrated that the incremental cost-effectiveness ratio of
screening CRC tumors for LS is comparable to other preventive cancer
screening services provided in the U.S. (Gudgeon et al., 2011; Ladabaum et al.,
2011; Mvundura et al., 2010; S D Ramsey et al., 2001). More specifically, costs
associated with screening tumors of patients < 50 years have been estimated in
three separate studies with the following results: $7,556 per life year saved (S D
Ramsey et al., 2001); $7,832 per life year saved (Mvundura et al., 2010), and
$27,900 per life year saved (Ladabaum et al., 2011). Despite the lower costs
associated with limiting screening to individuals under age 50, this approach
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would miss approximately 50% of LS cases (Mvundura et al., 2010). As such,
additional estimates have been calculated. A U.S. wide system of universal
voluntary screening with 2/3 uptake after counseling was determined to have an
incremental cost effectiveness ratio relative to age-targeted testing of $22,552
per life year saved (Mvundura et al., 2010). Two additional cost effectiveness
studies that have been published also concluded that costs associated with UTS
may be acceptable (Gudgeon et al., 2011; Ladabaum et al., 2011). More
specifically, Gudgeon et al. estimated that screening tumors of all patients who
are newly diagnosed with CRC within their single managed health care system
will cost a minimum of $10,369 per case detected (Gudgeon et al., 2011) Taking
a broader U.S. health system perspective, Ladabaum et al. calculated the
increased cost effectiveness ratio for UTS to be $88,700 per life year gained, as
compared to $44,200 per life-year gained when limiting screening to individuals <
70 years (Ladabaum et al., 2011). Differences in these cost-effectiveness models
presumably result from differences in their underlying assumptions as well as
differences in the number and types of factors that were taken into account. An
important limitation, pertinent to all of these models, is that assumptions may not
be consistent with real-world practice.
Cost-effectiveness of tumor screening is highly dependent on the behavior
of those who screen positive and their family members (Gudgeon et al., 2011;
Ladabaum et al., 2011; Mvundura et al., 2010). Although systematic reviews
have found adequate test uptake among individuals with CRC and their relatives
(Palomaki et al., 2009; “Recommendations from the EGAPP Working Group,”
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2009), centers that have already begun UTS for LS have found varying success
rates in terms of the percentage of patients with an abnormal screen who followthrough with genetic counseling/testing (Bellcross et al., 2011; South et al.,
2009). Without high compliance from patients, these types of large-scale public
health screening programs will fail to be effective in terms of both cost and ability
to decrease morbidity and mortality. Therefore UTS programs should be
evaluated to determine real-world effectiveness.
Educational Needs
With respect to UTS, Bellcross et al., eloquently and succinctly point out
that “multi-level education” will be needed to ensure the following:
“...that entities at all layers—patients, family members, health care providers,
public and private health systems, policy makers—are operating from the same
understanding of the rationale for universal LS screening, the importance of
genetic counseling and diagnostic testing for individuals whose tumor screens
are positive, and the need to follow through with identification of at-risk family
members and ensure appropriate surveillance of mutation-positive individuals”
(Bellcross et al., 2011, p. 7).
Education of the general public. At the most fundamental level,
educational efforts are needed to increase awareness of the existence of genetic
tests for hereditary cancer. According to the 2000 National Health Interview
Survey (NHIS), only 44.4% of the U.S. adult population had even heard of
genetic testing for inherited susceptibility to cancer (Wideroff, Thomas
Vadaparampil, Breen, Croyle, & Freedman, 2003). Awareness varied
substantially by race/ethnicity, with approximately 50% of whites having heard of
testing versus 33% of African Americans, 32% of American Indians/Alaskan
Natives, 28% of Asian/Pacific Islanders, and 21% of Hispanics (Wideroff et al.,
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2003). Data from the 2005 NHIS showed similar trends in racial/ethnic disparities
as well as an overall 2.9% decrease in awareness of genetic testing since 2000
(Vadaparampil, 2009). Results from the 2010 NHIS survey are not yet published,
but it is likely that the need to increase awareness still exists, particularly among
non-white racial/ethnic groups.
Additional genetics information is necessary for patients to understand
what genetic screening/testing will mean for them in order to make informed
decisions. Condit points out that determining which information is “decisionrelevant” is challenging (Condit, 2010); and she describes steps needed to
address the general lack of genetics education among the public as follows:
“If prescriptions for the contents of public education are not merely to expand to
the unrealistic desire to convey the entire universe of existing expert knowledge
of genetics, there remains a pressing need for carefully designed empirical
examinations of what information people actually can and will use and benefit
from most in their decision making processes (Condit, 2010, p. 7).
Although I strongly agree that additional research involving patients is
needed, there are some specific knowledge gaps, already identified among the
public, which may be particularly relevant. More specifically, the general public is
largely lacking in an understanding of molecular genetics (Condit, 2010). Without
basic knowledge about molecular genetics, it may be difficult to understand
various aspects regarding tumor screening for LS. However, the amount and type
of information that CRC patients need or desire in order to make informed
decisions about UTS is unknown. I suspect that many people view genetics a lot
like I view computers. I wouldn't really care to nor would I need to know details
about a computer virus. I would simply need to recognize that my computer got a
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virus, know who can fix it, determine whether my laptop could also be affected,
and find out what I can do to prevent getting a computer virus again. My
husband, on the other hand, loves computers. If I were to get a computer virus
he would probably start telling me all of the technical details about the virus and
what he needs to do to determine the extent of the damage. In turn, I would tune
him out and may even miss important information that I really need to know.
Similarly, patients may not care about the technical details of tumor screening,
which protein(s) is/are missing, or what additional reflex testing may be
performed. Genetics health professionals therefore run the risk that critical
information will be missed unless they engage patients in the process of
determining how much molecular genetic information to include in educational
materials.
Compared to molecular genetics, heredity is viewed as a much more
salient aspect of genetics by the general public (Condit, 2010). It is easier for
people to see the direct impact of heredity in their lives, which probably explains
why family history has a substantial influence on an individuals' perceptions of
whether cancer is likely to be hereditary (Lucke, Hall, Ryan, & Owen, 2008).
Individuals' understandings of inheritance may, however, conflict with the medical
perspective due to the complex ways in which people perceive vulnerability and
personalize risk (Walter, Emery, Braithwaite, & Marteau, 2004) UTS for LS may
be particularly challenging because human beings generally have difficulty
understanding probabilities (Visschers, Meertens, Passchier, & de Vries, 2009)
and individuals who lack a strong family history of cancer or who hold
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misconceptions may fail to see how screening and genetic counseling are
applicable to them.
There are several additional examples of how perceptions about heredity
could act as barriers to the achievement of the HP genomics objectives. One
example is the finding that variable penetrance alleles, including genes
associated with LS, can result in the perception that hereditary cancer “skips
generations” and lead to misconceptions regarding the probability that an
individual or their offspring inherited the disease causing allele (Henderson &
Maguire, 2000). Misconceptions about hereditary breast/ovarian cancer may be
even more prevalent or concerning because a fair number of individuals,
including health care providers, fail to take paternal family history into
consideration when assessing risks due to the mistaken belief that males cannot
inherit or cannot pass on the cancer causing allele to their offspring (Miesfeldt,
Cohn, Ropka, & Jones, 2001; Yong, Zhou, & Lee, 2003).
Education to address common misconceptions pertaining to heredity and
risk is important, but it will not address the many other attitudes, fears, or
misconceptions that may influence decisions related to genetic testing (Balmaña,
Stoffel, Emmons, Garber, & Syngal, 2004; Cragun, Malo, Pal, Shibata, &
Vadaparampil, 2012; Esplen et al., 2001, 2007; L. A. Keogh et al., 2009; Kinney,
DeVellis, Skrzynia, & Millikan, 2001; Scott D Ramsey, Wilson, Spencer,
Geidzinska, & Newcomb, 2003; Rose, Peters, Shea, & Armstrong, 2005; Sally W.
Vernon et al., 1999). For example, patients who take a fatalistic viewpoint or are
unaware of advantages and medical benefits of identifying hereditary cancer for
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themselves and/or their family members may be less likely to demonstrate
interest in or pursue genetic testing (Balmaña et al., 2004; Cragun et al., 2012;
Sally W. Vernon et al., 1999). Educating the public about the benefits of genomic
information is essential. Education about state and federal laws designed to
protect against genetic discrimination in the contexts of employment and health
insurance are also needed, as fears of genetic discrimination have been
negatively related to interest in or uptake of genetic counseling and/or genetic
testing (Balmaña et al., 2004; L. A. Keogh et al., 2009; Kinney et al., 2001; Scott
D Ramsey et al., 2003; Sally W. Vernon et al., 1999). Although it is possible that
fear of discrimination may have declined in recent years with the implementation
of the federal Genetic Information Nondiscrimination Act (GINA) in 2009, data
from a representative sample of Michigan residents in 2010 revealed that only
13% were aware of GINA (“Genetic Testing and Genetic Non-Discrimination
Laws,” 2011).
Education for health professionals and health educators. Health Care
Professionals also need to be educated about GINA. Results from a national
survey of family physicians approximately 17 months after GINA was signed
revealed fewer than half of respondents were aware of this federal law (Laedtke,
O’Neill, Rubinstein, & Vogel, 2011). Even more concerning, however, was that no
significant correlation was found between concerns about discrimination and
knowledge of GINA among these physicians (Laedtke et al., 2011). Additional
evidence for why this is a critical issue comes from another study which found
that physician's concern about genetic discrimination was a reason for non-
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referral among a minority of Californian physicians surveyed (Lowstuter et al.,
2008).
In addition to knowledge about GINA, health care professionals and
members of the public health workforce who may be involved with UTS or the
related HP genomics objective should, at a minimum, possess the following
genomics competencies: 1) a basic understanding of the rationale behind UTS;
2) the ability to identify the limits of his/her genomic expertise; and 3) knowledge
regarding where to go for information, resources, and referrals (Bellcross et al.,
2011; “Genomics|Training|Competencies,” n.d.). Additional genomics
competencies will be necessary for health care professionals who will be
interpreting tumor screening results and/or discussing them with patients. Given
that screening tests are not conclusive, health professionals must be educated
about best practices for discussing a positive screen and about the need to
emphasize the importance of follow-up genetic counseling and genetic testing to
their patients, even in the absence of a strong family history of cancer.
As part of the public health workforce, public health educators have been
identified as having the potential to play a unique role by helping health
professionals communicate with community groups and individuals regarding
genomic information and related technologies, relaying or reflecting communities'
concerns to health care professionals or policy makers, and providing
educational and health promotion services in the context of a multidisciplinary
team to facilitate informed decision-making related to genomics and health (L.-S.
Chen & Goodson, 2007). Even though over 88% of U.S. public health educators
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who responded to a survey strongly agreed or agreed with genomics
competencies that have been proposed by the CDC for the public health
education workforce (L.-S. Chen & Goodson, 2007;
“Genomics|Training|Competencies,” n.d.), they perceived many barriers to
incorporating genomics into health promotion (L.-S. Chen & Goodson, 2009).
Barriers included lack of genomics knowledge, limited training in genomics,
having to deal with lay public member's reaction, and lack of priority, time and
resources (L.-S. Chen & Goodson, 2009). Possible ways to remedy the
ambivalent attitudes and knowledge gap would be to incorporate more genomics
into the curriculum of public health education programs.
The inability to utilize the talents and skills of public health educators due
to their current lack of training and knowledge regarding genomics would be
unfortunate, but even more concerning is the potential that their lack of
knowledge will lead to misrepresentation of genomic information to the public and
the possibility that public health educators could hinder progress toward the HP
genomics objectives.
Educational resources for institutional implementation of UTS. As
more centers consider implementing UTS, there is a need for accessible
educational resources such as tumor screening protocol algorithms, samples of
laboratory reports, guidelines for interpreting results, fact sheets, ways to deal
with procedural concerns or issues that may arise, samples of patient
letters/brochures, information regarding insurance and reimbursement, and
lessons learned from other centers. Collecting and dissemination educational
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resources is one of the primary goals of the Lynch Syndrome Screening Network
(LSSN), which is a group of representatives from approximately 35-40 institutions
who have formed a collaborative group to improve Lynch syndrome screening
and increase the capacity for institutions to implement UTS.
Evolution of Genomic Research and Practice
“Scientific and technological advances in genomics are revolutionizing our
approach to genetic counseling and testing, targeted therapy, and cancer
screening and prevention, fulfilling the promise of personalized medicine (Weitzel
et al., p. 1) (Weitzel, Blazer, MacDonald, Culver, & Offit, 2011).”
In oncology, the use of presymptomatic testing for germline mutations and
the use of ‘‘targeted therapies’’ tailored to the molecular genetic characteristics of
tumors are often part of routine evaluation and care (Robson, Storm, Weitzel,
Wollins, & Offit, 2010; J. N. Weitzel et al., 2011). Despite a number of successes,
translating research into practice is often complex and there is always the risk
that promising genomic discoveries may never successfully be translated into
practice or that tests may be implemented widely before there is sufficient
evidence of clinical validity (i.e., accuracy with which the test predicts a particular
outcome (Burke et al., 2002) and/or clinical utility (i.e., capacity for the test result
to inform clinical decision making and facilitate the prevention of adverse health
outcomes) (Burke et al., 2010; Grosse & Khoury, 2006).
Since the completion of the human genome project a substantial amount
of research and resources have focused on identifying the contribution of genetic
variants to the pathology of common diseases such as cancer (S D Schully,
Benedicto, Gillanders, Wang, & Khoury, 2011). Many single nucleotide
polymorphisms (SNPs) associated with increased risks for cancer have been
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identified via genome wide association studies (Jostins & Barrett, 2011;
Wacholder et al., 2010). GWAS studies may be providing valuable information
about biological pathways involved in cancer and other diseases (Tuma, 2009).
However, these studies have generally found SNPs that confer only small relative
risks; and/or the clinical validity and clinical utility of testing for these SNPs
remain somewhat uncertain (Jostins & Barrett, 2011; Robson et al., 2010;
Wacholder et al., 2010).
To address the growing concern about potential limitations regarding the
practical relevance of genomic research to the primary causes and remedies of
diseases, an international, multidisciplinary meeting was held in May 2010 in
Ickworth, United Kingdom (Burke et al., 2010). Key themes from this meeting
centered around a need to reconfigure the focus of genomic research so that
greater attention is given to areas with greatest potential health impact and so
that a greater emphasis is placed on the translation of basic science to practical
applications (Burke et al., 2010). Although translational research appears to be
increasing in recent years (Muin J Khoury, Gwinn, & Ioannidis, 2010), nearly all
(98.2%) genetics-related grant funding by the National Cancer Institute from
Fiscal Year 2007 was dedicated to discovery research (S D Schully et al., 2011),
whereas translational research that evaluates a candidate genetic application to
develop evidence based recommendations, assesses how to integrate an
evidence-based recommendation into cancer care and prevention, or that
evaluates health outcomes and population impact has been extremely underrepresented in both funding and similarly in the published literature (S D Schully
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et al., 2011).
The new challenge for epidemiology is to work with allied disciplines to
integrate knowledge and effective interventions into various societal settings to
ensure that interventions have their intended effects on individual and public
health (Hiatt, 2010). The HP 2020 provisional genomics objective takes on this
challenge by focusing efforts on improving the identification of individuals who
have Lynch syndrome (LS) and other hereditary colorectal cancer (CRC)
syndromes so that effective prevention and treatment options can be
implemented to reduce associated morbidity and mortality.
Evidence in Favor of Lynch Syndrome (LS) Tumor Screening
Utilizing the ACCE (analytical validity; clinical validity; clinical utility; and
ethical, legal, and social issues) framework, the Evaluation of Genomics
Applications in Practice and Prevention (EGAPP) working group found sufficient
clinical validity and clinical utility evidence in favor of offering tumor screening to
all newly diagnosed patients with CRC for purposes of identifying family
members at increased risk for Lynch syndrome (LS) (“Recommendations from
the EGAPP Working Group,” 2009). EGAPP did not recommend a specific
protocol or screening methodology for universal tumor screening (UTS), but
possible screening methods have a number of different benefits and limitations
(Mvundura et al., 2010; Shia, 2008). Notably, immunohistochemistry (IHC) for the
presence or absence of DNA mismatch repair (MMR) proteins in tumor samples
is more cost effective than microsattelite instability (MSI) testing, particularly
when V500E mutation testing in the BRAF gene is added as an additional reflex

149

test in cases where the MLH1 stain is absent on IHC (Ladabaum et al., 2011;
Mvundura et al., 2010).
Regardless of the screening protocol that is chosen, abnormal results are
not considered diagnostic of LS. Therefore patients with an abnormal tumor
screen require subsequent germline testing of one or more of the genes that can
cause LS (i.e., MLH1, MSH2, MSH6, PMS2, and EPCAM) as well as genetic
counseling to discuss associated implications and recommendations for cancer
prevention or early detection.
Germline genetic testing has been distinguished from genetic screening
performed on tumors, in that the former involves DNA analysis from blood or
saliva to identify inherited mutations that increase risks for cancer, whereas the
latter is typically used to predict cancer prognosis or treatment response (Robson
et al., 2010). MSI and IHC are performed on tumor tissue and can provide
prognostic information (A. J. Clark, Barnetson, Farrington, & Dunlop, 2004;
Gologan & Sepulveda, 2005). Preliminary evidence also suggests that MSI and
IHC could possibly provide information about treatment response (de la Chapelle
& Hampel, 2010; Tejpar et al., 2011). However, these screening tests are unique
in that they have generally been employed for the purpose of determining
whether an individual is at increased risk for LS, thereby leading to debate about
whether or not explicit informed consent is necessary. On one hand, Chubak et
al. argue that informed consent for IHC may be required because unlike MSI,
IHC can reveal information about a patient's germline (Chubak, Heald, & Sharp,
2011). In contrast, others argue that because neither IHC nor MSI are definitive
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genetic tests, explicit informed consent is not required (Ladabaum et al., 2011).
Valid concerns have been raised that a lack of explicit informed consent may
infringe upon an individuals' autonomy or “right not to know”(Peres, 2010).
However, requiring explicit informed consent is concerning from a logistical
standpoint due to the time and effort it requires. Furthermore, suggesting to
patients that their cancer might be hereditary before screening is completed
could lead to unnecessary increases in anxiety and additional decisional burdens
among newly diagnosed CRC patients, the vast majority of whom do not have LS
(Peres, 2010).
Implications of Universal Genetic Testing Policies for Adult Populations
The impact that universal genetic testing policies will have on adult
populations is largely uncertain as UTS for LS is truly the first universal genetic
screening to be implemented for the purpose of detecting hereditary disease in
adults. Other genetic screening programs that have been widely implemented
are aimed at identifying genetic conditions in fetuses and infants or determining
carrier status among healthy couples to assess genetic risks for offspring.
Although not specific to adults, lessons learned from universal newborn
screening (NBS) may offer several insights into potential implications of universal
tumor screening (UTS). This is explored in more depth in the ethical implications
paper that is included as part of the dissertation.
One of the key ethical considerations involves informed consent.
Programs that automatically screen all tumors from newly diagnosed CRC
patients have the potential to identify the greatest number of patients with LS.
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This approach also raises ethical concerns related to autonomy (M. J. Hall,
2010). On the other hand, if screening requires explicit informed consent, this will
make implementation much more challenging and could reduce the number of
individuals with CRC who are screened for LS. Genetic testing of adults up until
this point has mainly been performed on individuals who actively sought out
genetic counseling and testing. With UTS programs, particularly those that do not
require explicit informed consent, the patient is being confronted with the
possibility of a genetic risk factor that he or she is not expecting, did not seek out,
and may not even want.
Assessing potential harms of UTS will be important. There have been no
published studies designed to identify risks or unintended outcomes associated
with UTS. Although risks are believed to be minimal (H. Hampel, 2010), a couple
of anecdotal reports from my own personal correspondence with genetic
counselors suggest that UTS can result in substantial psychological distress for
at least a few patients with who are erroneously led to believe they have LS.
Furthermore, in several studies that occurred prior to UTS implementation,
patients with CRC expressed concern that genetic testing for hereditary CRC
may lead to adverse psychological outcomes for themselves or their family
members (Kinney et al., 2000, 2001; Lerman, Marshall, Audrain, & GomezCaminero, 1996; Scott D Ramsey et al., 2003). Patients with CRC have also
expressed concerns about costs associated with genetic testing (Kinney et al.,
2001; Scott D Ramsey et al., 2003). Confirmatory genetic testing for LS is
approximately $1,000 to $3,000 and it is not always covered by insurance (J. N.
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Weitzel et al., 2011). Having a positive screen, but not being able to followthrough with genetic counseling and/or testing may invoke anxiety and worry.
UTS, if enacted widely throughout the U.S., therefore has the potential of adding
to the financial and/or psychological burdens of over 190,000 patients who are
diagnosed with CRC in the U.S. each year (“Colorectal Cancer Facts & Figures
2011-2013,” n.d.). Prior to wide-spread implementation, studies should be
conducted to identify whether there are any unanticipated harms associated with
UTS so that risks can be minimized.
Despite the possibility of negative outcomes, the potential benefits of UTS
are substantial and anecdotal reports have indicated that patients are often
appreciative of the additional information they obtain from UTS (Peres, 2010).
Nevertheless, it is possible that the estimates of benefit in terms of reducing
morbidity and mortality may be overstated. If penetrance in certain families
identified through UTS is lower than current estimates and age of cancer onset is
later, a higher cost-benefit ratio may result from applying existing cancer
screening protocols (Bellcross et al., 2011). As such, if studies continue to show
varying penetrance with consistent genotype/phenotype correlations,
recommendations may need to change to ensure that individuals do not undergo
unnecessary procedures that would be of little clinical benefit and could cause
harm (Kempers et al., 2011; Henry T Lynch, Lynch, Snyder, & Riegert-Johnson,
2011).
Comparisons between NBS and UTS are useful when considering the
potential impact of UTS. In addition, applying standardized state-wide laboratory
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and follow-up processes similar to those that have been implemented for NBS
has been proposed as a potential way to reduce cost and improve
standardization, quality of care, and access to genetic counseling by trained
health care providers (Bellcross et al., 2011). Thus NBS may serve as a model to
help decrease the likelihood of negative UTS outcomes.
Institutional Lynch Syndrome Screening Policies and Procedures
Published data on policies and procedures related to tumor screening for
Lynch syndrome (LS) are limited (Bellcross et al., 2011), and most of what is
known comes from the results of two surveys that were shared during the first
Lynch Syndrome Screening Network (LSSN) meeting in September of 2011.
Based on these surveys, at least 30 centers are performing routine screening for
LS on tumors from all newly diagnosed CRC patients and several others are
screening based on specific criteria. Some centers are also screening
endometrial tumors to identify additional patients at increased risk for LS
(Bellcross et al., 2011; Peres, 2010).
UTS protocols vary widely across institutions. Several specific details
come from a 2010 survey of institutions across the U.S. including 39 NCIdesignated Comprehensive Cancer Centers (NCI-CCCs) (63% response rate),
50 randomly selected ACS-accredited Community Hospital Comprehensive
Cancer Programs (COMPs) (50% response rate), and 50 randomly selected
Community Hospital Cancer Programs (CHCPs) (40% response rate) (Beamer et
al., 2012). Of the respondents, IHC and/or MSI is being conducted on at least
some tumors at 71% of NCI-CCCs, 36% of COMPs, and 15% of CHCPs. Most
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(48% ) use IHC, 14% use MSI, and 38% use both. Of the institutions performing
screening, 38% test all CRC patients, 27% test those diagnosed under the age of
50, 14% test those diagnosed under the age of 60, and 21% use other selection
criteria. Only 14% offer an option to opt-out of screening for LS and only 3.5%
offer pre-operative information on LS tumor screening. Centers reported that
results go to the surgeon alone (27.6%), to the surgeon and another provider
(55.2%), to a genetic health provider alone (6.9%), or to a non-surgeon and nongenetic health provider (6.9%); whereas 3.4% indicated that results go to no one.
Most of the centers expect the person receiving the results to initiate a referral to
genetics. However, among the NCI-CCCs 18% indicated that referrals were
initiated using an automatic electronic mechanism and 17% were initiated by a
specialist. The majority of centers have implemented a genetics referral tracking
mechanism and problems with patient follow-through with genetic counseling
were reported by 53% of the NCI-CCCs, 33% of COMPs, and 67% of CHCPs
that track this information.
Universal Tumor Screening (UTS) Evaluation
Data evaluating the real-world effectiveness of UTS programs is extremely
limited. As such, several studies that are not specific to UTS will also be included
in the following literature review in order to provide a better understanding of
three of the key steps that patients and/or at-risk family members must take in
order for UTS to be successful once it has been implemented. These key steps
include: 1) Patient Reach – patients must accept tumor screening (if consent is
required) and patients must follow-through with genetic counseling and testing in
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cases where screening is abnormal; 2) Cascade testing of family members
(Bellcross et al., 2011) – patients who are found to have LS need to
communicate with their at-risk family members who must then follow-through with
genetic counseling and testing; 3) Adherence to cancer screening
recommendations and/or cancer risk reduction through uptake of surgical options
by patients and family members who are diagnosed with LS. Although literature
pertaining to all of these steps will be reviewed below, the focus will be primarily
on patient reach, as this is most pertinent to my dissertation research.
UTS Evaluation: Patient Reach (i.e., follow-through with genetic counseling &
testing)
Factors related to genetic counseling and germline genetic testing uptake
may be similar; however, differences may also exist. Based on unpublished
survey results, it is clear that variability in patient follow-through with genetic
counseling exists across centers that are performing UTS. Differences in patient
reach could be the result of individual-level differences in patient populations.
However, it is also likely that variations in screening protocol or institutional
factors may help facilitate or hinder compliance with genetic counseling and
testing (P. M. Lynch, 2011).
The experience at Ohio State University, one of the first centers to
implement universal screening, found that uptake of genetic counseling dropped
substantially once their research protocol ended and clinical implementation of
UTS was begun. Under the research protocol, counseling and testing were free
and travel was not required because counseling could be provided by phone (H.
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Hampel et al., 2008). Once screening was initiated on a clinical basis, only 27%
of those who screened positive followed up with genetic counseling (South et al.,
2009).
In an editorial published in the journal Diseases of the Colon and Rectum,
Dr. Patrick Lynch reports that follow-through with genetic counseling at his
institution, M.D. Anderson, is about 80% (P. M. Lynch, 2011). This is an important
contrast to the experience reported at Ohio State where patient follow-through is
substantially lower (27% ). Differences between these centers may contribute to
this wide variability (P. M. Lynch, 2011). For example, instead of having to make
an appointment in a separate genetics department, as is the case at Ohio State,
genetic counselors are present within the GI centers at M.D. Anderson,
potentially making referrals “more seamless” (P. M. Lynch, 2011). Additional
insights into possible reasons for variability in patient follow-through come from a
variety of studies discussed in more detail below that are not directly related to
UTS.
Genetic counseling interest and uptake. Only a couple of studies have
explored issues related to interest or uptake of genetic counseling for hereditary
CRC. Secondary data analysis of surveys from patients with CRC who were at
various levels of risk for hereditary CRC reveal offers several insights. Compared
to those with no intention of making an appointment (n=70) to discuss genetic
testing for hereditary CRC, those with positive intention (n=18) perceived there to
be greater medical benefits from genetic testing (p=.02) and were less fearful of
insurance and/or employment discrimination (p=.04). They were also more likely
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to perceive themselves to be appropriate candidates for genetic testing
regardless of their personal and family history of cancer (p<.001) (Cragun et al.,
2012). A German study compared individuals at high risk for CRC based on
whether they attended a genetic information session (Monika Keller et al., 2004).
Those who attended the session reported more distress about the possibility of
CRC being hereditary. No group differences were found in terms of awareness of
potential hereditary predisposition or clinical criteria suggestive of LS.
Uptake of genetic counseling for hereditary breast cancer may also
provide relevant insights (Chin et al., 2005; O’Neill, Peters, Vogel, Feingold, &
Rubinstein, 2006; Thompson et al., 2002; Vadaparampil et al., 2009). Factors
shown to positively influence or correlate with genetic counseling uptake for
patients with breast cancer include increased awareness of genetic counseling
and/or hereditary breast cancer, perceived benefits of counseling, and a
perception that genetic counseling is personally relevant to them. Factors that
were negatively associated with pursuit of counseling include confusion about a
referral in the absence of a strong family history of cancer, financial concerns
about the cost of genetic counseling, and concerns about the potential for
negative outcomes as a result of having genetic testing.
In a recent study of endometrial cancer patients, 26 of 47 patients who
had an abnormal tumor screen for LS responded to a survey (Backes, Mitchell,
Hampel, & Cohn, 2011). Of these, 20 (77%) reported that they were referred by
their physician for genetic counseling, but only nine saw a genetic counselor. The
most common reason for not seeing a genetic counselor was lack of adequate
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insurance coverage or concern about the cost of the visit followed by anxiety
about the results. Nine patients also stated that they or their family members did
not want to know information regarding hereditary cancer risk.
Genetic testing interest and uptake. Interest or uptake of genetic testing
among patients with CRC has varied widely across studies (ranging from 17100%) (Balmaña et al., 2004; Esplen et al., 2007, 2001; Hadley et al., 2003; M
Keller et al., 2002; Monika Keller et al., 2004; L. A. Keogh et al., 2009; Kinney et
al., 2000, 2001; Loader, Shields, Levenkron, Fishel, & Rowley, 2002; Metcalfe,
Werrett, Burgess, Chapman, & Clifford, 2009; Scott D Ramsey et al., 2003;
Ramsoekh et al., 2007; S W Vernon et al., 1997). This wide variability may be
due to differences in recruitment of study participants and/or inconsistencies
between studies in terms of the patient population sampled, information provided
to participants, and ways in which cost and other contextual factors were
addressed. Two studies, which each analyzed responses from nearly 100
surveys of CRC patients, found that the respective percentages of CRC survivors
interested in genetic testing for hereditary CRC were 67% (Cragun et al., 2012)
and 72% (Kinney et al., 2000). These two studies provide the only published
estimates that could be identified regarding interest in genetic testing among
CRC patients who were not all at high risk for hereditary cancer or were not
already pursuing genetic counseling. Nevertheless, the level of interest in genetic
testing reported in these two studies may not be representative of CRC patients
in general due to sampling issues and potential participation bias.
Nonparticipants would in all likelihood be less inclined to pursue genetic testing
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for many of the same reasons they chose not to participate in the respective
surveys (e.g., medical complications from cancer treatment). As such, it is
possible that a substantial proportion of CRC patients (at least 28-33%) are not
interested in or are uncertain whether they would undergo genetic testing for
hereditary CRC if it were made available to them.
Among patients with CRC, statistically significant associations between
various demographic variables (i.e., gender, number of family members with
cancer, age) and interest in or uptake of genetic testing for hereditary CRC have
been inconsistent across studies (Cragun et al., 2012; Monika Keller et al., 2004;
Kinney et al., 2000; Loader et al., 2002; Sally W. Vernon et al., 1999). Some
studies have found that interest in or uptake of genetic testing for hereditary CRC
is associated with the following demographic factors: being a parent (Loader et
al., 2002); having more cancer in the family (Loader et al., 2002); having a larger
social network (Loader et al., 2002); younger age (Kinney et al., 2000); and less
advanced disease stage (Kinney et al., 2000); however, the magnitude of these
associations was relatively small. Furthermore, other studies of CRC patients
have either failed to find similar relationships or demographic variables do not
remain statistically significant after controlling for attitudinal variables (Cragun et
al., 2012; Monika Keller et al., 2004; Sally W. Vernon et al., 1999). Given that
demographic variables generally cannot be altered, attitudinal factors that
strongly correlate with interest in or uptake of genetic testing may serve as better
leverage points or targets for improving the reach of UTS for LS.
Among patients with CRC, interest in and uptake of genetic testing has
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consistently been associated with and/or attributed to perceptions of positive
outcomes of genetic testing, including: helping other family members;
determining cancer risks for offspring; improving the ability to make more
informed decisions about cancer treatment/screening; and/or increasing one's
ability to plan for the future (Balmaña et al., 2004; Cragun et al., 2012; Esplen et
al., 2001, 2007; Hadley et al., 2003; Kinney et al., 2001; Metcalfe et al., 2009;
Scott D Ramsey et al., 2003; Sally W. Vernon et al., 1999). More frequent
thoughts, worry, or distress about CRC being hereditary may also have a
significant positive correlation with interest in genetic testing (Kinney et al., 2000)
and intention to learn genetic test results (Sally W. Vernon et al., 1999). Although
few studies appear to have asked CRC patients about the influence of health
care providers on their decision, one study reported that CRC patients' decisions
to undergo genetic testing was influenced by a recommendation from a physician
or genetic counselor (Esplen et al., 2007).
Studies suggest that negative attitudes regarding testing (e.g., concerns
about negative psychological consequences and insurance discrimination) may
also influence genetic testing decisions (Balmaña et al., 2004; L. A. Keogh et al.,
2009; Kinney et al., 2000, 2001; Sally W. Vernon et al., 1999). However, in two
studies that have performed multivariable analyses, the relationship between
negative attitudes and either interest in testing or intention to receive test results
were no longer statistically significant after controlling for positive attitudes about
genetic testing (Cragun et al., 2012; Sally W. Vernon et al., 1999).
After controlling for attitudes toward testing, a belief that personal and/or
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family history makes individuals appropriate candidates for testing remained
significantly associated with interest in testing (Cragun et al., 2012). An
implication of this finding is that requiring explicit informed consent for tumor
screening may result in relatively low rates of uptake unless patients are
convinced that they are appropriate candidates for screening. Automatic
screening of all tumors may therefore be more successful as long as patients
who screen positive can be convinced that genetic counseling is appropriate for
them.
Although interest in genetic testing may be a necessary precursor for
action, uptake of testing is generally lower than interest (Monika Keller et al.,
2004). One potential reason for the discrepancy between interest and uptake
may be financial barriers. Based on the collective experience of members of the
Lynch Syndrome Screening Network, insurance typically covers the cost of
screening which generally ranges between $250-$500, depending on the
laboratory and screening strategy. The costs of germline testing are higher,
generally between $900 to $3,000 depending on the number of genes tested.
Lack of insurance or insufficient insurance coverage for genetic counseling and
germline testing has been shown to be an important barrier to interest in or
uptake of hereditary cancer counseling and genetic testing (Backes et al., 2011;
Chin et al., 2005; Cragun et al., 2012; Kinney et al., 2001; Scott D Ramsey et al.,
2003; Weitzel et al., 2011). In one study, the percentage of CRC patients who
indicated they would be willing to pay $2,000 for genetic testing (13.6%) was
substantially lower than the 67% who indicated being interested in having genetic
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testing before cost was mentioned (Cragun et al., 2012). Assessing the maximum
amount that individuals would be able or willing to pay and determining the
likelihood that insurance would cover costs associated with germline testing may
be helpful before implementing UTS, as this will likely affect overall effectiveness.
Although insurance and financial issues are individual barriers, changes to the
health care system and insurance plans will likely be needed so that cost barriers
do not prevent patients from choosing to undergo genetic counseling,
confirmatory germline testing, colonoscopy, and other cancer surveillance or
prevention measures.
Cascade testing of family members. High levels of patient followthrough with genetic counseling and genetic testing is essential to ensure that
UTS programs are effective. However, it is the patients' unaffected family
members who stand to gain the most benefit from UTS, and the prevention of
cancer in unaffected relatives is critical in UTS cost-benefit sensitivity analyses
(Gudgeon et al., 2011; Ladabaum et al., 2011; Mvundura et al., 2010). In order
for testing of family members to occur, patients must understand the potential
implications for family members, recognize the benefits of diagnosing LS in other
family members, and communicate this information effectively with at-risk family
members. Although genetic health professionals can play an important role in this
process (Mesters, Ausems, Eichhorn, & Vasen, 2005; Pentz et al., 2005), the
responsibility of informing family members often resides with the patients due to
confidentiality issues (“Genetics of Colorectal Cancer (PDQ®) - National Cancer
Institute,” n.d.).
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Several studies have explored genetic risk communication patterns among
patients with LS and their families (K. I. Aktan-Collan et al., 2011; Ersig, Hadley,
& Koehly, 2011; C. L. Gaff, Collins, Symes, & Halliday, 2005; Mesters et al., 2005;
Susan K Peterson et al., 2003; Elena M Stoffel et al., 2008). Individuals are
generally willing to share genetic test results with family members, but tend to
favor a cascade approach whereby they inform first-degree relatives and then
those family members inform other immediate family members (Gaff et al., 2005;
Mesters et al., 2005; Susan K Peterson et al., 2003; Elena M Stoffel et al., 2008).
Family role and gender differences have been reported in communication
patterns (Gaff et al., 2005; Koehly et al., 2003; Susan K Peterson et al., 2003).
Although communication is generally viewed as an open process (“Genetics of
Colorectal Cancer (PDQ®) - National Cancer Institute,” n.d.), several barriers
have been identified including: lack of close relationship, desire not to worry
relatives, presence of familial conflict, and perceptions that relatives were either
too young, would not understand, or would not be interested (Gaff et al., 2005;
Mesters et al., 2005; Elena M Stoffel et al., 2008).
Once informed about the potential hereditary risk, family members must
seek genetic counseling and genetic testing. A review of several studies revealed
that about half of family members pursued genetic counseling and most who
underwent counseling pursued germline testing (“Recommendations from the
EGAPP Working Group,” 2009). However, uptake of genetic testing for LS among
at-risk individuals can be highly variable and may depend on the context in which
testing is offered (“Genetics of Colorectal Cancer (PDQ®) - National Cancer
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Institute,” n.d.). Many factors influence whether family members pursue genetic
counseling/testing for LS, such as: perceived benefits to self and family
members; higher perceived risk of or worry about developing CRC; and concerns
about genetic discrimination, ability to cope with results, or cost (K. Aktan-Collan
et al., 2000; Claes, Denayer, Evers-Kiebooms, Boogaerts, & Legius, 2004;
Codori et al., 1999; K Glanz, Grove, Lerman, Gotay, & Le Marchand, 1999;
Hadley et al., 2003; L. Keogh et al., 2011; Kinney et al., 2001; Lerman et al.,
1999, 1996; J. T. Lowery, Marcus, Horick, Finkelstein, & Ahnen, 2011; Petersen
et al., 1999; Ramsoekh et al., 2007; Sally W. Vernon et al., 1999; Warner,
Curnow, Polglase, & Debinski, 2005).
Cancer screening adherence. In order for individuals with LS to
decrease associated morbidity and mortality it is important that they follow
appropriate cancer screening guidelines and/or pursue surgical options to reduce
cancer risks. In a review article, adherence to colonoscopy recommendations
among individuals with LS was found to range from 53% to 100%
(“Recommendations from the EGAPP Working Group,” 2009). Adherence to
gynecologic surveillance ranged from 69% to 97% in three studies of women who
either have LS or are at 50% risk for LS (V. R. Collins et al., 2007; Heikki J
Järvinen et al., 2009; Anja Wagner et al., 2005) Little is known about uptake of
prophylactic surgeries to reduce risks for endometrial and ovarian cancer.
Colon cancer screening adherence among individuals with LS or
individuals who are at high risk for hereditary CRC has been associated with
reminder letters, strong family history of cancer, having a medical
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recommendation to screen, having been referred for a genetic evaluation, and
encouragement to screen from family members (Bleiker et al., 2005; Ersig,
Hadley, & Koehly, 2009; Murff, Peterson, Greevy, Shrubsole, & Zheng, 2007;
Rees, Martin, & Macrae, 2008; Elena M Stoffel et al., 2010). Many of the barriers
to colonoscopy in high risk individuals are similar to those in the general
population (e.g., discomfort, cost, embarrassment) (Bleiker et al., 2005).
Additional steps for successful UTS implementation. There are
several additional steps involving health care professionals that are likely to be
necessary to the success of UTS. These include effective communication of
screening results, patient referrals, and coordination between various specialists
and primary care providers to facilitate the process by which patients and their
family members receive genetic counseling, genetic testing, and appropriate
screening. Detailed information regarding these steps has not been reported and
research and additional research in this area is needed.
Summary
The Healthy People (HP) 2020 provisional genomics objective is intended
to help translate genomic medicine into individual and public health benefits
through improving the identification of individuals with hereditary colorectal
cancer (CRC). Achievement of the HP 2020 provisional genomics objective has
the potential to substantially reduce morbidity and mortality among unaffected
relatives of CRC patients who are identified with Lynch syndrome (LS). Making a
diagnosis of LS in patients who already have CRC may also benefit the patients
directly, given that having LS may influence clinical treatment and will certainly
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alter future screening recommendations due to high risks for additional cancers.
Universal tumor screening (UTS), whereby tumors from all newly
diagnosed patients with CRC are screened for Lynch Syndrome (LS), has the
potential to help achieve this HP objective and result in population health benefits
at a reasonable cost. However, in order for this approach to be successful,
education will be needed at many levels. At a minimum, all individuals involved
with UTS and patients who are found to have an abnormal screen should be
aware of the rationale for UTS, the importance of genetic counseling and
diagnostic testing for individuals with abnormal tumor screens (regardless of
family history or age at diagnosis), the need for follow-through with identifying atrisk family members, and the importance of increased cancer surveillance for all
individuals identified with LS. Additional education will be needed to dispel
misconceptions about inheritance, to increase awareness of state and federal
laws that are designed to protect against genetic discrimination, and to improve
awareness of the positive health benefits associated with making a diagnosis of
LS if appropriate cancer screening recommendations are followed. Educational
resources that are being compiled by the Lynch Syndrome Screening Network
(LSSN) will be extremely valuable in the dissemination of UTS, but systematic
evaluation of existing UTS programs will also be needed to fully inform centers
that are considering how to best implement UTS at their institution. Additional
research and collaborative efforts are needed to help prioritize or determine
additional educational efforts that may be necessary in order to help
practitioners, health educators, patients, and other stakeholders achieve the HP
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2020 genomics objective.
The feasibility of UTS has been demonstrated in research and clinical
settings. However, prior to widespread implementation of UTS, lessons from
universal newborn screening and potential ethical, legal and social implications of
universal genetic screening for adults should be considered. Further research
into “real-world” implementation is needed to determine whether there are any
risks or unintended consequences associated with UTS and to collect additional
data that is necessary to justify the development of infrastructure and cost that
would be required for implementation of UTS on a national level (Bellcross et al.,
2011). To assess “real-world” effectiveness the following data will be critical:
patient reach (i.e., follow-through with genetic counseling and testing after an
abnormal screen); initiation of cascade testing of at-risk family members;
adherence to recommended cancer surveillance for individuals identified with LS;
and uptake of surgical prevention options.
Among centers already performing UTS, there is evidence of wide
institutional variability in terms of UTS screening protocols and patient reach.
Reasons for this institutional variability have not been explored. Research has
established that patient factors may influence interest in and uptake of genetic
counseling and testing outside the context of UTS, but data is needed to confirm
that similar patient factors contribute to follow-through with genetic counseling
and testing among patients who receive an abnormal tumor screen. There is also
some evidence to suggest that contextual factors (e.g., patient-provider
communication and policies or practices of health insurance providers and health
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care institutions) may be influential in patient follow-through with genetic
counseling and testing, either directly by creating barriers/facilitators or indirectly
by altering patients' attitudes, knowledge, and perceptions. Comparing existing
UTS programs can determine the extent to which different protocols/procedures
are effective or ineffective in specific contexts in order to help identify best
practices. This type of research is a critical step toward reaching the longer-term
goals of optimizing current UTS programs and wide-spread diffusion of effective
UTS practices.
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